SPYRAL PIVOTAL - SPYRAL HTN -OFF MED Clinical Investigation Plan 
Versi on 12 .0 Page 1 of 139  
Medtronic Confidential  
056-F275,  v3.0 Clinical Investigation Plan Template
SPYRAL PIVOTAL – SPYRAL HTN -OFF MED 
Clinica l Investigation Pla n 
Version 12.0 
22 October 2020 
IDE #: G150036 
NCT #: [STUDY_ID_REMOVED]
Global Sponsor  
Medtronic Vascular, Inc.  
3576 Unocal Place  
Santa Rosa, California 95403  
United States  
Phone:  +1 (800) 633-8766  
Note: this clinical study is funded by the sponsor  
Regional Sponsors  
Medtronic Australasia Pty. Ltd  
2 Alma Road, Macquarie Park, NSW 2113  
Australia  
Phone: (+61) 2 0 9857 9000  Medtronic Bakken Research Center (BRC) B.V.  
Endepolsdomein 5,  
6229 GW Maastricht,  
The Netherlands  
Phone : +31-43-35-66-566 
Medtronic of Canada, Ltd.  
99 Hereford Street  
Brampton, Ontario, L6Y 0R3 
Canada  
Phone: +1 -800-268-5346 Medtronic Japan Co., Ltd  
1-2-70 Konan,  
Minato- ku, Tokyo 108- 0075 
Japan  
Phone: (+81) 3 -6774 -4611 
Confidentiality Statement  
The information contained in this document is confidential and the proprietary property of 
Medtronic. Any distribution, copying, or disclosure without the prior written authorization of 
Medtronic is strictly prohibited. Persons to whom the information is disclosed must know 
that it is confidential and that it may not be further disclosed by them.  

SPYRAL PIVOTAL - SPYRAL HTN -OFF MED Clinical Investigation Plan  
  
 Version  12 .0 Page 2 of 139  
 
Medtronic Confidential  
  056-F275, v3 .0 Clinical Investigation Plan Template  
  Approval sheet  
 
Author (document owner)/CSM/Medical Writer:  
Pamela McKenna   Sr. Pr in. Clinical Research Specialist  
(name)   (functional role)  
Electronic sign-off  Electronic sign-off 
(signature)   (date) (dd MMM yyyy)  
Clinical Leadership:  
Vanessa DeBruin   Clinical Research Director  
(name)   (functional role)  
Electronic sign-off  Electronic sign-off 
(signature)   (date)  (dd MMM yyyy)  
   
Sandeep Brar   Sr. Clinical Research Director  
(name)   (functional role)  
Electronic sign-off  Electronic sign-off 
(signature)   (date) (dd MMM yyyy)  
   
Vinod Parthasarathy   APAC CL Lead   
(name)   (functional role)  
Electronic sign-off  Electronic sign-off 
(signature)   (date) (dd MMM yyyy)  
   
Christina Zhong   VP of Clinical Research  
(name)   (functional role)  
Electronic sign-off  Electronic sign-off 
(signature)   (date) (dd MMM yyyy)  
   
Garrett Pilcher   Sr. Clinical Research Director  
(name)   (functional role)  
Electronic sign-off   Electronic sign-off  
(signature)   (date) (dd MMM yyyy)  
   
Aarthi Kamath    Sr. Clinical Research Specialist  
(name)   (functional role)  
SPYRAL PIVOTAL - SPYRAL HTN -OFF MED Clinical Investigation Plan  
  
 Version  12 .0 Page 3 of 139  
 
Medtronic Confidential  
  056-F275, v3 .0 Clinical Investigation Plan Template  
  Electronic sign-off  Electronic sign-off 
(signature)   (date) (dd MMM yyyy)  
Statistics Management:  
Minglei Liu   Senior Statistics 
Manager  
(name)   (functional role)  
Electronic sign -off  Electronic sign -off 
(signature)   (date) (dd MMM yyyy)  
QA:  
Jennifer Loushin   Senior Clinical Quality 
Compliance Specialist  
(name)   (functional role)  
Electronic sign-off  Electronic sign-off 
(signature)   (date)  (dd MMM yyyy)  
 
Regulatory Affairs:  
Anna Dyer   Regulatory Affairs 
Manager  
(name)   (functional role)  
Electronic sign-off  Electronic sign-off 
(signature)   (date)  (dd MMM yyyy)  
 
Safety:  
Carine van Deursen    Clinical Safety 
Specialist  
(name)   (functional role)  
Electronic sign-off  Electronic sign-off 
(signature)   (date)  (dd MMM yyyy)  
 
Monitoring:  
PJ Belmont   Sr. Clinical Research 
Monitor  
(name)   (functional role)  
Electronic sign-off  Electronic sign-off 
(signature)   (date)  (dd MMM yyyy)  
 
Therapy Subject Matter Expert:  
Oscar Sanchez, MD   Sr. Clinical Research 
Manager  
(name)   (functional role)  
SPYRAL PIVOTAL - SPYRAL HTN -OFF MED Clinical Investigation Plan  
  
 Version  12 .0 Page 4 of 139  
 
Medtronic Confidential  
  056-F275, v3 .0 Clinical Investigation Plan Template  
  Electronic sign-off  Electronic sign-off 
(signature)   (date) (dd MMM yyyy)  
Change History record  
 
Version History  
Version  Summary of Changes  Author  
1.0 Initial  Vanessa DeBruin  
2.0 Changes include the list below:  
1. Updated Time Course  
2. Addition of the Medtronic SEEQ™ Mobile Cardiac 
Telemetry (MCT) System  
3. Revision s of exclusion criteria 
4. Updated/clarified safety and efficacy endpoints  
5. Added baseline duplex ultrasound if obtained per standard 
of care 
6. Updated anti -platelet/anti -coagulation language  
7. Added Drug testing for Hypertensive Crises  
8. Added/revised adverse event reporting language in Japan 
and Australia 
9. Added contact information for the services providers  
10. Updated Blood Pressure Measurement Procedures  
11. Added list of Appendices  
12. Minor formatting, typo, and clarifying language  changes 
throughout protocol  Vanessa DeBruin  
3.0 Changes include the list below:  
1. Updated approval signatories  
2. Updated Time Course  
3. Updated total number of subjects to be screened 
from 400 to 700  
4. Revisions of inclusion and exclusion criteria  
5. Clarified study ISO14155:2011 compliant except for 
AEs not reported for Control subjects after 12 months 
post-randomization 
6. Updated Section E.6 Study device/product 
traceability  
7. Updated Section F Study Methods  
8. Revised  Figure 8 for consistency with protocol 
changes  
9. Added CT/MRA Service Provider on Section L.1.1 
10. Updated Section L.7 Blood Pressure Measurement 
Procedures  
11. Minor formatting, typo, and clarifying language  
changes throughout protocol  Vanessa DeBruin  
4.0 1. Updated approval signatories  
2. Updated Time Course  Vanessa DeBruin  
SPYRAL PIVOTAL - SPYRAL HTN -OFF MED Clinical Investigation Plan  
  
 Version  12 .0 Page 5 of 139  
 
Medtronic Confidential  
  056-F275, v3 .0 Clinical Investigation Plan Template  
  3. Updated total number of subjects to be screened from 
700 to approximately 750 to align with increase in number of 
subjects randomized  
4.       Updated total number of subjects to be randomized to 
state up to 170 
5. Added ‘drug naïve subjects’ only when ref erring to the 
diastolic blood pressure reason for screen failure at the 2 w eek 
screening visit for Figure 8. 
6. Removed “non- fasting” when referring to blood draws  
7. Clarified when crossover will be determined 
8. Added “Updated address for Cardiovascular Research 
Foundation 
9. Removed statement that a 6 French sheath should be used 
for renal angiogram  
4.1 1. Corrected pagination errors caused by conversion from word 
to Portable Document Format  Vanessa DeBruin  
5.0 1. Updated approval signatories  
2. Updated number of participating centers to “up to 50”.  Vanessa DeBruin  
6.0 Changes include the list below:  
1. Updated Approval Signatories  
2. Updated Regional Sponsors  
3. Updated Time Course  
4. Added Canada, Including Regulations And Adverse Event 
Reporting Language  
5. Updated Total Number Of Subjects To Be Screened From 750 To 1800  
6. Updated Total Number Of Subjects To Be Randomized 
To Approximately  433  
7. Revisions Of Inclusion And Exclusion Criteria 
8. Updated/Clarified Safety And Efficacy Endpoints  
9. Removal Of The Medtronic SEEQ™ Mobile Cardiac 
Telemetry (MCT) System  
10. Addition Of 24 Month Renal Duplex Ultrasound (DUS)  
11. Updated Training Requirements  
12. Updated Procedure Section 
13. Addition Of SF36 Survey (Quality Of Life)  
14. Updated Visit Windows  
15. Updated Sample Size 
16. Addition Of Lipid Panel (Total, High- Density Lipoprotein 
Cholesterol, Low -Density Lipoprotein Cholesterol, Total 
Cholesterol),Uric Acid And High- Sensitivity CRP (Hs -
CRP) Laboratory Tests  
17. Updated Clinical Experience Section  
18. Updated Supply Of Investigational Devices/Products 
Section  
19. Revision Of The Follow -Up Schedule 
20. Updated Data Analysis And Reporting  
21. Medication Titration Section Replaced With Medication 
Re-Introduction For Subjects With 3M Office Systolic 
Blood Pressure  (SBP)≥ 140 mmhg Section  
22. Clarified Crossover Process  Marina Ostanniy  
SPYRAL PIVOTAL - SPYRAL HTN -OFF MED Clinical Investigation Plan  
  
 Version  12 .0 Page 6 of 139  
 
Medtronic Confidential  
  056-F275, v3 .0 Clinical Investigation Plan Template  
  23. Updated Unavoidable Adverse Events Table  
24. Updated Adverse Event Reporting Requirements Table 
25. Added 24 Month Duplex Ultrasound Requirement  
26. Revision of the QOL surveys administration schedule  
27. Updated Blood Pressure Measurement Procedures  
28. Revised Figures And Tables Throughout Protocol For 
Consistency With Protocol Changes  
29. Updated List Of Providers ( Section L.1.1)  
30. Minor Formatting, Typo, And Clarifying Language 
Changes Throughout Protocol  
7.0 Changes include the list below:  
1. Replacement of 24  Month Renal Duplex Ultrasound 
(DUS) with 12 Month  Renal Imaging  and Updated 
Number of 12 M Images From 50 to “a minimum of 100 
and up to 433 ” Throughout  Protocol .  
2. Added “ ≥40% Decline In eGFR” as a Secondary Safety 
Endpoint  
3. Added Renal Artery Stenosis Evaluation at 12 Months to 
Data Analysis And Reporting  
4. Updated References  
5. Minor Formatting, Typo, And Clarifying Language Changes Throughout Protocol  
6. Updated Figure 10 with visit requirements.  Marina Ostanniy  
8.0 1. Clarify that subjects who have already completed their 12 
month follow -up at time of protocol approval will be 
required to undergo renal imaging at their next scheduled follow- up unless they have a renal angiogram due to 
crossover. 
2. Added clarification on medication re -introduction visits 
between 3 and 6 months follow- up.  
3. Minor Formatting, Typo, And Clarifying Language Changes Throughout Protocol  
4.  Updated Figure 10 with visit requirements  
5. Added clarification to Crossover process  
6. Updated Study Name  Vanessa DeBruin  
9.0 1. Update  to clarify  that SV1 can occur after 10:30am, if Informed 
Consent Form is signed at SV1.  
2. Update to clarify medications use prior to consent at SV1  
3. Update F.10 Crossover Procedures to align with Table 2 
a.  EQ-5D and SF -36: not needed at Crossover Baseline.   
b. Drug testing and witness pill taking requeded at 
Baseline  
4. Update F.7 Follow -Up Procedures and F.10 Crossover 
Procedures to clarify that when the ABPM is repeated,  office blood pressure and drug testing must be repeated on day the 
ABPM is applied before each repeated ABPM  
5. Update to clarify  that High- sensitivity CRP is not required to be 
measured for subjects enrolled at sites where high- sensitivity 
CRP test cannot be locally performed  
6. Exclusion criteria #1: added that patients who received catheter 
or surgical treatment for Atrial Fibrillation and are in sinus rhythm 
are not excluded.  Marina Ostanniy  
SPYRAL PIVOTAL - SPYRAL HTN -OFF MED Clinical Investigation Plan  
  
 Version  12 .0 Page 7 of 139  
 
Medtronic Confidential  
  056-F275, v3 .0 Clinical Investigation Plan Template  
  7. Exclusion criteria #14: update to state ‘Individual  who requires 
more than occasional use (e.g. PRN) of narcotic drugs over the 
month prior to Screening Visit 1.’ 
8. Exclusion Criteria #17: indicate that subjects need to be off NSAIDS for 1 month prior to SV2, not enrollment.  
9. Updated statistics section, including sample size section and 
interim analyses to reflect change 
10. Updates to reflect OBP device without printer  
11. Updated reasons when ABPM can be repeated to include if 
ABPM guidelines were not followed. 
12. Clarification added around cuff size for OBP and ABPM 
13. Updated with most recent clinical data  
14. Added/revised adverse event reporting language i n Australia  
15. Minor formatting, typo and clarifying language changes 
throughout the protocol  
 
10.0 1. Updated Section E7 to include alternate Follow -up methods to 
allow more flexibility during extenuating circumstances, such as a global pandemic . 
2. 12- month imaging requirements clarified for UK and German 
subjects .3. Incorporated  latest version of ISO14155 updates  
3. Formatting and administrative updates  
 Pamela McKenna  
11.0 1. Admin istrative update to remove the following sentence from the 
section E.7 ‘Follow -up Procedures’.  ‘These alternative methods 
have no potential impact on patient safety, do not affect data 
integrity and do not introduce study bias. ’  This sentence was 
added in version 10.0 of the CIP which was not implemented 
prior to version 11.0.  Pamela McKenna  
12.0 1. Administrative update to align heading lettering with prior CIP 
versions.  Pamela McKenna  
  
  
SPYRAL PIVOTAL - SPYRAL HTN -OFF MED Clinical Investigation Plan  
  
 Version  12 .0 Page 8 of 139  
 
Medtronic Confidential  
  056-F275, v3 .0 Clinical Investigation Plan Template  
  TABLE OF CON TENTS  
 
A SYNOPSIS  ............................................................................................................... 14 
B GENERAL INFORMATION  ..................................................................................... 28 
B.1 Introduction  ....................................................................................................................... 28 
 Clinical Experience Using the Single Electrode RF renal denervation system  ...... 28 
 Clinical Experience Using the Multi Electrode RF renal denervation system 
(SPYRAL)  ............................................................................................................... 31 
B.2 Device information  ............................................................................................................ 39 
 The Symplicity ™ multi- electrode renal denervation system  .................................. 39 
 Symplicity Spyral ™ Catheter .................................................................................. 39 
 Symplicity G3 ™ Generator ..................................................................................... 40 
 Labeling  .................................................................................................................. 42 
 Intended Clinical Performance ............................................................................... 43 
B.3 Comparator information  .................................................................................................... 44 
C STUDY PLAN  .......................................................................................................... 45 
C.1 Study Objective ................................................................................................................. 45 
C.2 Clinical Endpoints  ............................................................................................................. 45 
 Additional analyses  ................................................................................................ 47 
C.3 Study Population ............................................................................................................... 47 
C.4 Study Design  .................................................................................................................... 48 
C.5 Randomization and blinding ............................................................................................. 48 
C.6 Sample Size  ...................................................................................................................... 49 
C.7 Number of investigation sites and study duration  ............................................................. 51 
D SUBJECT SELECTION  ........................................................................................... 51 
D.1 Inclusion criteria  ................................................................................................................ 51 
D.2 Exclusion criteria ............................................................................................................... 52 
E STUDY PREPARATION PROCEDURES  ................................................................ 54 
E.1 Investigator/Investigational site selection  ......................................................................... 54 
SPYRAL PIVOTAL - SPYRAL HTN -OFF MED Clinical Investigation Plan  
  
 Version  12 .0 Page 9 of 139  
 
Medtronic Confidential  
  056-F275, v3 .0 Clinical Investigation Plan Template  
  
 Investigator selection criteria .................................................................................. 54 
 Investigational site selection criteria  ....................................................................... 54 
 Clinical Trial Agreement  ......................................................................................... 55 
 Curriculum Vitae  ..................................................................................................... 55 
E.2 Ethics  ................................................................................................................................ 55 
 EC/IRB approval  ..................................................................................................... 55 
 Patient Information and Informed consent process  ............................................... 56 
 Revisions in Patient Information and Informed Consent Form  .............................. 57 
 Regulatory submission  ........................................................................................... 57 
E.3 Regulatory compliance  ..................................................................................................... 57 
E.4 Training requirements  ....................................................................................................... 58 
E.5 Clinical study materials and clinical study -specific equipment  ......................................... 59 
E.6 Study device/product handling and traceability  ................................................................ 59 
 Supply of investigational devices/products  ............................................................ 60 
 Storage and handling of investigational devices/products  ..................................... 60 
 Device return procedures/products  ........................................................................ 60 
 Device/product disposition requirements  ............................................................... 61 
F STUDY METHODS  .................................................................................................. 61 
F.1 Point of enrollment  ............................................................................................................ 61 
F.2 Screening Visit 1  ............................................................................................................... 63 
F.3 Medication Washout Period  .............................................................................................. 63 
F.4 Two Week Screening Visit  ................................................................................................ 63 
F.5 Screening Visit 2  ............................................................................................................... 64 
F.6 Procedure  ......................................................................................................................... 66 
F.7 Follow -Up Procedures  ...................................................................................................... 68 
F.8 Escape Medication Protocol during Off Medication Period  .............................................. 72 
F.9 Medication Re- Introduction for Subjects with 3M Systolic OBP ≥ 140 mmHg  ................. 72 
F.10  Crossover Procedures  ...................................................................................................... 73 
SPYRAL PIVOTAL - SPYRAL HTN -OFF MED Clinical Investigation Plan  
  
 Version  12 .0 Page 10 of 139  
 
Medtronic Confidential  
  056-F275, v3 .0 Clinical Investigation Plan Template  
  F.11  Confirmatory Blood Draws to Assess Renal Function ...................................................... 76 
F.12  Drug testing for Emergency Room visit or Hospitalization for Elevated Blood Pressure . 77 
F.13  Data collection requirements  ............................................................................................ 77 
F.14  Role of sponsor’s representatives  .................................................................................... 85 
F.15  Source documents  ............................................................................................................ 85 
F.16  Adverse events and device deficiencies  .......................................................................... 85 
 Definition/classification  ........................................................................................... 85 
 Recording, reporting, and review of Adverse Events  ............................................. 88 
 Recording, reporting, and review of Device Deficiencies  ....................................... 89 
 Adverse Event Reporting Requirement s ................................................................ 90 
 Data Safety Monitoring Board and Clinical Events Committee  .............................. 93 
 Emergency contact details in case of serious AEs  ................................................ 93 
F.17  Subject accountability  ....................................................................................................... 93 
 Missed Follow -up Visits  .......................................................................................... 93 
 Unscheduled Follow -up Visits  ................................................................................ 93 
 Subject Withdrawal or Lost To Follow -up ............................................................... 94 
 Subject Exit From Study  ......................................................................................... 94 
F.18  Study deviations and CIP changes ................................................................................... 95 
 Request for approval of study deviations  ............................................................... 95 
 Reporting requirements for study deviations .......................................................... 96 
 Amendments to the Clinical Investigation Plan  ...................................................... 97 
G QUALITY CONTROL PROCEDURES  ..................................................................... 97 
G.1 Procedures for database management  ............................................................................ 97 
 Data collection  ........................................................................................................ 97 
 Source data to be directly recorded on the Case Report Forms ............................ 98 
 Time windows for completion and submission of Case Report Forms  .................. 98 
 Data review and proc essing  ................................................................................... 98 
G.2 Monitoring procedures  ...................................................................................................... 98 
SPYRAL PIVOTAL - SPYRAL HTN -OFF MED Clinical Investigation Plan  
  
 Version  12 .0 Page 11 of 139  
 
Medtronic Confidential  
  056-F275, v3 .0 Clinical Investigation Plan Template  
  
 Accessibility of investigational site staff and study materials  ................................. 99 
 Audits and investigation site inspections  ................................................................ 99 
G.3 Study suspension or early termination  ............................................................................. 99 
 Early study suspension or termination  ................................................................. 100 
 Early investigation site suspension or termination  ............................................... 100 
 Procedures for planned study closure, termination or suspension  ...................... 100 
 Criteria for unblinding  ........................................................................................... 101 
G.4 Study close out  ............................................................................................................... 102 
H DATA ANALYSIS AND REPORTING  ................................................................... 102  
H.1 Analysis of clinical data  .................................................................................................. 102 
 Analysis Sets ........................................................................................................ 102 
H.2 Primary Safety Objective  ................................................................................................ 103 
H.3 Secondary Safety Objectives  ......................................................................................... 105 
 Renal Artery Stenosis Evaluation at 12 Months  ................................................... 106 
H.4 Primary Efficacy Objective  .............................................................................................. 106 
H.5 Secondary Efficacy Objective ......................................................................................... 107 
 Simulation of Primary and Secondary Efficacy Endpoint Operating Characteristics
 108 
H.6 Other Secondary Efficacy Endpoints  .............................................................................. 109 
H.7 Additional Objectives  ...................................................................................................... 110 
H.8 Safety Evaluation  ............................................................................................................ 110 
H.9 Subgroup Analyses  ........................................................................................................ 111 
H.10  Publication Policy ............................................................................................................ 111 
I STUDY MANAGEMENT  ........................................................................................ 112  
I.1 Study staff ....................................................................................................................... 112 
I.2 Advisory committees  ...................................................................................................... 112 
 Executive Steering Committee  ............................................................................. 112 
 Data Safety Monitoring Board (DSMB)  ................................................................ 113 
SPYRAL PIVOTAL - SPYRAL HTN -OFF MED Clinical Investigation Plan  
  
 Version  12 .0 Page 12 of 139  
 
Medtronic Confidential  
  056-F275, v3 .0 Clinical Investigation Plan Template  
  
 Clinical Events Committee (CEC)  ........................................................................ 113 
 Publications Review Committee  ........................................................................... 113 
I.3 Records and reports  ....................................................................................................... 114 
 Investigator records  .............................................................................................. 114 
 Investigator reporting responsibilities  ................................................................... 115 
 Sponsor records  ................................................................................................... 116 
 Spon sor reporting responsibilities  ........................................................................ 117 
 Record retention  ................................................................................................... 118 
I.4 Miscellaneous  ................................................................................................................. 119 
 Insurance  .............................................................................................................. 119 
 Subject compensation and indemnification  .......................................................... 119 
 Subject confidentiality  ........................................................................................... 119 
J RISKS AND BENEFITS  ......................................................................................... 120  
J.1 Anticipated Clinical Benefits  ........................................................................................... 120 
J.2 Risks ............................................................................................................................... 121 
J.3 Minimization of Risk  ........................................................................................................ 124 
J.4 Risk-to-Benefit Rationale  ................................................................................................ 125 
K REFERENCES  ....................................................................................................... 126  
L APPENDICES  ........................................................................................................ 130  
L.1 Names and addresses  .................................................................................................... 130 
 List of contact persons  ......................................................................................... 130 
 List of participating investigational sites and investigators ................................... 132 
L.2 Case Report Forms  ........................................................................................................ 132 
L.3 Sample Investigator Agreement  ..................................................................................... 132 
L.4 Abbreviations  .................................................................................................................. 133 
L.5 Definitions  ....................................................................................................................... 134 
L.6 Center for Medicare and Medicaid Services (CMS) IDE Study Criteria  ......................... 135 
L.7 Blood Pressure Measurement Procedures  .................................................................... 135 
SPYRAL PIVOTAL - SPYRAL HTN -OFF MED Clinical Investigation Plan  
  
 Version  12 .0 Page 13 of 139  
 
Medtronic Confidential  
  056-F275, v3 .0 Clinical Investigation Plan Template  
  L.8 Sample Patient Information and Informed Consent Form .............................................. 139 
L.9 Subject Blinding Assessment  ......................................................................................... 139 
L.10  EQ-5D (Quality of Life) Survey  ....................................................................................... 139 
L.11  SF-36 (Quality of Life) Survey  ........................................................................................ 139 
L.12  ABPM Guidelines ............................................................................................................ 139 
L.13  Serious or Unanticipated Adverse Event Report (Rush form) - Japan only  .................... 139 
L.14  Angiographic Core Laboratory Guidelines  ..................................................................... 139 
L.15  Renal Duplex Ultrasound (DUS) Core Laboratory Guidelines  ....................................... 139 
L.16  Magnetic Resonance Angiography (MRI)/Computerized Tomography (CT) Core 
Laboratory Guidelines  .................................................................................................... 139 
L.17  Blood Core Laboratory Guidelines  ................................................................................. 139 
L.18  Drug Testing Core Laboratory Guidelines  ...................................................................... 139 
 
 
 
 
 
SPYRAL PIVOTAL - SPYRAL HTN -OFF MED Clinical Investigation Plan  
  
 Version  12 .0 Page 14 of 139  
 
Medtronic Confidential  
  056-F275, v3 .0 Clinical Investigation Plan Template  
  
A SYNOPSIS 
Title 
Global Clinical Study  of Renal Denervation with the Symplicity Spyral™i multi- elect rode renal 
denervation system in Patients with  Uncontrolled Hypertension in the Absence of 
Antihypertensive Medications . 
Purpose  
The purpose of this study  is to test the hypothesis that renal denervation decreases blood 
pressure and is safe when studied in the absence of antihypertensive medications.  
Design  
Multi- center, international,  prospective, single blinded, 1:1 randomized, interventional, sham -
controlled study . 
Medical device/product  
The Symplicity Spyral™ multi-electrode renal denervation catheter (Symplicity SpyralTM 
catheter) and the Symplicity G3TM renal denervation RF generator (Symplicity G3TM generator) 
will be used in this clinical study . These components of the SymplicityTM renal denervation 
system are investigational in the United States, Canada and Japan (referred to as MDT- 2115). 
Both the Symplicity Spyral™ catheter and Symplicity G3TM generator are commercially 
available in Australia and countries where CE -mark applies.  Additional geographies may be 
added to the clinical study and the approval  status will be documented under a separate cover.  
Objective  
The objective of this study  is to test the hypothesis that renal denervation is  safe and reduces 
systolic blood pressure  (SBP)  in patients with uncontrolled hypertension compared to a sham -
controlled population, in the absence of antihypertensive medications.  In this study,  
“uncontrolled hypertension” is defined as an office  systolic blood pressure (SBP) ≥ 150 mmHg 
and <180 mmHg, an office Diastolic Blood Pressure (DBP)  ≥90 mmHg and a 24- hour 
Ambulatory Blood Pressure Monitoring (ABPM) average SBP ≥140 mmHg to <170 mmHg, all  
of which are measured at Screening Visit 2 (per Appendix L7) . Data obtained without the 
confounding presence of antihypertensive medications will be used to confirm the effect of 
renal denervation on elevated blood pressure. The data collected in this study will be used to 
support regulatory submissions around the world to obtain market approval for the Symplicity 
Spyral™ multi -electrode renal denervation catheter (Symplicity SpyralTM catheter) and the 
Symplicity G3TM renal denervation RF generator, from regulatory entities,  including, but not 
limited to : the Pharmaceuticals and Medical Devices Agency (PMDA), Health Canada, and 
the U.S. Food and Drug Administration (FDA).  
  
 
 
i Trademarks may be registered and are the property of their respective owners.  
SPYRAL PIVOTAL - SPYRAL HTN -OFF MED Clinical Investigation Plan  
  
 Version  12 .0 Page 15 of 139  
 
Medtronic Confidential  
  056-F275, v3 .0 Clinical Investigation Plan Template  
  Primary Endpoints  
There are two primary endpoints  in this study (one safety and one efficacy) . The study will be 
considered successful if both the primary safety and efficacy endpoint hypotheses  are met.  
 
Powered Primary Safety Endpoint  
• Incidence of Major Adverse Events (MAE), defined as a composite of the following 
events, through one -month post -randomization (6 months for new renal artery 
stenosis)  
− All-cause mortality  
− End Stage Renal Disease (ESRD)  
− Significant embolic event resulting in end- organ damage  
− Renal artery perforation requiring intervention  
− Renal artery dissection requiring intervention 
− Vascular complications  
− Hospitalization for hypertensive crisis not related to confirmed non -
adherence with medications or the protocol  
− New renal artery stenosis > 70%, confirmed by angiography and as determined by the angiographic core laboratory  
Powered Primary Efficacy Endpoint  
• Baseline adjusted change (using Analysis of Covariance) in systolic blood pressure 
(SBP) from baseline (Screening Visit 2) to 3 months post -procedure as measured 
by 24- hour Ambulatory Blood Pressure Monitoring (ABPM). 
Secondary Endpoints  
Power ed Secondary  Efficacy Endpoint  
• Baseline adjusted change ( using Analysis of Covariance)  in office systolic b lood 
pressure from baseline (Screening Visit 2) to 3 months post -procedure.  
Secondary  Safety  Endpoints  
• Acute/Procedural Safety Secondary Endpoints – Compared Between Groups at 1 
Month Post -Procedure:  
− Significant embolic event resulting in end-organ damage  
− Renal artery perforation requiring intervention  
− Renal artery dissection requiring intervention 
− Vascular complications  
− End-Stage Renal Disease 
− ≥40% decline in eGFR  
− New Myocardial Infarction 
SPYRAL PIVOTAL - SPYRAL HTN -OFF MED Clinical Investigation Plan  
  
 Version  12 .0 Page 16 of 139  
 
Medtronic Confidential  
  056-F275, v3 .0 Clinical Investigation Plan Template  
  − New Stroke  
− Renal artery re-intervention 
− Major bleeding according to TIMI definition (i.e. intracranial hemorrhage, 
≥5g/dl decrease in hemoglobin concentration, a ≥15% absolute decrease in hematocrit, or death due to bleeding within 7 days of the procedure)  
− Increase in serum creatinine > 50% from Screening Visit 2  
− New renal artery stenosis > 70%, confirmed by angiography and as determined by the angiographic core laboratory  
− Hospitalization for hypertensive crisis not related to confirmed non -
adherence with medications or the protoc ol  
• Chronic Safety Secondary Endpoints – Compared Between Groups at 3, 6, 12, 24, 
and 36 Months Post - Randomization:  
− All-cause mortalit y 
− End-Stage Renal Disease 
− ≥40% decline in eGFR  
− New Myocardial Infarction 
− New Stroke  
− Renal artery re- intervention 
− Major bleeding according to TIMI definition (i.e. intracranial hemorrhage, ≥5g/dl decrease in hemoglobin concentration, a ≥15% absolute decrease 
in hematocrit, or death due to bleeding within 7 days of the procedure)  
− Increase in serum creatinine > 50% from Screeni ng Visit 2  
− New Renal artery stenosis >70%, confirmed by angiography  and as 
determined by the angiographic core laboratory  
− Hospitalization for hypertensive crisis not related to confirmed non -
adherence with medications or the protocol   
• Secondary Efficacy Endpoints – Compared Between Groups  
− Change in systolic blood pressure (SBP) from baseline (Screening Visit 2) 
as measured by 24 -hour Ambulatory Blood Pressure Monitoring (ABPM) at 
3, 6, 12, 24 and 36 months post -procedure.  
− Change in office systolic blood pressure from baseline (Screening Visit 2) at 1, 3, 6, 12, 24 and 36 months post -procedure.  
− Incidence of achieving target office systolic blood pressure (SBP <140 mmHg) at 1, 3, 6, 12, 24 and 36 months post -procedure.  
− Change in office diastolic blood pressure from baseline (Screening Visit 2) at 1, 3, 6, 12, 24 and 36 months post -procedure.  
− Change in diastolic blood pressure from baseline (Screening Visit 2) as measured by 24- hour Ambulatory Blood Pressure Monitoring (ABPM) at 3, 
6, 12, 24 and 36 months post -procedure.  
SPYRAL PIVOTAL - SPYRAL HTN -OFF MED Clinical Investigation Plan  
  
 Version  12 .0 Page 17 of 139  
 
Medtronic Confidential  
  056-F275, v3 .0 Clinical Investigation Plan Template  
  • Summary of Quality of Life (QOL) Measures (EQ5D and SF36)  
Additional analyses  
The following additional analyses will be conducted:  
• Antihypertensive medication usage throughout the study, including escape 
subjects prior to 3 -months and subjects  reintroduced to medications  after 3 
months  
• Additional procedural characteristics e.g. treatment duration, frequency of distal 
renal artery treatment, ablations per vessel, location of ablations, number of ablations per patient and other characteristics will be analyzed to assess  their 
impact on blood pressure. 
Subject population  
Patients with  uncontrolled hypertension will be enrolled in accordance with the Inclusion and 
Exclusion criteria specified in the protocol. Approximately 1800 subjects will be screened in 
order to randomize a total of approximately 433  subjects ; this includes up to 80 subjects used 
as an informative prior (see Section C.6).  The study will be conducted at  up to 50 study  
centers in the United States, Japan , Australia , Canada and countries where CE mark applies. 
Additional geographies may be added to the clinical study at a later date and the approval 
status will be documented under a separate cover.  Enrollment  is expected to take 
approximately 33 months. Subjects may participate in the study  from the time of signing 
consent until completion of three  years of follow -up after procedure as described in Table 1 
through  Table 3. Control (sham) subjects may be offered renal denervation therapy 
(crossover) after their -6 month follow -up visit and will be followed -up for two years, according 
to  Table 2. 
Screening Criteria  
Eligible patients will be screened for participation into the study  if they are aged between  20-
80 years, have a diagnos is of hypertension, and whom, in the judgment of the investigator, 
will have a blood pressure within the range required for randomization (ABPM SBP ≥140 
mmHg  and <170 mmHg , office SBP ≥ 150 mmHg  and <180 mmHg  and office DBP ≥90 mmHg  
measured according to guidelines in Appendix L.7) in the absence of antihypertensive 
medications or following antihypertensive medication withdrawal. 
Inclusion criteria  
1. Individual is ≥ 20 and ≤ 80 years old at time of enrollment  (consent) . 
2. Individual has an office systolic blood pressure (SBP) ≥ 150 mmHg  and <180 mmHg  
and an office DBP ≥90 mmHg  measured at Screening Visit 2, according to the 
guidelines in Appendix L.7. 
3. Individual has a 24 -hour Ambulatory Blood Pressure Monitoring (ABPM) average  
SBP ≥140 mmHg  and <170 mmHg  measured at Screening Visit 2  according to 
guidelines in Appendix L.7: ABPM is considered valid if the number of successful 
daytime readings captured is ≥ 21 and the number of successful nighttime readings 
captured is ≥ 12.  
SPYRAL PIVOTAL - SPYRAL HTN -OFF MED Clinical Investigation Plan  
  
 Version  12 .0 Page 18 of 139  
 
Medtronic Confidential  
  056-F275, v3 .0 Clinical Investigation Plan Template  
  4. Individual agrees to have all study procedures performed, and is competent and 
willing to provide written, informed consent to participate in this clinical study .  
5. Individual is willing to discontinue current antihypertensive medications at Screening Visit 1 through the three- month post -procedure visit.  
Exclusion criteria  
1. Individual has one or more of the following conditions:  stable or unstable angina 
within 3 months of enrollment, myocardial infarction within 3 months  of enrollment ; 
heart failure, cerebrovascular accident or transient ischemic attack, or atrial fibrillation  at any time . Patients are permitted to take aspirin or clopidogrel for 
cardiovascular risk reduction. Patients who received catheter or surgical treatment 
for Atrial Fibrillation and are in sinus rhythm are not excluded.  
2. Individual has undergone prior renal denervation. 
3. Individual has renal artery anatomy that is ineligible for treatment including:  
a. Main renal artery for each kidney less than 3mm or greater than 8mm  
b. Lacks a main renal arterial vessel (greater than 3mm and less than 8mm in diameter)  for each kidney that  does not allow 4 simultaneous  quadrantic 
(4SQ) radio frequency ablations in the main renal artery or equivalent 
(defined as 4SQ ablations in all branch vessels greater than 3mm and less 
than 8mm)  
4. Presence of FMD (defined as visible beading of the artery on angiography) . 
5. Has >50% stenosis in any treatable vessel. 
6. Has a renal artery stent placed <3 months prior to the denervation procedure. 
7. Presence of an aneurysm defined as any localized increase in the diameter of the 
vessel. 
8. Treatment area within 5mm of a s egment in the renal artery which contains any of 
the following:  
a. Atheroma,  
b. Calcification, or 
c. Renal artery stent  
9. Individual has an estimated glomerular filtration rate (eGFR) of < 45 mL/min/1.73m2, 
using the 4 variable  MDRD calculation  (in mL/min per 1.73 m2 = 175 x SerumCr-1.154 
x age-0.203 x 1.212 (if patient is black) x 0.742 (if female)).  (Note: an eGFR calculation 
specific to Japanese patients will be used for subjects enrolled in Japan) . 
10. Individual has documented type 1 diabetes mellitus or poorly -controlled type 2 
diabetes mellitus with glycosylated hemoglobin greater than 8.0% . 
11. Individual is taking SGLT2 inhibitors or GLP -1 agonists  that have been prescribed < 
90 days prior to Screening Visit 1 or who does not plan to r emain on these drugs for 
the duration of the trial.  
12. Individual has had ≥1 episode(s) of  orthostatic hypotension not related to medication 
changes  within the past year or has a reduction of SBP of ≥20 mmHg  or DBP of ≥10 
mmHg  within 3 minutes of standing coupled with symptoms during the screening 
process  (at SV2) . 
SPYRAL PIVOTAL - SPYRAL HTN -OFF MED Clinical Investigation Plan  
  
 Version  12 .0 Page 19 of 139  
 
Medtronic Confidential  
  056-F275, v3 .0 Clinical Investigation Plan Template  
  13. Individual requires chronic oxygen support or mechanical ventilation other than 
nocturnal respiratory support for sleep apnea (e.g. CPAP, BiPAP) . 
14. Individual who requires more than occasional use (e.g. PRN) of narcotic drugs over 
the month prior to Screening Visit 1.  
15. Individual has documented primary pulmonary hypertension.  
16. Individual has an untreated secondary cause of hypertension (either known or 
suspected) or is t aking drugs that increase sympathetic tone that could contribute to 
hypertension .  
17. Individual has frequent intermittent or chronic pain that results in treatment with non-
steroidal anti -inflammatory  drugs (NSAIDs)  for two or more days per week over the 
month prior to Screening Visit 2. 
18. Individual with HIV on anti- retroviral drug therapy without documentation that 
hypertension preceded initiation of anti -retroviral drug treatment.  
19. Individual has a scheduled or planned surgery that, in the opinion of the Investigator, 
may affect study  endpoints.  
20. Individual has a documented condition that would prohibit or interfere with ability to obtain an accurate blood pressure measurement using the protocol -specified 
automatic /office  blood pressure monitor (e.g., upper arm circumference outside cuff 
size ranges available by geography or arrhythmia that interferes with automatic monitor’s pulse sensing and prohibits an accurate measurement) . 
21. Individual works night  shifts . 
22. Individual has severe cardiac valve stenosis for which, in the opinion of the 
investigator, a significant reduction of blood pressure is contraindicated.  
23. Individual has a documented confounding medical condition, which in the opinion of the investigator, may adversely affect the safety of the participant (e.g., patients with 
clinically significant peripheral vascular disease, aortic aneurysm, bleeding disorders 
such as thrombocytopenia, hemophilia, or significant anemia).  
24. Individual is pregnant, nursing or planning to become  pregnant  during the course of 
the study  follow- up. (Note: Pre-menopausal female participants must have a 
negative serum or urine human chorionic gonadotropin (hCG) pregnancy test prior 
to angiography ). 
25. Individual has a known unresolved history of drug use or alcohol dependency, lacks the ability to comprehend or follow instructions, or would be unlikely or unable, in the 
opinion of the investigator, to comply with study  follow- up requirements.  
26. Individual is currently enrolled in a concurrent investigational drug or device study , 
unless approved by the study sponsor . (Note: For the purpose of this protocol, 
participants involved in extended follow -up studies for products that were 
investigational but are currently commercially available are not considered enrolled in an investigational study ). 
SPYRAL PIVOTAL - SPYRAL HTN -OFF MED Clinical Investigation Plan  
  
 Version  12 .0 Page 20 of 139  
 
Medtronic Confidential  
  056-F275, v3 .0 Clinical Investigation Plan Template  
  27. Individual is currently taking anti-mineralocorticoid  drugs . (Note: Subjects may be 
enrolled as long as anti -mineralocorticoid drugs are weaned off at least 8 weeks p rior 
to Screening Visit 1).  
28. Individual has an active peptic ulcer or upper gastrointestinal (GI) bleeding within the 
prior six months  from consent . 
29. Individual has a history of bleeding diathesis or coagulopathy or will refuse blood transfusions . 
30. Individual has polycystic kidney disease, unilateral kidney,  atrophic kidney  or history 
of renal transplant . 
Treatment  
Following Screening Visit 1  (SV1) , eligible subjects will undergo a minimum of three and a 
maximum of four week s of an antihypertensive medication (anti-HTN meds) washout  period. 
If at any time the average of 3 seated office Blood Pressure (OBP) readings results in a SBP 
≥180 mmHg , the subject will be considered a screen failure and will be exited from the study,  
and anti -HTN meds  will be  restarted at the investigator ’s discretion .  
 
Subjects who continue to meet eligibility criteria will return for Screening Visit 2 (SV2) . Subjects 
who were not previously treated with anti-HTN meds  and subject s who had discontinued anti-
HTN meds for  minimum of four weeks prior to SV1 (considered drug naïve)  will also return for 
Screening Visit 2 within three to four weeks . Subjects who continue to meet eligibility criteria 
after completion of Screening Visit 2  and who have received randomization approval by the 
Sponsor  will be randomized.  
 The renal denervation or control procedure  will occur within  a maximum of two weeks  (14 
calendar days)  following completion of Screening Visit 2.  
 Following the renal denervation or control  procedure, subjects will be followed at 2, 4,  6, 8, 10  
weeks  and 3M  post-procedure.  
 At any time, if the subject’s office SBP  ≥180 mmHg as measured per protocol with a 
confirmatory BP measurement within 72 hours, the subject can  be put back on an anti- HTN 
medication regimen per the investigator’s discretion.   If possible, but at the discretion of the 
investigator , the subject will be asked to wear the 24h ABPM and have blood drawn for a 
Chem 7 panel , and antihypertensive drug testing,  and urine collected for antihypertensive drug 
testing, prior to being put back on medications. The subject will then be exited from the off -
medication portion of the study and will be followed according to instructions listed in Table 3. 
At the three  months  (90 days)  follow- up, after office and valid ambulatory blood pressure 
measurements are obtained, subjects will be reintroduced to standard medical therapy , if 
required,  according to Section F.9.  
 All subjects  will be followed annual ly through 36 months post procedure ( Table 1), except 
Crossover subjects.  Subjects and blinded study  personnel will be unblinded to the 
randomization assignment at 6 months. Control (sham) subjects may be offered renal 
denervation therapy (crossover) after their 6-month follow -up visit , according to Section F.10.  
Crossover subjects will return for office visits at 1, 3, 6, 12 and 24 months post -renal 
denervation procedure ( Table 2) .  
SPYRAL PIVOTAL - SPYRAL HTN -OFF MED Clinical Investigation Plan  
  
 Version  12 .0 Page 21 of 139  
 
Medtronic Confidential  
  056-F275, v3 .0 Clinical Investigation Plan Template  
  Interim Analyses  
Interim analyses will take place after 210 and 240 subjects  (excluding the first consecutively 
randomized 80 subjects in the SPYRAL HTN -OFF MED study)  have 3- month efficacy 
endpoint data available. T his will require randomizing approximately 247 and 282 subjects to 
account for attrition .  A decision to stop or continue the study  will be made after each interim 
analysis has been reviewed.  If the study does not stop at an interim analysis, randomization 
will continue to the maximum study size of N=300 evaluable subjects (requiring approximately 
353 randomized subjects to account for attrition).More details on the interim analyses can be 
found in the study Statistical Analysis Plan.  
 
Time Course  
Start of enrollment (consent): June  2015  
Planned completion of randomization: November 2019 
Planned study  close- out:  April 2023  
  
SPYRAL PIVOTAL - SPYRAL HTN -OFF MED Clinical Investigation Plan  
  
 Version  12 .0 Page 22 of 139  
 
Medtronic Confidential  
  056-F275, v3 .0 Clinical Investigation Plan Template  
  Clinical Procedures  
Table 1: Schedule of Testing for All Subjects (See Table 2 for Crossover Subjects’ Testing)  
3 Months  (90 days) : 76-104 days  - 4 Months  (120 days) :113 -127 days - 6 Months  (180 days) : 
166-194 days  - 12 Months  (360 days) : 330 -390 days - 24 Months  (720 days) : 690 -750 days - 36 
Months  (1080 days) : 1050 -1110 days  
   Post-Procedure 
(Wk= ± 3 days) (M=months ± 14 days for 3M and 6M visits;  ±7 days for 4M visit;  ± 30 
days for 12M -36M visits)  
Required 
Assessments  SV1 3 Wk 
Washout 
(minimum)  
with 
screening 
visit at Wk 
2 (see next 
column)  2 Wk visit 
(Screening)  
± 3 days  SV2 
(within 
3-4 wk 
of 
SV1)  Procedure Prior to 
Discharge 2 
Wk 4 
Wk 6 
Wk 8 
Wk 10 
Wk  
3M 
  
 
4M 
visit for 
BP≥140 
mmHg at 3M 
(± 7 days)  6M 12M  24M  36M  
Medical History  X 
                
Clinical assessment   X X   X X X3 X X3 X X X X X X 
Medications  
prescribed  according  
to section  F.9 if SBP 
≥ 140 mmHg            X X     
Witnessed pill intake 
(if subject is taking 
antihypertensive 
medications), Complete after OBP measurements.             X X X X 
Renal Denervation or 
Sham Procedure     X             
SPYRAL PIVOTAL - SPYRAL HTN -OFF MED Clinical Investigation Plan  
 
  Version  12 .0 Page 23 of 139  
 
Medtronic Confidential  
  056-F275, v3 .0 Clinical Investigation Plan Template  
  3 Months  (90 days) : 76-104 days  - 4 Months  (120 days) :113 -127 days - 6 Months  (180 days) : 
166-194 days  - 12 Months  (360 days) : 330 -390 days - 24 Months  (720 days) : 690 -750 days - 36 
Months  (1080 days) : 1050- 1110 days  
   Post-Procedure 
(Wk= ± 3 days) (M=months ± 14 days for 3M and 6M visits;  ±7 days for 4M visit;  ± 30 
days for 12M -36M visits)  
Required 
Assessments  SV1 3 Wk 
Washout 
(minimum)  
with 
screening 
visit at Wk 
2 (see next 
column)  2 Wk visit 
(Screening)  
± 3 days  SV2 
(within 
3-4 wk 
of 
SV1)  Procedure Prior to 
Discharge 2 
Wk 4 
Wk 6 
Wk 8 
Wk 10 
Wk  
3M 
  
 
4M 
visit for 
BP≥140 
mmHg at 3M 
(± 7 days)  6M 12M  24M  36M  
Office Blood 
Pressure according to 
guidelines in Appendix L.7  X X X  X X X X3 X X3 X X X X X X 
24-Hour  ABPM 
according  to 
guidelines in Appendix L.7    
X        X  X X X X 
Blood Test s (uric 
acid, lipid panel and 
high- sensitivity CRP 
(hs-CRP )7   
X              
Blood Tests (Chem -
7) 4   X  X  X    X  X X X X 
Blood Tests (renin 
and aldosterone)    X        X      
Serum or Urine 
Pregnancy Test    
X              
Drug testing    X        X X X X X X 
SPYRAL PIVOTAL - SPYRAL HTN -OFF MED Clinical Investigation Plan  
 
  Version  12 .0 Page 24 of 139  
 
Medtronic Confidential  
  056-F275, v3 .0 Clinical Investigation Plan Template  
  3 Months  (90 days) : 76-104 days  - 4 Months  (120 days) :113 -127 days - 6 Months  (180 days) : 
166-194 days  - 12 Months  (360 days) : 330 -390 days - 24 Months  (720 days) : 690 -750 days - 36 
Months  (1080 days) : 1050- 1110 days  
   Post-Procedure 
(Wk= ± 3 days) (M=months ± 14 days for 3M and 6M visits;  ±7 days for 4M visit;  ± 30 
days for 12M -36M visits)  
Required 
Assessments  SV1 3 Wk 
Washout 
(minimum)  
with 
screening 
visit at Wk 
2 (see next 
column)  2 Wk visit 
(Screening)  
± 3 days  SV2 
(within 
3-4 wk 
of 
SV1)  Procedure Prior to 
Discharge 2 
Wk 4 
Wk 6 
Wk 8 
Wk 10 
Wk  
3M 
  
 
4M 
visit for 
BP≥140 
mmHg at 3M 
(± 7 days)  6M 12M  24M  36M  
Renal Artery 
Imaging - 
Angiogram    
 X             
Renal Artery 
Imaging    
X5          X1 X6 (X)6 (X)6 
Blinding Assessment      X      X  X    
EQ-5D and SF -36   X        X  X X X X 
Mortality 
Assessment2   
   X X  X  X  X X X X 
Medication Review, 
Event Review  All adverse events (AE) and medication review   
After 12 months, previously reported AEs will need to be reviewed and updated as needed . Serious AE and 
all medication 
review   
1 DUS required as first line imaging modality at 6M. Repeat DUS, MRA , CT, or angiogram to be used if DUS is nondiagnostic . Renal angiogr aphy must be used if  repeat  DUS/CTA/MRA is nondiagnostic or stenosis >60 -70% is suspected.  
The 6M DUS w ill not be required for subjects crossing over at 6M  visit. 
2 Conduct if follow -up missed.  
3 If medically necessary, phone contact may be replaced with office visit. Office blood pressure (according to guidelines in Appendix L.7 ), only needs to be obtained if an office visit occurs.   
4 Bicarbonate will not be measured for subjects enrolled in Japa n and Europe . 
5 Submit baseline duplex ultrasound , CT, or MRA  if obtained per standard of care  within one year from the date of Screening Visit 1 6 DUS/ CTA/MRA  required as first line imaging modality at 12M (and 24M and 36M as applicable).  Repeat 
DUS, MRA, or CTA to be used if prior imaging modality is nondiagnostic. If repeat DUS/CTA/MRA is nondiagnostic or evidence of a cl inically significant stenosis (>60 -70%) is indicated, an angiogram must be obtained and submitted to 
the Angiographic Core Laborato ry.  Subjects who have already completed their 12 -month without renal imaging will be required to undergo renal imaging at their next scheduled follow -up unless they have a renal angiogram due to crossover. 
For participating sites in Germany and the UK, on ly DUS or renal MRA imaging at the 12 -month follow -up visit (or 24 or 36M follow -up as applicable) will be performed. For these countries, if the initial DUS or initial renal MRA is non -
SPYRAL PIVOTAL - SPYRAL HTN -OFF MED Clinical Investigation Plan  
 
  Version  12 .0 Page 25 of 139  
 
Medtronic Confidential  
  056-F275, v3 .0 Clinical Investigation Plan Template  
  diagnostic, a repeat DUS or repeat renal MRA should be performed. If t he initial imaging modality or subsequent repeat(s) are non -diagnostic, the investigator should choose the repeat imaging modality (DUS or MRA) that is expected to 
yield the required information for a diagnostic study.  
7 High -sensitivity CRP is not require d to be measured for subjects enrolled at sites where high -sensitivity CRP test cannot be locally performed . 
Table 2: Schedule of Testing for Crossover Subjects   
1 Month: 14 – 44 days  
3 Months: 76- 104 days - 6 Months: 166 -194 days  - 12 Months: 330- 390 days  - 24 Months: 
690-750 days  Post-Procedure 
 (M=months ± 14 days for 3M and  6M visits; ± 30 days for 12M -24M visits)  
Required Assessments   
Baseline  Renal 
Denervation  Prior to 
Discharge 1M 3M 6M 12M  24M  
Clinical assessment  X   X X X X X 
Blood Tests (Chem -7)*** X  X X X X X X 
Blood Test s (uric acid , lipid panel and high-
sensitivity CRP (hs -CRP) )******  X (prior to 
procedure )*****        
Office Blood Pressure  according to 
guidelines in Appendix L.7  X 
 X X X X X X 
Witnessed pill intake (if subject is taking 
antihypertensive medications), Complete 
after OBP measurements. X 
   X X X X 
Serum or Urine Pregnancy Test   X (prior to 
procedure)        
24-Hour ABPM according to guidelines in 
Appendix L.7  X 
   X X X X 
EQ-5D and SF -36     X X X X 
Renal Denervation   X       
SPYRAL PIVOTAL - SPYRAL HTN -OFF MED Clinical Investigation Plan  
 
  Version  12 .0 Page 26 of 139  
 
Medtronic Confidential  
  056-F275, v3 .0 Clinical Investigation Plan Template  
  1 Month: 14 – 44 days  
3 Months: 76- 104 days - 6 Months: 166 -194 days  - 12 Months: 330- 390 days  - 24 Months: 
690-750 days  Post-Procedure 
 (M=months ± 14 days for 3M and  6M visits; ± 30 days for 12M -24M visits)  
Required Assessments   
Baseline  Renal 
Denervation  Prior to 
Discharge 1M 3M 6M 12M  24M  
Drug Testing  X    X X X X 
Renal Artery Imaging - Angiogram   X       
Renal Artery Imaging       X* X**** X**** 
Mortality Assessment**     X X X X X 
Medication Review, Event Review  All adverse events (AE) and medication review  
After 12 months, previously reported AEs will need to be reviewed and updated as needed  Serious AE and all 
medication review  
  * DUS required as first line imaging modality at 6M. Repeat DUS, MRA, CT or angiogram to be used if DUS is non-diagnostic . Renal angiogr aphyy must be used if repeat DUS/CTA/MRA is nondiagnostic or 
stenosis >60 -70% is suspected.  
  ** Conduct if follow -up visit missed  
  *** Bicarbonate will not be measured for subjects enrolled in Japan  and Europe  
**** DUS/ CTA/MR A  required as first line imaging modality at 12M (and 24M as applicable).  Repeat DUS, MRA, or CTA to be used if prior imaging modality is nondiagnostic. If repeat DUS/CTA/MRA is nondiagnostic or evid ence of a 
clinically significant stenosis (>60 -70%) is i ndicated, an angiogram must be obtained and submitted to the Angiographic Core Laboratory.  Subjects who have already complet ed their 12 -month without renal imaging will be required to 
undergo renal imaging at their next scheduled follow -up unless . For participating sites in Germany and the UK, only DUS or renal MRA imaging at the 12 -month follow -up visit (or 24 M follow -up as applicable) will be performed. For these 
countries, if the initial DUS or initial renal MRA is non -diagnostic, a repeat DUS or rep eat renal MRA should be performed. If the initial imaging modality or subsequent repeat(s) are non -diagnostic, the investigator should choose the repeat 
imaging modality (DUS or MRA) that is expected to yield the required information for a diagnostic study .*****If not already collected at SV2  
******  High -sensitivity CRP is not required to be measured for subjects enrolled at sites where high -sensitivity CRP test cannot be locally performed  
 
  
SPYRAL PIVOTAL - SPYRAL HTN -OFF MED Clinical Investigation Plan  
 
  Version  12 .0 Page 27 of 139  
 
Medtronic Confidential  
  056-F275, v3 .0 Clinical Investigation Plan Template  
  Table 3: Schedule of Testing through 36 M onths for Subjects with office SBP ≥180 mmHg (confirmed via 2 sets of measurements) or Escape via 
Investigator Discretion during Off -Medication Period Post -randomization 
3 Months: 76- 104 days - 6 Months: 166- 194 days - 12 Months: 
330-390 days  - 24 Months: 690- 750 days  - 36 Months: 1050-
1110 days  Post-Procedure 
 (Wk= ± 3 days, M=months ± 14 days for 3M and 6M visits; ± 30 days for 12M -36M visits)  
Required Assessments   
Prior to Discharge  2Wk 4Wk 6Wk 8Wk 10Wk  3M 6M 12M  24M  36M  
Office Blood Pressure according to 
guidelines in Appendix L.7  X X X X X X X X X X X 
Renal Artery Imaging         X1 X3 (X)3 (X)3 
Mortality Assessment2  X X X X X X X X X X 
Medication Review, Event Review  All adverse events (AE) and medication review  
 
 After 12 months, previously reported AEs will need to be reviewed and updated as needed  
 Serious AE and all medication 
review  
1 DUS required as first line imaging modality at 6M. Repeat DUS, MRA, CT, or angiogram to be used if DUS is nondiagnostic.  Renal angiography must be used if repeat DUS/CTA/MRA is nondiagnostic or stenosis 
>60-70% is suspected.  
2 Conduct if follow -up visit missed   
3 DUS/ CTA/MRA  required as first line imaging modality at 12M (and 24M and 36M as applicable).  Repeat DUS, MRA, or CTA to be used if prior imaging modality is nondiagnostic. If repeat DUS/CTA/MRA is nondiagnostic or 
evidence of a clinically significant stenosis (>60 -70%) is indicated, an angiogram must be obtained and submitted to the Angiographic Core Laboratory.  Subjects who have alread y completed their 12 -month without renal imaging will be 
required to undergo renal imaging at their next scheduled follow -up. For participating sites in Germany and the UK, only DUS or renal MRA imaging at the 12 -month follow -up visit (or 24 or 36M follow -up as applicable) will be 
performed. For these countries, if the initial DUS or initial renal MRA is non -diagnostic, a repeat DUS or repeat renal MRA should be performed. If the initial imaging modality or subsequent repeat(s) are  non-diagnostic, the investigator 
should choose the repeat imaging modality (DUS or MRA) that is expected to yield the required information for a diagnostic study.
SPYRAL PIVOTAL - SPYRAL HTN -OFF MED Clinical Investigation Plan  
  
 Version  12 .0 Page 28 of 139  
 
Medtronic Confidential  
  056-F275, v3 .0 Clinical Investigation Plan Template  
  
B GENERAL INFORMATION 
B.1 Introduction  
Chronic activation of the sympathetic nervous system (SNS) has been identified by preclinical 
and clinical literature as a common and key factor in disease states such as hypertension, 
heart failure, and chronic kidney disease1,2,3. The renal sympathetic nerves are a major 
contributor to the complex pathophysiology of elevated SNS activity and hypertension.  
Therapeutic renal denervation, the deliberate disruption of the sympathetic nerves connecting 
the kidneys with the central nervous system, has been shown to be an effective means of 
modulating elevated SNS activity - both by reducing the sympathetic control of renal function 
(renin release, sodium excretion and renal blood flow) and by removing the renal afferent 
sympathetic contribution to central sympathetic elevation4. It is important to note that the 
kidneys maintain appropriate electrolyte and volume homeostasis, despite being denervated, as demonstrated by the human kidney transplant experience
5. Prior to pharmacological 
treatment, hypertension was sometimes treated in man with complex invasive procedures, 
such as surgical nephrectomy and even radical surgical sympathectomy.  
Medtronic has developed a radiofrequency catheter with multiple electrodes, as a minimally 
invasive means of achieving renal sympathetic denervation. Bilateral renal denervation will be 
performed using a percutaneous, catheter- based system that delivers radiofrequency (RF) 
energy through the luminal surface of each renal artery at four locations simultaneously. In 
comparison to the previous single- electrode Symplicity™  renal denervation system, the multi -
electrode catheter provides the physician with a pre- defined and consistent ablation pattern 
that is intended to improve the accuracy of treatment. The RF energy may be delivered to up to 4 electrodes simultaneously, allowing for a single treatment  in each renal artery  and thus 
reduces the total procedure time compared to the single -electrode Symplicity renal 
denervation system. If the physician elects to complete multiple treatments in one artery, 
subsequent treatments are easily accommodated by re -positioning the cath eter proximally (at 
least 5 mm) and de -selecting electrodes via the graphical user interface on the Symplicity G3  
generator. With reduced procedure time, the patient is potentially exposed to less radiation 
and radiopaque contrast injections. The electrode s are mounted on to a self -expanding Nitinol 
shaft that takes a spiral configuration allowing electrode contact with the vessel wall. An evaluation of the results of pre- clinical ( in-vivo ) and in-vitro testing supporting the use of the 
Symplicity Spyral ca theter and Symplicity G3 generator as investigational devices in human 
subjects is included in the Investigator’s Brochure.  Medtronic has performed a comprehensive 
set of bench testing and preclinical studies that have shown that this manner of low -power 
ablation produces distinct, focal, sterile lesions that subsequently heal, resulting in no clinically 
relevant long -term sequelae to either the vessel or the kidney.  
 Clinical Experience  Using the Single Electrode RF renal denervation system  
SYMPLICITY HTN -1 and SYMPLICITY HTN -2 
Initial human studies of patients with resistant hypertension have demonstrated that the 
SymplicityTM renal denervation (RDN) system can safely denervate the kidney and that renal 
denervation has resulted in significant and sustained reductions of blood pressure out to three years
6,7. SYMPLICITY HTN -1 utilized the SymplicityTM renal denervation system  (which 
SPYRAL PIVOTAL - SPYRAL HTN -OFF MED Clinical Investigation Plan  
  
 Version  12 .0 Page 29 of 139  
 
Medtronic Confidential  
  056-F275, v3 .0 Clinical Investigation Plan Template  
  
included the single electrode catheter design)  for treating patients with resistant hypertension. 
A total of 153 resistant hypertension patients with baseline office  systolic blood pressure (SBP)  
≥160 mmHg  on ≥3 antihypertensive medications  were treated. At the primary endpoint, 6 
months post -denervat ion, the investigators reported a -22/-10 mmHg  change in office SBP. 
Blood pressure reductions at 12, 24, and 36 months were -27/-14 mmHg , -29/-14 mmHg , and 
-32/-14 mmHg , respectively. There were no unanticipated adverse device effects or serious 
device- related or procedure- related complications. Through the 36-month follow -up, there 
were  no late serious adverse events and no clinically significant changes in mean eGFR were 
reported8.  
The SYMPLICITY HTN- 2 randomized, controlled study  was conducted on a similar patient 
population as SYMPLICITY HTN- 1 and the efficacy of RDN with the SymplicityTM catheter was 
compared with conventional medical therapy. Mean baseline blood pressure for the treatment 
group was 178/97 mmHg ± 18/16 mmHg; mean baseline blood pressure for the control group was 178/98 mmHg ± 16/17 mm Hg.  
Ambulatory blood- pressure recordings were available for 20 patients in the renal denervation 
group, showing a mean decrease of 11/7 mm Hg (SD 15/11; p=0 ・006 for systolic blood 
pressure change, p=0 ・014 for diastolic blood pressure change) from baseline to 6 months, 
whereas averages did not change for 25 patients in the control group ( –3/–1 mm Hg [19/12]; 
p=0・51 for systolic, p=0 ・75 for diastolic).    
At the 6 -month primary end point, the investigators reported a -32/-12 mmHg  change in office 
SBP in the RDN group compared to a +1/0 change in the control group (p<0.0001).
9 At 24 
months subjects in both RDN and cross -over groups had significant and sustained blood 
pressure reductions . 
Thirty -six month results showed sustained lowering of office blood pressure at 3 years in 
subjects with severe, treatment -resistant hypertension without serious safety concerns. Blood 
pressure reduction at 36 months was -33/-14 mm Hg in the RDN group. In the Pooled RDN 
and crossover group, BP reduction at 30 months was -34/-13 mm Hg (n=69). Blood pressure 
reductions were achieved in absence of increases in blood pressure medications.  
The safety profile for this study has been consistent with the SYMPLI CITY HTN- 1 study. In 
the SYMPLICITY HTN -2 population, there was one renal artery dissection from the injection 
of contrast into the renal artery wall during dye angiography; the lesion was stented without 
further consequences. One patient endured prolonged hospitalization in the crossover group 
due to hypotension following the RDN procedure. IV fluids were administered along with a 
decrease in antihypertensive medications and the patient was discharged without further 
incident. Other than these events with follow- up to 36 months, no other device- , procedure- , 
or therapy -related serious adverse events related to the delivery of radiofrequency energy to 
the renal artery with the Symplicity Flex™ catheter were reported.  Importantly, the results of  
the SYMPLICIT Y HTN- 2 study  reaffirm the results of the SYMPLICITY HTN- 1 study  and 
showed a significant improvement in blood pressure reduction compared to optimal medical management in the control, without having a safety signal.  
SYMPLICITY HTN -3  
The SYMPLICITY HTN-3 Clinical Study  was a multi -center, prospective, single- blind, 
randomized and controlled study  that randomized 53 5 subjects in a 2:1 ratio to renal  
denervation plus best medical therapy vs. best medical therapy in the United States . The 6 -
SPYRAL PIVOTAL - SPYRAL HTN -OFF MED Clinical Investigation Plan  
  
 Version  12 .0 Page 30 of 139  
 
Medtronic Confidential  
  056-F275, v3 .0 Clinical Investigation Plan Template  
  
month SYMPLICITY HTN -3 clinical study  results were presented at the 63rd Scientific 
Sessions of the American College of Cardiology (ACC) March, 2014 and published 
concurrently in the New England Journal of Medicine10. In office SBP,  change (from baseline 
to 6-month follow -up) between the renal denervation arm and the control arm as the primary 
efficacy endpoint was a statistically non- significant difference of 2.39 mmHg  [95% CI: -2.12 ~ 
6.89, p=0.26], with a SBP reduction of 14.1  mmHg  in the renal denervation arm vs. 11.7mmHg  
reduction in the control arm. The secondary endpoint was the comparison of SBP change 
(from baseline to 6 month follow -up) in mean 24- hour ambulatory blood pressure (ABP) 
between the renal denervation arm and the control arm  using an automated ambulatory blood 
pressure monitor (ABPM) . The result was a statistically non- significant difference of 1.96  
mmHg , [95% CI, -1.06 to 4.97, p=0.98], with a SBP reduction of 6.8 mmHg  in the renal 
denervation arm vs. 4.8  mmHg  reduction in the control arm. The major explanation for the 
difference in  efficacy findings between HTN -3 and the prior HTN -1 and HTN -2 studies was the 
inclusion of sham to the control arm.  
The SYMPLICITY HTN -3 study  met the primary safety endpoint, with a major adverse events 
rate of 1.4% (upper 95% confidence bound 2.9%) in the renal denervation arm, which was 
significantly (p<0.001) less than the pre -specified objective performance criterion of 9.8%.   
Twelve -month11data indicated there was no difference in major adverse events between the 
denervation and control groups. Subjects in the denervation group, control group that did not 
cross over , and control group subjects that crossed over at 6 months showed similar 
reductions in office and ambulatory blood pressure 12 months post -randomization.  
Subjects randomized into SYMPLICITY HTN -3 were planned to be followed- up for 5 years 
post-procedure. However, it was decided to prematurely terminate t he study after completion 
of 3-year follow -up visits fo r active subjects. Subjects had been allowed to cross -over from 
sham to treatment after the completion of the 6- month follow -up visit. In the overview below, 
the office blood pressure results for all treated subjects  with the data available at the time of 
study closure is shown ( Figure 1). 
 
Figure 1: Change In Office Blood Pressure Through 36 And 48 -Months Post -
Randomization  

SPYRAL PIVOTAL - SPYRAL HTN -OFF MED Clinical Investigation Plan  
  
 Version  12 .0 Page 31 of 139  
 
Medtronic Confidential  
  056-F275, v3 .0 Clinical Investigation Plan Template  
  
GLOBAL SYMPLICITY REGISTRY (Conducted using Single electrode and multi 
electrodes RF renal denervation system s)   
The Global SYMPLICITY Registry is a prospective, multi -center, single- arm, non -
interventional and open label registry that will collect descriptive data from a minimum of 3000 
patients that receive renal denervation using the commercially available components of the 
SymplicityTM renal denervation system . Enrollment is ongoing in the Global SYMPLICITY 
Registry.  
 
As of 04 October 2017, 2603 patients had been enrolled. The purpose of the registry is to document the long- term safety and effectiveness of renal denervation in a real -world patient 
population with hypertension. Of the 2515 subjects enrolled at the time of presentation at EuroPCR 2017, 2237 patients were treated with the Symplicity Flex™  catheter (Medtronic’s 
first generation RDN catheter) and 278 with the Symplicity Spyral™ catheter. In the 849 
Symplicity Flex™  subjects with 36 -month follow -up data available, office blood pressure 
decreased on average by -16.5/ -6.27 mmHg (p<0.001) from baseline to 36 months. In addition, 
353 subjects had matched baseline and 6 months ambulatory blood pressure measurements (ABPM), although ABPM is not required in the GSR. In these subjects, the ambulatory systolic 
blood pressure reduction was -8.0 mmHg at 36 months.  
The renal denervation procedure was associated with minimal complications and no 
unanticipated adverse device effects. Similar to SYMPLICITY HTN -1, HTN- 2, and HTN -3, 
renal denervation did not elicit a significant change in measured renal function from baseline 
to 6 months.
12 
 Clinical Experience Using the Multi Electrode RF renal denervation system  
(SPYRAL)  
Multi -electrode RF Renal Denervation System  Feasibi lity Study (Spyral FIM)  
The SYMPLICITY  Spyral FIM was a prospective, single- arm, non -randomized feasibility study 
to evaluate acute procedural and long term safety and effectiveness of the multi -electrode 
renal denervation system. Fifty (50) subjects were treated at four centers in Australia and New 
Zealand. Follow -up data through six months was presented at EuroPCR 2014114. The mean 
baseline office blood pressure was 181/95 ± 17/12 mmHg  and patients were taking an average 
of 4.6 ± 1.3 antihypertensive medications. Mean baseline ambulatory systolic and diastolic BP 
were 154.4 ± 17.4 mm Hg and 80.9 ± 11.7 mm Hg during 24 -hour ABPM, respectively.  There 
was a reduction in 24 -hour ambulatory blood pressure measurement at 6 months with a 
change in systolic blood pressure of -5.7 mmHg and a change in diastolic of -4.5 mmHg. At 
12 months, the difference in systolic ambulatory blood pressure from baseline was -7.5 mmHg 
and the difference in diastolic was -6.0 mmHg. The mean systolic ambulatory blood pressure 
change from baseline was decreased by 7.6 mmHg at the 36 month visit.  
At six months post treatment, there was a -20/-7 mmHg  change in office blood pressur e 
(Figure 2) and subjects were on an average of 4.8 ± 1.1 antihypertensive medications. Sixty -
six percent  of patients had an office SBP reduction of at least 10 mmHg  at 6 months.  Follow -
up data through 12 months were published in EuroIntervention in May 201540. The mean 
change of office systolic blood pressure  at 36 months  from baseline was -20.8 ± 28.6 mmHg.  
SPYRAL PIVOTAL - SPYRAL HTN -OFF MED Clinical Investigation Plan  
  
 Version  12 .0 Page 32 of 139  
 
Medtronic Confidential  
  056-F275, v3 .0 Clinical Investigation Plan Template  
  
Twenty -eight out of 41 (68.3%)  of the subjects achieved a reduction in systolic BP of ≥ 10 mm 
Hg while 53.7%(22/41) had a systolic BP reduction of ≥ 20 mm Hg.  
 
 
Figure 2: Change In Office Blood Pressure From Baseline Through 6 Months  
 
There were no unanticipated adverse device effects. Three subjects  developed a 
pseudoaneurysm at the femoral access site and two of these subjects  also reported a 
hematoma. All five access site related events were treated without any subsequent 
complicatio n. Follow -up renal artery imaging (duplex ultrasound) was performed at six months 
post treatment, with no reports of renal artery stenosis. One subject  had a myocardial 
infarction (MI) one month after renal denervation treatment. The subject  underwent a 
percutaneous coronary intervention (PCI) and was stented. The MI event was reviewed and 
determined to be unrelated to the device, therapy, or procedure by the Clinical Events Committee.  
 The change in Serum Creatinine at 36 months was 0.1 ± 0.2 (p=0.014 for change from 
baseline). The change in eGFR at 36 months was -6.7 ± 16.6 (p=0.013 for change from 
baseline). There were 2 cardiovascular deaths (4.3%), 3 subjects with MI (6.5%), 3 subjects 
with serum cre atinine elevation > 50% (6.5%), 3 subjects with vascular complications (6.5%), 
and 2 subjects with stroke (4.3%). These are all at levels that are expected in a patient population of severe drug resistant hypertension.  
 
The Symplicity Spyral™ catheter and Symplicity G3
TM generator had a sustained safety profile 
at 36 months with 2 deaths  described above, no new hypertensive crises and no end stage 
renal disease at the time of the 36 month data analysis. The 2 deaths were adjudicated by the 
CEC as not related to the device, therapy or procedure. One subject died from a subarachnoid hemorrhage while the other subject died from an intracranial hemorrhage.  
SPYRAL COHORT OF THE  GLOBAL SYMPLICITY REGISTRY (GSR) 
An addendum to the GSR allowed use of the Symplicity Spyral catheter and Symplicity G3 
generator following CE mark approval in Europe. In addition to the general registry, a sub -
study of patients treated with the Spyral catheter is being enrolled. This registry sub- study will 
be 100% monitored for increased data quality. The recommended f ollow- up for these patients 
is 3, 6, and 12 months and then annually for a minimum of 3 years and up to 5 years. Data 

SPYRAL PIVOTAL - SPYRAL HTN -OFF MED Clinical Investigation Plan  
  
 Version  12 .0 Page 33 of 139  
 
Medtronic Confidential  
  056-F275, v3 .0 Clinical Investigation Plan Template  
  
from 278 subjects in the Spyral sub -study was presented at EuroPCR 2017 with data out to 
two years for 108 subjects. Subjects presented with a mean ambulatory systolic blood 
pressure of 157 ± 18mm Hg  and a mean baseline office systolic blood pressure of 171 ± 23 
mmHg.   
Ambulatory SBP showed sustained reductions to two years with a mean decrease of 10.4 mmHg. Sustained reductions in office SBP were also reported to two years with a mean 
reduction of 12 mmHg.  These data demonstrate that renal denervation in this real world 
population resulted in significant reductions in both ambulatory and office blood pressure that were sustained out to 2 years post -procedure with a very low rate of safety events.  
Safety results from the Spyral sub -study of the GSR  to 24 months continue to support the 
safety profile of the Symplicity Spyral™ catheter.  
SPYRAL HTN- OFF MED 80 PATIENT COHORT 
SPYRAL HTN- OFF MED is a multicenter, international, single- blind, randomized, sham -
controlled trial. Eligible patients are drug- naive or discontinue their antihypertensive 
medications. Patients with an office systolic blood pressure (SBP) of 150 mm Hg or greater 
and less than 180 mm Hg, office diastolic blood pressure (DBP) of 90 mm Hg or greater, and 
a mean 24 -h ambulatory SBP of 140 mm Hg or greater and less than 170 mm Hg at second 
screening, have renal angiography and are randomly assigned to renal denervation  or sham 
control. Patients, caregivers, and those assessing blood pressure are blinded to randomization 
assignments.  
While study enrollment is ongoing, data from the initial 80 patients with 3 months follow up 
from the SPYRAL HTN -OFF MED study was presented at ESC Congress in August 2017.  
Concurrently, an article presenting the data was published in the Lancet.  A brief summary of 
the SPYRAL HTN -OFF MED data is provided below.  
The primary endpoint, change in 24- h blood pressure at 3 months, was compared between 
groups. Drug surveillance was done to ensure patient compliance with absence of antihypertensive medication. The primary analysis was done in the intention- to-treat 
population. Safety events were assessed at 3 months.  
Between June 25, 2015, and January 30, 2017, 353 patients were screened. 80 patients were 
randomly assigned to renal denervation (n=38) or sham control (n=42) and followed up for 3 
months at 21 centers in the USA, Europe, Japan, and Australia.  
There were no major adverse events in either group. No major procedural or clinical safety 
events were observed in either the renal denervation or sham control groups throughout the 3 months. Specifically,  there were no deaths or occurrences of myocardial infarction, stroke, 
major bleeding, serum creatinine elevation greater than 50%, significant embolic events, vascular complications, renal artery re- intervention, new or worsening renal failure, or 
hypertensive emergency or crisis.  
Office and 24 -h ambulatory blood pressure decreased significantly from baseline to 3 months 
in the renal denervation group ( Figure 3). No significant changes were seen in the sham -
SPYRAL PIVOTAL - SPYRAL HTN -OFF MED Clinical Investigation Plan  
  
 Version  12 .0 Page 34 of 139  
 
Medtronic Confidential  
  056-F275, v3 .0 Clinical Investigation Plan Template  
  
control group. The mean difference between the groups favored renal denervation for 3- month 
change in both office and 24- h blood pressure from baseline: 24- h SBP –5·0 mm Hg (95% CI 
–9·9 to –0·2; p=0·0414), 24- h DBP –4·4 mm Hg ( –7·2 to –1·6; p=0·0024), office SBP –7·7 
mm Hg (– 14·0 to –1·5; p=0·0155), and office DBP –4·9 mm Hg ( –8·5 to –1·4; p=0·0077). 
Baseline- adjusted analyses showed similar findings.  
 
Figure 3: Changes At 3 Months In Office And Ambulatory Sbp And  Dbp For Renal 
Denervation And Sham Control Groups  
These initial results from SPYRAL HTN -OFF MED provide biological proof of principle for the 
blood- pressure -lowering efficacy of renal denervation. The data indicates that denervation is 
safe with no major adverse events to 3 months. This data will be utilized as the informative 
prior dataset for the SPYRAL PIVOTAL - SPYRAL HTN -OFF MED, which is a continuation of 
the current SPYRAL HTN -OFF MED study.  
SPYRAL Pivotal - SPYRAL HTN- OFF MED First Interim Analysis  
The SPYRAL PIVOTAL - SPYRAL HTN- OFF MED study is a multi -center, international, 
prospective, single blinded, randomized, interventional, sham -controlled study. In order to test 
the hypothesis that renal denervation decreases blood pressure and is safe when studied in 
the absence of antihypertensive medications, study subjects will be randomized to the 
Denervation or Control group in a 1:1 fashion. In addition to subjects being blinded to their 
randomization assignment, site personnel involved in the measurement of office blood 
pressure will also be blinded to study subjects’ randomization assignment through the primary endpoint to prevent potential bias of results. Subjects will be studied in the absence of 
antihypertensive medications to assess the impact of renal denervation on systolic blood 
pressure in the absence of medication.  
Study enrollment was stopped for efficacy after the first intetim analysis in February 2020. 
Data from the initial 80 patients with 3 months follow up from the SPYRAL HTN- OFF MED  
study   was combined with data from the initial 251 patients  with 3 months follow up from the 

SPYRAL PIVOTAL - SPYRAL HTN -OFF MED Clinical Investigation Plan  
  
 Version  12 .0 Page 35 of 139  
 
Medtronic Confidential  
  056-F275, v3 .0 Clinical Investigation Plan Template  
  
SPYRAL PIVOTAL -SPYRAL HTN -OFF MED  study and  was presented at ACC World 
Congress of Cardiology  in March 2020 .  Concurrently, an article presenting the data was 
published in the Lancet.  A brief summary of the SPYRAL PIVOTAL -SPYRAL HTN- OFF MED 
data is provided below.  
The primary endpoint, change in 24- h blood pressure at 3 months, was compared between 
groups . Drug surveillance was done to ensure patient compliance with absence of 
antihypertensive medication. The primary analysis was done in the intention- to-treat 
population. Safety events were assessed to 3 months.  
 
From June 25, 2015, to Oct 15, 2019, 1519 patients were enrolled, of whom 1188 were 
excluded because they did not meet inclusion criteria. 166 were randomly assigned to renal 
denervation and 165 to the sham procedure  (80 were included in the pilot and 251 in 
Pivotal) . 
 There were no major safety events reported at 1 month.  There was one major safety event 
in each treatment  group up to 3 months (one admission to hospital for  hypertensive crisis or 
emergency in the renal denervation group and one new stroke in the sham procedure 
group),  and neither was attributed to the device or trial  procedures.  
 For the primary efficacy endpoint of changes from baseline in 24 -h systolic blood pressure at 
3 months,  there was a significant difference between the renal denervation and sham 
procedure groups. This endpoint was met with a posterior probability of superiority greater 
than 0.999 and a treatment difference of -3.9 mm Hg (95% BCI -6.2 to -1.6). For the 
secondary efficacy endpoint of difference in 3- month changes in office systolic blood 
pressure between the two groups, the difference was significant and the endpoint was met (difference -6.5 mm Hg (95% BCI -9.6 to -3.5), with posterior probability of superiority of 
more than 0. 999. The blood pressure changes analysed using the prespecified ANCOVA -
adjusted frequentist analysis of the overall population show similar changes in blood 
pressure to Bayesian results (
Figure 4).  
SPYRAL PIVOTAL - SPYRAL HTN -OFF MED Clinical Investigation Plan  
  
 Version  12 .0 Page 36 of 139  
 
Medtronic Confidential  
  056-F275, v3 .0 Clinical Investigation Plan Template  
  
 
Figure 4: Changes in 24- h and office systolic and diastolic blood pressure from baseline to 3 
months  
 
SPYRAL HTN- ON MED 80 -PATIENT COHORT  
SPYRAL HTN -ON MED is a multicenter, international, single- blind, randomized, sham -
controlled trial. Eligible patients are on a stable dose of one to three antihypertensive 
medications for at least 6 weeks. Patients with an office systolic blood pressure (S BP) of 150 
mm Hg or greater and less than 180 mm Hg, office diastolic blood pressure (DBP) of 90 mm Hg or greater, and a mean 24- h ambulatory SBP of 140 mm Hg or greater and less than 170 
mm Hg at second screening, have renal angiography and are randomly assigned to renal 
denervation or sham control. Patients, caregivers, and those assessing blood pressure are 
blinded to randomization assignments.  
While study enrollment is ongoing, data from the initial 80 patients with 6 months follow up 
from the SPYRAL H TN-ON MED study was presented at ESC Congress in May 2018.  
Concurrently, an article presenting the data was published in The Lancet42. A summary of the SPYRAL HTN -ON MED data is provided below.  
The primary endpoint, change in 24- h blood pressure at 6 months, was compared between 
randomization groups. Drug surveillance was done to ensure patient compliance with absence of their prescribed antihypertensive medication. The primary analysis was done in the 
intention- to-treat population. Safety events were assessed at 6 months.  

SPYRAL PIVOTAL - SPYRAL HTN -OFF MED Clinical Investigation Plan  
  
 Version  12 .0 Page 37 of 139  
 
Medtronic Confidential  
  056-F275, v3 .0 Clinical Investigation Plan Template  
  
Between June 22, 2015, and June 14, 2017, 467 patients were screened. 80 patients were 
randomly assigned to renal denervation (n=38) or sham control (n=42) and followed up for 6 
months at 25 centers in the USA, Europe, Japan, and Australia.  
There were no major adverse events in either group. No major procedural or clinical safety 
events were observed in either the renal denervation or sham control groups throughout the 6 months. Specifically, there were no deaths or occurrences of myocardial infarction, stroke, major bleeding, serum creatinine elevation greater than 50%, significant embolic events, 
vascular complications, renal artery re- intervention, new or worsening renal failure, or 
hypertensive emergency or crisis.  
Office and 24 -hour ambulatory blood pressure decreased significantly from baseline to 6 
months in the renal denervation group ( Figure 5 ). No significant changes were s een in the 
sham -control group. The mean difference between the groups favored renal denervation for 
6-months change in both office and 24- h blood pressure from baseline: 24- h SBP –7·4 mm 
Hg (95% CI –12.5 to –2.3; p=0·0051), 24- h DBP –4·1 mm Hg ( –7·8 to –0.4; p=0·0292), office 
SBP –6.8 mm Hg ( –12.5 to –1.1; p=0·0205), and office DBP –3.5 mm Hg ( –7.0 to –0; 
p=0·0478). Baseline- adjusted analyses showed similar findings.  
 
Figure 5: Changes at 6 Months in Office and Ambulatory SBP and DBP for Renal Denervation 
and Sham Control Groups  
 

SPYRAL PIVOTAL - SPYRAL HTN -OFF MED Clinical Investigation Plan  
  
 Version  12 .0 Page 38 of 139  
 
Medtronic Confidential  
  056-F275, v3 .0 Clinical Investigation Plan Template  
  
These initial results from SPYRAL HTN -ON MED in combination with SPYRAL HTN- OFF 
MED demonstrated biological proof of principle for the blood- pressure -lowering efficacy of 
renal denervation. The data indicates that renal denervation is safe with no major adverse 
events at 3 and 6 months. The SPYRAL HTN -ON MED data will be utilized as the informative 
prior dataset for the continuation of the current SPYRAL HTN -ON MED study.  
Clinica l Summary and Future Studies  
Extensive data has been collected on the predicate of the Symplicity Spyral™ catheter, the 
single -electrode Symplicity ™ catheter. This includes data from the SYMPLICITY HTN- 1 study  
(36 months), the SYMPLICITY HTN -2 study  (36 mo nths), as well as the data from the 
SYMPLICITY HTN -3 Study  (36 months) and the Global SYMPLICITY Registry.  
The data from the Spyral FIM study using the multi- electrode renal denervation system 
supports the procedural and acute safety of this device in treating subjects with uncontrolled hypertension. Six months post -procedure there was a significant reduction in office BP 
compared to baseline.  This reduction continued through 36 months follow -up. Safety events 
reflect those commonly seen with arterial access and none related to the renal denervation 
device or treatment were reported.  
The combined experience from these studies in over 4206 subjects enrolled to date indicates 
that use of the Symplicity
TM renal denervation system to denervate the kidneys is safe. In 
contrast to findings from earlier studies, patients treated with RDN in SYMPLICITY HTN- 3 did 
not have a significant reduction in office and ambulatory BP at 6 months compared to the control group, and the primary efficacy endpoint was not met. Possible confounding factors 
such as inadequate denervation during the procedure, the target patient population studied, 
and uncontrolled medication adherence are believed to have impacted the SYMPLICITY H TN-
3 results. The aim s of this stud y is to demonstrate the acute procedural safety , document the 
effect of renal denervation on blood pressure control with simultaneous RF energy delivery at 
multiple sites using Medtronic’s next generation Symplicity Spyra l
TM catheter  and address the 
confounding factors observed in SYMPLICITY HTN- 3.  
 The SPYRAL FIM, GSR Spyral sub -study, and SPYRAL HTN -OFF MED Feasibility study 
include 388 patients and demonstrate safety and efficacy of the Spyral renal denervation system in resistant hypertensive, real- world, and off med populations, respectively.  
Specifically, results from the SPYRAL HTN -OFF MED trial provide biological proof of principle 
for the efficacy of catheter -based renal denervation to reduce blood pressure in patients with 
hypertension not treated with antihypertensive medications. The study  demonstrated a 
clinically significant reduction in office and 24 -h ambulatory SBP and DBP at 3 months in 
patients with mild to moderate hypertension following renal denervation in the absence of 
antihypertensive medications that was not observed in the sham control group. There were no 
major safety events in either group despite the absence of pharmacological therapy from enrolment to the 3 -month follow -up and a more aggressive renal denervation procedure than 
that of previous trials in this setting, extending into renal artery branch vessels.  
SPYRAL PIVOTAL - SPYRAL HTN -OFF MED Clinical Investigation Plan  
  
 Version  12 .0 Page 39 of 139  
 
Medtronic Confidential  
  056-F275, v3 .0 Clinical Investigation Plan Template  
  
B.2 Device information  
 The Symplicity ™ multi-electrode renal denervation system  
The SymplicityTM multi-electrode renal denervation system (Symplicity Spyral™ catheter and 
Symplicity G3TM generator) is comprised of a single  use, disposable catheter and a reusable 
radiofrequency (RF) generator. The intended use is to deliver low -level radiofrequency energy 
through the wall of the renal artery to denervate the human kidney. The Symplicity  Spyral ™ 
catheter and Symplicity G3TM generator  received  CE Mark in  October  2013 and has been 
commercially available in  selected  geographies outside the United States, Canada, and Japan.  
The Symplicity SpyralTM catheter is manufactured at Medtronic Ireland. The Symplicity G3TM 
generator is manufactured by Plexus Corp.  (Pinnacle Hill , Kelso TD5 8XX, UK ) for Medtronic 
Inc. 
 Symplicity Spyral ™ Catheter  
The Symplicity SpyralTM catheter is an iteration of the single -electrode SymplicityTM catheter 
and when used with the Symplicity G3TM generator will allow for rapid treatment of renal 
arteries by simultaneously delivering radiofrequency energy to four electrodes. The Symplicity 
Spyral ™ catheter consists of a distal, self -expanding array of four gold electrodes radially 
spaced by approximately 90 degrees in a spiral configuration ( Figure 6). To minimize the 
thermal effects on the renal artery wall, the design allows for continuous blood flow throughout the treatment, allowing cooling of the artery wall and electrodes during treatment. The catheter  
is advanced to the treatment site by tracking over a 0.014  inch guidewire using a rapid 
exchange based catheter system ( Figure 7). The proximal end of the guidewire is inserted 
through the spiral flexible array via the straightening tool, reducing the system into a low profile 
straight configuration that is 6F compatible and ready for delivery to the renal artery treatment site. A radiopaque marker is embedded  in the catheter approximately 1 mm proximal from the 
tip to assist in the positioning of the catheter using fluoroscopic guidance . After the device is 
placed in a desired position for ablation in accordance with the IFU, the guidewire is retracted 
proximally to allow the pre- shaped nitinol spiral electrode array to expand radially and place 
the electrodes in contact  with the arterial wall in a spiral pattern. The Symplicity Spyral ™ 
catheter is designed to attain acceptable electrode- vessel positioning and wall contact with 
less overall manipulation and/or interpretation as compared to the single -electrode 
Symplicity
TM catheter design. After treatment, the guidewire can be advanced distally to 
straighten the electrode array and allow for removal from the vessel into the guide catheter for placement into the contra- lateral renal artery where the treatment procedure is repeated.  
SPYRAL PIVOTAL - SPYRAL HTN -OFF MED Clinical Investigation Plan  
  
 Version  12 .0 Page 40 of 139  
 
Medtronic Confidential  
  056-F275, v3 .0 Clinical Investigation Plan Template  
  
 
Figure 6: Spiral Configuration of Four Gold Electrodes  
The self -expanding electrode array consists of nitinol stranded tubing to maintain spiral shape -
set and guidewire lumen integrity during the procedure.  The gold electrodes are placed over 
a polymer outer cover that provides insulation from nitinol tubing and bi -filar wires that deliver 
the RF energy and measure temperature. The proximal end of the self -expanding electrode 
array assembly is attached to the intermediate shaft assembly. The intermediate shaft 
assembly balances the flexibility between the proximal shaft and electrode array assembly. 
The intermediate shaft assembly contains a guidewire lumen that terminates at the rapid 
exchange (RX) guidewire exit port. The jacketed proximal stainless steel hypotube joins the 
delivery system to the handle and integrated cable. The cable connector connects directly into 
the Symplicity G3 ™ generator.  
 
Figure 7: Overview of Symplicity Spyral™ Catheter  
Unlike the single -electrode SymplicityTM catheter, which had to be rotated to treat different 
segments of the vessel, the electrodes in the multi -electrode spiral arrangement are positioned 
to cover all four quadrants of the artery’s circumference. The catheter is for single- use only 
and is ster ilized by E -beam irradiation. It is provided in a hooped configuration within a tray  
sealed with a coated Tyvek ® lid.  
 Symplicity G3 ™ Generator  
The Symplicity G3™ generator is an iteration of the existing SymplicityTM generator and is 
intended to provide a safe and effective means of delivering RF energy to the Symplicity 
Spyral ™ and SymplicityTM catheters for controlled ablation of tissue. The Symplicity G3™ 
generator has been designed with the following features:  
Rapid Exchange exit port  
Self-Expanding Electrode array 
Assembly  
Straightening Tool  
Connector  
SPYRAL PIVOTAL - SPYRAL HTN -OFF MED Clinical Investigation Plan  
  
 Version  12 .0 Page 41 of 139  
 
Medtronic Confidential  
  056-F275, v3 .0 Clinical Investigation Plan Template  
  
• Automated safety algorithms similar in all aspects of safety and energy delivery 
and stoppage to previous SymplicityTM RF generator  
• Non-adjustable treatment parameters  
• System performance self -checks at power on and during system operation  
• Simultaneous firing of all four electrodes  
• Option to sel ect/deselect electrodes per physician discretion 
• Touch- screen interface, which allows the user to individually select or de -select 
the electrodes  
• Internal RFID tag within the Symplicity SpyralTM catheter, to communicate with an 
RFID antenna located inside the Symplicity G3TM generator to ensure the catheter 
cannot be re -used  
o Note: In Japan, the RFID module will be turned off  
• Messages and audible indicators to the operator with system status information including treatment application, warning indications and error indication  
• Universal power supply  
• Remote as optional component allowing extension of user interface  
 
 
 
Figure 8: Symplicity  G3™ Generator  
The Symplicity SpyralTM catheter leverages the safety aspects of the original algorithm while 
incorporating new features to allow for a shorter treatment time. Treatments are initiated by an operator using an optional foot switch, remote control, or a button on the front of the 
generator and may also be manually stopped by the operator using these same methods. As with the previous generator the default treatment parameters cannot be changed by the 
operator . 
Monopolar RF energy is delivered through each electrode, requiring the use of a dispersive 
electrode to provide a return path for currents exiting the catheter. Similar to the previous 

SPYRAL PIVOTAL - SPYRAL HTN -OFF MED Clinical Investigation Plan  
  
 Version  12 .0 Page 42 of 139  
 
Medtronic Confidential  
  056-F275, v3 .0 Clinical Investigation Plan Template  
  
generation Symplicity TM generator, temperature and impedance values are monitored at 
each electrode and used to provide input to an algorithm c ontrolling power delivery for 
individual electrodes (Figure 9).  
 
 
Figure 9: RF on Screen  
The following ancillary components may be used with the Symplicity G3TM generator.  
• Symplicity G3TM generator cart - an optional accessory as a convenience to 
facilitate movement of the generator  within the operating room. The generator 
cart may be provided as part of the clinical study  in applicable geographies . 
• Foot switch  
• Digital Visual Interface (DVI -D) cable - enables the user to extend the visual 
display of the Symplicity G3TM generator user interface to standard monitors 
within the cath lab  
• Wired remote control - enables the user to control the generator from within the 
sterile field  
 Labeling  
The Sy mplicity  SpyralTM catheter and Symplicity G3TM generator  will include , but not limited to , 
the following labeling information in geographies where the product is not commercially 
available: 
• That the device is  intended for investigational use in geographies where the product 
is not approved  
• Identification number   
• Model number   
• Lot/Serial number  

SPYRAL PIVOTAL - SPYRAL HTN -OFF MED Clinical Investigation Plan  
  
 Version  12 .0 Page 43 of 139  
 
Medtronic Confidential  
  056-F275, v3 .0 Clinical Investigation Plan Template  
  
• Storage condition 
• Expiration date  
• Name and address of the sponsor  
In geographies, where the product is not commer cially  approved, l abeling will be provided 
according to geography requirements.  
An Instructions for Use document is included with each Symplicity SpyralTM catheter and a 
User’s Manual is included with each Symplicity G3TM generator.  
 Intended Clinical Performance  
In the past , surgical nephrectomy, and even radical surgical sympathectomy, were both used 
to treat severe hypertension. Importantly, a denervated kidney maintains appropriate 
electrolyte and volume homeostasis as demonstrated in the human transplant experience. 
The Sy mplicity SpyralTM catheter offers a significantly less -invasive approach to treating 
hypertension  - a straightforward, catheter -based procedure with four electrodes spatially 
distributed along a spiral simultaneously delivering radiofrequency energy to sho rten 
procedure time.  
The catheter is introduced percutaneously to the renal artery via a commercially -available 
sheath and 6F guiding catheter suitable for renal artery intervention, using the femoral artery 
as the access site. A 6F sized commercially -available guide catheter and a commercially -
available hemostatic introducer sheath may be used in the placement of the catheter. The 
treatment involves the delivery of a relatively low -power and precisely focused RF energy of 
up to 6.5W to each electrode, sim ultaneously through the wall of the renal artery to disrupt the 
surrounding renal nerves. The low -power RF ablation has been shown to effectively disrupt 
the renal nerves (located in the adventitia of the renal artery, as depicted in 8) without 
adversely affecting the wall of the artery  or surrounding organs . 
 
Figure 10 : Illustration of renal artery anatomy  
Medtronic has performed a comprehensive set of bench testing and preclinical studies  that 
have shown that this manner of low-power ablation produces distinct, focal, sterile lesions that 
subsequently heal, resulting in no clinically relevant long- term sequelae to  either the vessel or 
the kidney. The ability to denervate using this approach has been demonstrated to effectivel y 
reduce renal nerve activity.    Nerves  
Lumen  
 
 
Endothelium  
 
 
 
Media  
 
 
Adventitia  
 
 
 
Fat 
SPYRAL PIVOTAL - SPYRAL HTN -OFF MED Clinical Investigation Plan  
  
 Version  12 .0 Page 44 of 139  
 
Medtronic Confidential  
  056-F275, v3 .0 Clinical Investigation Plan Template  
  
Recent  preclinical studies  and histological analyses  15-17 observed that renal nerves may have 
a positional bias, suggesting the distal nerves are closer to the arterial lumen ( Figure 11 ). 
Targeted renal ablation in the distal main and bra nches of the renal arteries may increase the 
amount  of nerve ablation and decrease the variability of denervation response.  
 
Figure 11 : Illustration Of Peri -Arterial Renal Nerve Location  
Initial clinical evidence18,19from commercial experience supports the combination of branch 
and main renal artery treat ments providing a larger and more consistent decrease in blood 
pressure while maintaining the safety profile  of renal denervation that was  previously 
established. Utilization of the branch and main renal artery treatment approach will be 
evaluated in this  SPYRAL  PIVOTAL - SPYRAL HTN -OFF MED  clinical study  to confirm the 
safety and efficacy of this approach.  
B.3 Comparator information 
A review of hypertension studies of antihypertensive medications was undertaken in concert 
with a thorough review of the S YMPLICITY HTN-3 data. Based on this, Medtronic plans to 
follow the accepted pharmaceutical model for hypertension studies and utilize a washout 
period. This will involve a  3-4 week  washout period free of antihypertensive medications 
followed by a 12 week post -procedure comparison of the investigational therapy ( Denervation  
group) to a group receiving the sham procedure ( Control group ). Washout and discontinuation 
of antihypertensive medications during the off -medication period should eliminate medication 
adherence  concerns and address both lack of adherence and medication changes as potential 
confounding factor s identified  in SYMPLICITY HTN -3. Inclusion of a sham procedure in the 
control group will help “blind” the subject to their randomization group. 
Inclusion and Exclusion criteria traditionally used in pharmaceutical studies20 will be utilized 
as they have historically ensured that only patients with true hypertension (vs white coat) are 
included and also ensure that these patients are not borderline hypertensive (ABP close to 
135 mmHg  and Office SBP close to 140  mmHg). Subjects will undergo regular office visits 
that include blood pressure measur ement to ensure safety during the off -medication period.  

SPYRAL PIVOTAL - SPYRAL HTN -OFF MED Clinical Investigation Plan  
  
 Version  12 .0 Page 45 of 139  
 
Medtronic Confidential  
  056-F275, v3 .0 Clinical Investigation Plan Template  
  
C STUDY PLAN  
C.1 Study Objective  
The objective of this study  is to test the hypothesis that renal denervation decreases blood 
pressure and is safe when studied in the absence of antihypertensive medications.  In this 
study,  “uncontr olled hypertension” is defined as an office  systolic blood pressure (SBP)  ≥ 
150 mmHg and <180 mmHg, an office DBP ≥90 mmHg and a 24 -hour Ambulatory Blood 
Pressure Monitoring (ABPM) average SBP ≥140 mmHg to <170 mmHg, all of which are  
measured at Screening Visit 2 (per Appendix L7) .  
Data obtained without the presence of antihypertensive medications will be used to confirm 
the effect of renal denervation on elevated blood pressure.   
The data collected in this study will be used to support regulatory submissions around the 
world to obtain market approval for the Symplicity Spyral™ multi -electrode renal denervation 
catheter (Symplicity SpyralTM catheter) and the Symplicity G3TM renal denervation RF 
generator , from regulatory entities, including, but not limited to : the Pharmaceuticals and 
Medical Devices Agency (PMDA), Health Canada, and the U.S. Food and Drug Administration 
(FDA).  
 
C.2 Clinical E ndpoints  
Primary Endpoints  
 
There are two primary endpoints  in this study (one safety and one efficacy) . The study will be 
considered successful if both the primary safety and efficacy endpoint hypotheses  are met  
 
Powered P rimary Safety Endpoint  
• Incidence of Major Adverse Events (MAE), defined as a composite of the following events, through one month post -randomization (6 months for new renal artery 
stenosis)  
− All-cause mortality  
− End-stage Renal Disease (ESRD)  
− Significant embolic event resulting in end- organ damage  
− Renal artery perforation requiring intervention  
− Renal artery dissection requiring intervention 
− Vascular complications  
− Hospitalization for hypertensive crisis not related to confirmed non -
adherence with medications or the protocol.  
− New renal artery stenosis > 70%, confirmed by angiography and as determined by the angiographic core laboratory  
SPYRAL PIVOTAL - SPYRAL HTN -OFF MED Clinical Investigation Plan  
  
 Version  12 .0 Page 46 of 139  
 
Medtronic Confidential  
  056-F275, v3 .0 Clinical Investigation Plan Template  
  
Powered Primary Efficacy Endpoint  
• Baseline adjusted change (using Analysis of Covariance)  in systolic blood 
pressure (SBP) from baseline (Screening Visit 2) to 3 months post -procedure as 
measured by 24- hour Ambulatory Blood Pressure Monitoring (ABPM). 
Secondary Endpoints  
Powered Secondary Efficacy Endpoint  
• Baseline adjusted  change ( using Analysis of Covariance)  in office systolic blood 
pressure from baseline (Screening Visit 2) to 3 months post -procedure.  
Secondary Safety Endpoints  
• Acute/Procedural Safety Secondary Endpoints – Compared Between Groups at 1 
Month Post-Procedure:  
− Significant embolic event resulting in end- organ damage  
− Renal artery perforation requiring intervention  
− Renal artery dissection requiring intervention 
− Vascular complications  
− End-Stage Renal Disease 
− ≥40% decline in eGFR  
− New Myocardial Infa rction  
− New Stroke  
− Renal artery re- intervention 
− Major bleeding according to TIMI definition (i.e. intracranial hemorrhage, 
≥5g/dl decrease in hemoglobin concentration, a ≥15% absolute decrease 
in hematocrit, or death due to bleeding within 7 days of the procedure)  
− Increase in serum creatinine > 50% from Screening Visit 2  
− New renal artery stenosis > 70%, confirmed by angiography and as 
determined by the angiographic core laboratory  
− Hospitalization for hypertensive crisis not related to confirmed non -
adherence with medications or the protocol.  
• Chronic Safety Secondary Endpoints – Compared Between Groups at   3, 6, 12, 
24, and 36 Months Post - Randomization:  
− All-cause mortality  
− End-Stage Renal Disease 
− ≥40% decline in eGFR  
− New Myocardial Infarction 
− New Stroke  
SPYRAL PIVOTAL - SPYRAL HTN -OFF MED Clinical Investigation Plan  
  
 Version  12 .0 Page 47 of 139  
 
Medtronic Confidential  
  056-F275, v3 .0 Clinical Investigation Plan Template  
  
− Renal artery re- intervention 
− Major bleeding according to TIMI definition (i.e. intracranial hemorrhage, 
≥5g/dl decrease in hemoglobin concentration, a ≥15% absolute decrease 
in hematocrit, or death due to bleeding within 7 days of the procedure)  
− Increase in serum creatinine > 50% from Screening Visit 2  
− New renal artery stenosis > 70%, confirmed by angiography and as 
determined by the angiographic core laboratory  
− Hospitalization for hypertensive crisis not related to confirmed non -
adherence with medications or the protocol.  
• Secondary  Efficacy Endpoints – Compared Between Groups  
− Change in systolic blood pressure (SBP) from baseline (Screening Visit 2) as measured by 24 -hour Ambulatory Blood Pressure Monitoring (ABPM) at 
3, 6, 12, 24 and 36 months post-procedure.  
− Change in office systolic blood pressure from baseline (Screening Visit 2) at 1, 3, 6, 12, 24 and 36 months post -procedure.  
− Incidence of achieving target office systolic blood pressure (SBP <140 mmHg) at 1, 3, 6, 12, 24 and 36 months post -procedure.  
− Change in office diastolic blood pressure from baseline (Screening Visit 2) at 1, 3, 6, 12, 24 and 36 months post -procedure.  
− Change in diastolic blood pressure from baseline (Screening Visit 2) as measured by 24- hour Ambulatory Blood Pressure Monitoring (ABPM) at 3, 
6, 12, 24 and 36 months post -procedure.  
• Summary of Quality of Life (QOL) Measures (EQ5D and SF36)  
 Additional analyses  
The following additional analysis will be conducted:  
• Antihypertensive medication usage throughout the study, including escape subjects prior to 3- months and subjects  reintroduced to medications after 3 
months  
• Additional procedural characteristics e.g. treatment duration, frequency of distal renal artery treatment, ablations per vessel, location of ablations, number of 
ablations per patient and other characteristics will be analyzed to assess  their 
impact on blood pressure.  
C.3 Study P opulation  
This study  will randomize subjects who meet the criteria as detailed in the Subject Selection 
portion of this Clinical Investigation Plan. Potentially eligible subjects will be consented and 
entered into a screening period to cease all antihypertensive medications and establish a 
baseline 24- hour ABPM and office systolic blood pressure. Approximately  433 subjects 
(including the first consecutively randomized 80 subjects in the SPYRAL HTN -OFF MED 
study) will be allowed to be randomized.   
SPYRAL PIVOTAL - SPYRAL HTN -OFF MED Clinical Investigation Plan  
  
 Version  12 .0 Page 48 of 139  
 
Medtronic Confidential  
  056-F275, v3 .0 Clinical Investigation Plan Template  
  
Eligible subjects will be randomized at a 1:1 ratio to:  
• Denervation group: Subjects are treated with the renal denervation procedure 
after randomization.  
• Control  group: Subjects undergo a sham renal denervation procedure.  
C.4 Study D esign  
The SPYRAL PIVOTAL - SPYRAL HTN- OFF MED study  is a multi- center, international, 
prospective, single blinded, randomized, interventional, sham -controlled study . In order to  test 
the hypothesis that renal denervation decreases blood pressure and is safe when studied in 
the absence of antihypertensive medications , study subjects will be randomized to the 
Denervation or Control group in a 1:1 fashion.  In addition to s ubjects being blinded to their 
randomization assignment, site personnel involved in the measurement of office blood 
pressure will also be blinded to study  subjects’ randomization assignment through the primary 
endpoint to prevent potential bias  of results . See section C. 5 for blinding techniques. Subjects 
will be studied  in the absence of antihypertensive medications t o assess the impact of renal 
denervation on systolic blood pressure in the absence of medication.  
The Symplicity SpyralTM catheter and Symplicity G3TM generator provide a spiral pattern of 
denervation, ensuring circumferential nerve ablation that is expected to  minimize procedure 
variability . One Symplicity G3TM generator is used with a Symplic ity SpyralTM catheter in 
subjects randomized to the denervation group, or if applicable, in control subject s eligible for 
cross- over.  
It is anticipated that several subjects will no longer meet study  eligibility after the medication 
washout period, renal  artery  imaging, or measurement of OBP , ABPM, and renal function. 
Approximately  1800 patients will be enrolled to randomize approximatel y 433 subjects  
(including the first 80 consecutively randomized to the SPYRAL HTN -OFF MED study)  in the 
study . 
C.5 Randomization and blinding  
Randomization will be stratified by study  center at a 1:1 ratio to:  
• Denervation group: Subjects remain blinded and are treated with the renal 
denervation procedure.  
• Control  group: Subjects remain blinded and remain on the catheterization  lab 
table for at least 20 minutes prior to introducer sheath removal.  
Investigational sites will access randomization allocation via a password -protected system that 
can only be accessed by those approved by the study  sponsor.  
All study  staff and necessary hospital personnel will be instructed that subjects are not to be 
informed of their randomization assignments and appropriate measures should be taken to 
minimize the risk of premature unblinding.  
The Investigator performing the catheterization lab procedures and his/her designated study  
staff will be blinded to a subject’s randomization group  up until the angiography is completed 
and inclusion/exclusion confirmed . However, investigators performing study  follow- up visits 
SPYRAL PIVOTAL - SPYRAL HTN -OFF MED Clinical Investigation Plan  
  
 Version  12 .0 Page 49 of 139  
 
Medtronic Confidential  
  056-F275, v3 .0 Clinical Investigation Plan Template  
  
and the subject’s referring/managing physicians will not be proactively informed of a subject’s 
treatment assignment to minimize potential bias in the subject ’s care decisions. However, to 
specifically minimize potential bias in the measurement of Office BP and ABPM, each investigational site will specify several designated “blinded” members of their study  staff that 
will not be informed of the subject’s group assignments and will be responsible for performing 
the office blood pressure measurements , conducting ABPM preparation and printing results 
upon a patient completing the ABPM. Prior to unblinding, the blinding effectiveness will be 
assessed by asking blinded study  staff which group they believe the subject was randomized 
to.  
Subjects will be blinded during the renal angiogram by a combination of conscious sedation, sensory isolation (e.g., blindfold and music), and lack of familiarity to the procedural details 
and duration (i.e., subjects will not know the difference between the renal angiography procedure alone and the renal angiography and denervation procedure). Subjects will continue to be blinded by only interacting with blinded site personnel through th e 6 month 
follow- up visit post -procedure. Blinding  effectiveness will be assessed by asking the subject 
which group they believe they were randomized to. All subjects will be unblinded after the 
completion of their required 6-month follow -up testing.  
If the subject’s medical condition requires knowledge of the randomization group in order to 
provide adequate care, prior to unblinding, contact the study  sponsor with the justification for 
proposed unblinding.  
C.6 Sample Size 
This study will be conducted as an adaptive Bayesian trial with an informative prior.  A 
Bayesian power prior approach
38,39 in conjunction with a discount function will be used to 
incorporate the historical data. The discount function reduces the strength of the historical data 
if disagreements are observed with the current data.  
The prior data consists of the first consecutively randomized 80 subjects  in the SPYRAL HTN-
OFF MED study. The weight of the prior data will be adjusted using a discount function, which 
scales from 0 to 1, according to the similarity of the prior and pivotal data. This discount function adjusts the amount of weight the prior receives. This prevents the use of an 
informative prior where exchangeability issues are present (e.g., the prior and pivotal data are 
quite different). This discount function approach was proposed by the Medical Device 
Innovative Consortium (MDIC) working group and is a collaborative effort between FDA and 
industry through the MDIC
36,37 If the analyses show a high level of agreement for pivotal data 
compared to the prior, the prior will be weighted at or near 100%. If the pivotal data perform worse than or much better than the prior, then the prior will receive very little or zero weight. The Bayesian adaptive design is set up to enroll patients until a sufficient sample size is 
achieved to have high probability of meeting the endpoint.  
The sample size will vary from 210 to 300 (not including the first consecutively randomized 80 
patients)  subjects due to the adaptive nature of the trial . This will require randomizing  
approximately  247 to 353 subjects to account for an expected 15% attrition  at 3-months. The 
interim analyses will take place when N=210 and N=240 subjec ts have 3- month follow -up data 
visit, with a maximum study size of 300 subjects i f the study does not stop at either interim 
look.
 The SPYRAL PIVOTAL - SPYRAL HTN- OFF MED study will thus in total randomize  
approximately 433 subjects  (including the first consecutively randomized 80 subjects) . Interim 
analyses will be conducted and reviewed by the DSMB, along with an independent 
SPYRAL PIVOTAL - SPYRAL HTN -OFF MED Clinical Investigation Plan  
  
 Version  12 .0 Page 50 of 139  
 
Medtronic Confidential  
  056-F275, v3 .0 Clinical Investigation Plan Template  
  
organization that will be performing the Bayesian analyses. Medtronic personnel will not have 
access to any unblinded results prior to the primary endpoint analyses. At each interim 
analysis, enrollment may be stopped for futility or efficacy . Both the primary and secondary 
effectiveness endpoints will be evaluated during these interim looks and enrollment will only stop at an interim analysis if both endpoints meet the following stopping criteria.  
1. The first interim analysis takes place when the first 210 subjects have 3- month 
follow- up data available (requiring approximately 247 randomized subjects to 
account for  attrition). The Bayesian efficacy analysis will be performe d and 
P[suc] will be calculated, where P[suc] is the probability of accepting the 
alternative efficacy endpoint hypotheses , 
𝑃𝑃�𝜇𝜇 < 0�𝑦𝑦,𝑦𝑦0,𝛼𝛼0�(𝑦𝑦,𝑦𝑦0,𝜆𝜆,𝑘𝑘)�, , and is 
defined in detail in section H4.  
a. If P[suc] > 0.975 for both the primary and secondary efficacy endpoints, 
then the study has met the efficacy hypotheses and enrollment will be stopped. Any additional subjects that have been enrolled before the 
decision is made to stop for efficacy will be pooled with the existing 
subjects and analyzed as a secondary cohort.  
b. We calculate the probability of futility based on the maximum study size 
of 300 evaluable subjects which requires us to impute the outcomes for 
subjects who have not yet been enrolled. If the posterior probability of 
futility from this calculation is < 0.05 for both the primary and secondary 
efficacy endpoints, then the study will have met the futility boundary and 
enrollment will be stopped. . Further details can be found in the study 
SAP. Any additional subjects that have been enrolled before the decision 
is made to stop for futility will be pooled with the existing subjects and analyzed as a secondary cohort.  
c. If P[suc] is ≥0.05 and ≤0.975 for either  the primary or secondary efficacy 
endpoints, then subject enrollment will continueto the second interim 
analysis.  
2. If the study doesn’t stop for efficacy or futility at the first interim analysis then 
enrollment will continue until the second interim analysis when 3 -mont h follow -
up data is available for the first 240 subjects (requiring approximately 282 randomized subjects to account for attrition ). The Bayesian efficacy analysis 
will be performed and P[suc] will be calculated.  
a. If P[suc] > 0.975 for both the primary and secondary efficacy endpoints, 
then the study has met the efficacy hypotheses and enrollment will be 
stopped. Any additional subjects that have been enrolled before the 
decision is made to stop for efficacy will be pooled with the existing 
subjects and analyzed as a secondary cohort.  
b. We calculate the probability of futility based on the maximum study size 
of 300 evaluable subjects which requires us to impute the outcomes for 
subjects who have not yet been enrolled. If the posterior probability of 
futility from this calculation is < 0.05 for both the primary and secondary 
efficacy endpoints, then the study will have met the futility boundary and 
enrollment will be stopped. Further details can be found in the study SAP. Any additional subjects that have been enrolled before the 
decision is made to stop for futility will be pooled with the existing 
subjects and analyzed as a secondary cohort.  
c. If P[suc] is ≥0.05 and ≤0.975 for either  the primary or secondary efficacy 
endpoints, then we continue enrolling subject s to the final analysis.  
SPYRAL PIVOTAL - SPYRAL HTN -OFF MED Clinical Investigation Plan  
  
 Version  12 .0 Page 51 of 139  
 
Medtronic Confidential  
  056-F275, v3 .0 Clinical Investigation Plan Template  
  
3. If the study  does n’t stop for efficacy or futility at the second interim analysis 
then enrollment will continue until the maximum study size of 300 subjects with 
3-month follow -up data (requiring approximately 353 randomized subjec ts to 
account for  attrition). The Bayesian efficacy analysis will be performed and 
P[suc] will be calculated. 
a. If P[suc] > 0.975 for the primary efficacy endpoint, then we have met 
the primary efficacy hypothesis.   
b. If P[suc] > 0.975 for the secondary efficacy endpoint, then we have met 
the secondary efficacy  hypothesis.  
C.7 Number of investigation sites and study  duration  
The study is expected to be conducted in up to 50 sites located around the world.  A multi- site, 
multi- national design helps to ensure a representative sample of the global population as well 
as maintaining  a reasonable enrollment duration. Participating geographies may include 
countries such as the United States, Japan, Australia, Canada, and countries where CE mar k 
applies. A list of participating investigational sites including Investigators’ names who are 
responsible for conducting the trial, their title, address, and telephone number(s)  are provided 
separately and will be maintained within the study files at each site. Additional geographies 
may be added to the clinical study at a later date and the approval status  will be  documented 
under a separate cover . Enrollment to the prospective cohort  is expected to take 
approximately 33 months. Individual investigati onal sites may randomize up to 20% of the total 
study  subject s. At least 50% of randomized subjects, excluding the first consecutively -
randomized 80 subjects, must be randomized from sites in North America  (US and Canada) . 
Subjects will participate in the study  from the time of signing consent until study  exit or the 
time of completion of 3  years of follow -up post-procedure . Control (sham) subjects will be 
followed -up for two years  post-procedure, if they (and their study doctor) agree to have the 
renal denervation procedure after their 6 month follow -up, “crossover” . 
If a site does not enroll any subjects into the study within three months of activation, they may 
forfeit their part icipation in the clinical study to another site to ensure timely enrollment.  
 
D SUBJECT  SELECTION  
D.1 Inclusion criteria  
1. Individual is ≥ 20 and ≤ 80 years old at time of enrollment  (consent) . 
2. Individual has an office systolic blood pressure (SBP) ≥ 150 mmHg  and <180 mmHg , 
and a diastolic blood pressure (DBP) ≥90 mmHg  at Screening Visit 2, according to 
guidelines in Appendix L.7. 
3. Individual has a 24 -hour Ambulatory Blood Pressure Monitoring (ABPM) average 
SBP ≥140 mmHg  and <170 mmHg  at Screening Visit 2  according to guidelines in 
Appendix L.7: ABPM is considered valid if the number of successful daytime 
readings captured is ≥ 21 and the number of successful nighttime readings captured 
is ≥ 12.  
SPYRAL PIVOTAL - SPYRAL HTN -OFF MED Clinical Investigation Plan  
  
 Version  12 .0 Page 52 of 139  
 
Medtronic Confidential  
  056-F275, v3 .0 Clinical Investigation Plan Template  
  
4. Individual agrees to have all study  procedures performed, and is competent and 
willing to provide written, informed consent to participate in this clinical study .  
5. Individual is willing to discontinue current antihypertensive medications at Screening 
Visit 1 through the three month post -procedure visit.  
D.2 Exclusion criteria  
1. Individual has one or more of the following conditions: stable or unstable angina 
within 3 months of enrollment, myocardial infarction within 3 months  of enrollment ; 
heart failure, cerebrovascular accident or transient ischemic attack, or atrial 
fibrillation  at any time . Patients are permitted to take aspirin or clopidogrel  for 
cardiovascular risk reduction.  Patients  who received catheter or surgical treatment 
for Atrial Fibrillation and are in sinus rhythm are not excluded.  
2. Individual has undergone prior renal denervation.  
3. Individual has renal artery anatomy that is ineligible for treatment including:  
a. Main renal artery for each kidney less than 3mm or greater than 8mm  
b. Lacks a main renal arterial vessel (greater than 3mm and less than 8mm in diameter) for each kidney that d oes not allow 4 simultaneous quadrantic 
(4SQ) radio frequency ablations in the main renal arter y or equivalent 
(defined as 4SQ ablations in all branch vessels greater than 3mm and less than 8mm)  
4. Presence of FMD (defined as visible beading of the artery on angiography)  
5. Has >50% stenosis  in any treatable vessel  
6. Has a renal artery stent placed <3 months prior to the denervation procedure 
7. Presence of an aneurysm defined as any localized increase in the diameter of the vessel 
8. Treatment area within 5mm  of a segment in the renal artery which contains any of 
the following:  
a. Atheroma,  
b. Calcification,  or  
c. Renal artery stent  
9. Individual has an estimated glomerular filtration rate (eGFR) of <45 mL/min/1.73m2, 
using the 4 variable MDRD calculation  (in mL/min per 1.73 m2 = 175 x SerumCr-1.154 
x age-0.203 x 1.212 (if patient is black) x 0.742 (if female). (NOTE: an eGFR calculation 
specific to Japanese patients will be used for subjects enrolled in Japan)   
10. Individual has documented type 1 diabetes mellitus or poorly -controlled type 2 
diabetes mellitus with glycosylated hemoglobin greater than 8.0% . 
11. Individual is taking SGLT2 inhibitors or GLP -1 agonists that have been prescribed < 
90 days from Screening Visit 1 or who does not plan to remain on these drugs for the duration of the trial 
12. Individual has had ≥1 episode(s) of  orthostatic hypotension not related to medication 
changes within the past year or reduction of SBP of ≥20 mmHg  or DBP of ≥10 mmHg  
within 3 m inutes of standing coupled with symptoms during the screening process  
(at SV2) . 
SPYRAL PIVOTAL - SPYRAL HTN -OFF MED Clinical Investigation Plan  
  
 Version  12 .0 Page 53 of 139  
 
Medtronic Confidential  
  056-F275, v3 .0 Clinical Investigation Plan Template  
  
13. Individual requires chronic oxygen support or mechanical ventilation other than 
nocturnal respiratory support for sleep apnea (e.g. CPAP, BiPAP). 
14. Individual who requires more than occasional use (e.g. PRN) of narcotic drugs over 
the month prior to Screening Visit 1.   
15. Individual has documented primary pulmonary hypertension.  
16. Individual has an untreated secondary cause of hypertension (either known or 
suspected ) or is taking drugs that increase sympathetic tone and could contribute to 
hypertension.  
17. Individual has frequent intermittent or chronic pain that results in the treatment with 
non-steroidal anti -inflammatory  drugs (NSAIDs)  for two or more days per week over 
the month prior to Screening Visit 2. 
18. Individual with HIV on anti- retroviral drug therapy without documentation that 
hypertension preceded initiation of anti -retroviral drug treatment.  
19. Individual has a scheduled or planned surgery that, in the opinion of the Investigator, 
may affect study  endpoints.  
20. Individual has a documented condition that would prohibit or interfere with ability to obtain an accurate blood pressure measurement using the protocol -specified 
automatic /office  blood pressure monitor (e.g., upper arm circumference outside cuff 
size ranges available by geography or arrhythmia that interferes with automatic monitor’s pulse sensing and prohibits an accurate measurement).  
21. Individual works night shifts.  
22. Individual has severe cardiac valve stenosis for which, in the opinion of the 
investigator, a significant reduction of blood pressure is contraindicated.  
23. Individual has a documented confounding medical condition, which in the opinion of 
the investigator, may adversely affect the safety of the participant (e.g., patients with 
clinically significant peripheral vascular disease, aortic aneurysm, bleeding disorders 
such as thrombocytopenia, hemophilia, or significant anemia).  
24. Individual is pregnant, nursing or planning to become pregnant during the course of 
the study  follow- up. (Note: Female participants of childbearing potential must have 
a negative serum or urine human chorionic gonadotropin (hCG) pregnancy test prior to angiography .) 
25. Individual has a known unresolved history of drug use or alcohol dependency, lacks the ability to comprehend or follow instructions, or would be unlikely or unable, in the 
opinion of the investigator, to comply with study  follow- up requirements.  
26. Individual is currently enrolled in a concurrent investigational drug or device study , 
unless approved by the study sponsor . (Note: For the purpose of this protocol, 
participants involved in extended follow -up studies for products that were 
investigational but are currently commercially available are not considered enrolled in an investigational study ). 
SPYRAL PIVOTAL - SPYRAL HTN -OFF MED Clinical Investigation Plan  
  
 Version  12 .0 Page 54 of 139  
 
Medtronic Confidential  
  056-F275, v3 .0 Clinical Investigation Plan Template  
  
27. Individual is currently taking anti-mineralocorticoid drugs. (Note: Subjects may be 
enrolled as long as anti -mineralocorticoid drugs are weaned off at least 8 weeks p rior 
to Screening Visit 1).  
28. Individual has an active peptic ulcer or upper gastrointestinal (GI) bleeding within the 
prior six months  from consent . 
29. Individual has a history of bleeding diathesis or coagulopathy or will refuse blood transfusions . 
30. Individual has polycystic kidney disease, unilateral kidney,  atrophic kidney , or history 
of renal transplant.   
E STUDY  PREPARATION PROCEDURES  
E.1 Investigator/Investigational  site selection  
 Investigator selection criteria 
The role of the principal investigator is to implement and manage the day -to-day conduct of 
the clinical study  as well as ensure data integrity and the rights, safety and well -being of the 
subjects involved in t he clinical study . 
An investigator  may be included in the  clinical study  if compliant with the following 
requirements: appropriately qualified practitioners legally entitled to practice, and experienced 
in the diagnosis and treatment of patients requiring renal denervation .  
 Investigational  site selection criteria  
An investigational  site may be selected for participation in the clinical study  if compliant with 
the following requirements :  
• Investigator should have adequate staff that is accessible and has time to 
manage the study . 
• Investigator should have adequate staff to perform blinded blood pressure measurements.  
• Investigator , and co- investigators  (if applicable) and all key site staff  must be 
willing to provide his/her Curriculum Vitae . 
• Investigational site must be willing to comply with the Clinical Investigation Plan and data collection requirements, including timely reporting of Adverse Events  
and Device Deficiencies  as required by the Clinical Investigation Plan. 
• Investigational site has demonstrated experience with conducting clinical (device) studies that comply with applicable regulatory standards . 
• Investigational site is willing to participate in follow- up of patients for three years . 
SPYRAL PIVOTAL - SPYRAL HTN -OFF MED Clinical Investigation Plan  
  
 Version  12 .0 Page 55 of 139  
 
Medtronic Confidential  
  056-F275, v3 .0 Clinical Investigation Plan Template  
  
• Investigational site has an internet connection with sufficient speed of data 
transfer . 
• Investigational site agrees to one RDN operator per site, unless an exception is 
granted in writing by the Sponsor  
 Clinical Trial Agreement  
Medtronic contracts with participating institutions/investigators through a Clinical Trial 
Agreement that defines the scope and responsibilities and associated compensation related 
to carrying out the obligations under a clinical study sponsored by Medtronic.  
A Clinical Trial Agreement shall be  in place, signed by the participating investigational  site 
and/or principal investigator of each investigational  site, as per the local legal requirements, 
and returned to Medtronic prior to the commencement of any clinical study  activities . The 
investigator is indicating approval of the Clinical Investigation Plan and subsequent 
amendments, by a fully executed agreement. Amendments to this Clinical Investigation Plan 
shall be agreed upon between Medtronic and investigator(s) and be recorded with a justification for the amendments.  
 Curriculum Vitae  
A current signed and dated Curriculum Vitae from the princip al investigator , all co -investigators  
and all key site staff  participating in this  clinical study  as listed on the Delegated Task List shall 
be obtained, evidencing the required qualifications, including the year and where obtained, and including  their curren t position at the investigational  site. The signature on the CV must 
be dated within 3 years prior to the date of activation of the investigational  site.  
 
E.2 Ethics  
 EC/IRB approval  
Here and throughout the document, “EC/IRB” is the term that will be used collectively in 
reference to an Institutional Review Board (IRB), Ethics Committee (EC), Medical Ethics Committee (MEC), Head of Medical Institution (HOMI), Human Research Ethics Committee (HREC), Research Ethics Board (REB) unless otherwise stated.  
Prior to enrolling subjects in this  clinical study , each investigational  site’s EC/IRB  will be 
required to approve the current Clinical Investigation Plan, the Patient Information and 
Informed Consent  form, including any other written information to be provided to the subject s 
and, if applicable, the Investigator’s Brochure.  
EC/IRB approval of the clinical study  must be received in the form of a letter and provided to 
Medtronic before  commencement of the clinical study at an investigational  site. The approval 
letter must contain the version or date of the documents approved. If this information is not 
contained in the approval letter, it must be retrievable from the corresponding submission 
letter. In addition, the approval letter needs to be accompanied by an EC/IRB  roster or letter 
of compliance, to allow verification that the investigator, other investigational  site personnel , 
and/or Medtronic personnel are not members of the EC/IRB . If they are members of the 
SPYRAL PIVOTAL - SPYRAL HTN -OFF MED Clinical Investigation Plan  
  
 Version  12 .0 Page 56 of 139  
 
Medtronic Confidential  
  056-F275, v3 .0 Clinical Investigation Plan Template  
  
EC/IRB , written documentation is required stating that he/she did not participate in the 
approval process. If the EC/IRB imposes any additional requirements (e.g. safety reports, 
progress reports etc.), Medtronic will prepare the required documents and send the m to the 
investigator for reporting to the EC/IRB. Investigators must inform Medtronic of any change in status of EC/IRB approval once the investigational  site has started enrolment. If any action is 
taken by an EC/IRB with respect to the clinical study , that information will be forwarded to 
Medtronic by the respective investigator.  
Medtronic may revise the Clinical Investigational Plan (CIP), Investigator’s Brochure (IB)  (if 
applicable) , Instructions for Use (IFU), Case Report Forms (CRF), Patient Information and 
Informed Consent Form and other study  documents during study  when revision(s) is 
determined necessary. Medtronic  will submit revisions to the regulatory authorities  and will 
also request that sites submit to their EC/IRB for review per national and local requirements .  
In Japan, all protocol amendment s will be reviewed by  the sponsor and principal investigator . 
Upon agreement of the protocol changes, the Amended Protocol Signatur e Document must 
be signed or sealed and dated by the sponsor and investigator and submitted to the director 
of the investigational site according to the procedures of the investigational site. As necessary, the sponsor and investigator must comply with added requirements of IRB.  
 Patient Information and Informed consent process  
The investigator or authorized designee must obtain written informed consent before any clinical study  related activity takes place.  
The patient  will receive the EC/IRB -approved Patient Information (if required by geography)  
and Informed Consent Form. During the consent discussion the investigator or his/her  
authorized designee must fully inform the patient  of all aspects of the clinical study  that are 
relevant to the patient’s decision to participate in the clinical study . If a patient is illiterate, an 
impartial witness must be present during the entire informed consent discussion. All items 
addressed in the Patient Information and the Informed Consent Form must be read aloud and 
explained. The language used shall be as non- technical as possible and must be 
understandable to the patient and the impartial witness, where applicable.  
The patient must have ample time and opportunity to read and understand the Patient 
Information and the Informed Consent Form, to inquire about details of the clinical study , and 
to decide whether or not to participate in the clinical study . All questions about the clinical 
study  should be answered to the satisfaction of the patient. 
Neithe r the investigator, nor the investigational  site staff shall coerce or unduly  improper  
influence or induce a patient  to participate or to continue to participate in the clinical study . 
The informed consent process shall not waive or appear to waive the patient’s rights.  
When the patient  decides to participate in the clinical study , the Patient Information and 
Informed Consent Form must be signed and personally dated by the patient  and investigator  
or authorized designee. If applicable, the witness shall also sign and personally date the 
consent form to attest that the information in the Patient Information and Informed Consent 
Form was accurately explained and clearly understood by the patient , and that informed 
consent was freely given.  
SPYRAL PIVOTAL - SPYRAL HTN -OFF MED Clinical Investigation Plan  
  
 Version  12 .0 Page 57 of 139  
 
Medtronic Confidential  
  056-F275, v3 .0 Clinical Investigation Plan Template  
  
After all persons have signed and dated the Patient Information and Informed Consent Form , 
the investigator must provide the patient with a copy of the signed and dated Patient 
Information  and Informed Consent Form.   
A patient contact card will be made available to the patient  with emergency contact numbers . 
In Japan, the patient and investigator may provide their seal (with printed name) in lieu of a 
signature.   
The patient will be informed about the rights to “withdraw from the study  at any time”, “withdraw 
without any disadvantage and without having to provide reason” . 
 Revisions in Patient Information and Informed Consent Form  
Medtronic will inform the investigators whenever information becomes available that may be relevant to the subject’s confirmed participation in the clinical study . The investigator or his/her 
authorized designee should inform the subject in a timely manner.  
Medtronic will revise the written Patient Information and Informed Consent Form whenever new information becomes available that may be relevant to the subject’s confirmed 
participation in the clinical study . The revised information will be sent to the investigator for 
approval by the EC/IRB  and local regulatory authority, if applicable. After approval by the 
EC/IRB, a copy of this information must be provided to the participating subjects, and the 
informed consent process as described above needs to be repeated.  
 Regulatory submission  
In countries where submission to the regulatory authority is required per local law, no patients will be enrolled in the  clinical study  until the particular regulatory authority has approved the 
current Clinical Investigation Plan for the clinical study  and other documents as required 
according to the local requirements. 
If the regulatory authority imposes any additional requirements (e.g. safety reports, progress 
reports etc.), Medtronic will prepare the required documents and send them to the respective 
authority.  
Other documents that are referred to in this Clinical Investigation Plan are listed below and will be made available upon request: 
• Investigator’s Brochure (if applicable)  
• Case Report Forms  
E.3 Regulatory compliance  
This clinical study  will be conducted in compliance with Declaration of Helsinki  2013, the latest 
version of international standard ISO 14155  ('Clinical Investigation of medical devices for 
human subjects  – Good Clinical Practice '), laws and regulations of the countr ies in which the 
clinical study  is conducted, including data protection laws,  the Clinical Investigation Agreement 
and the Clinical Investigation Plan. The study is compliant with the latest version of ISO14155  
with the exception of adverse event collection after 12 months follow -up.  
SPYRAL PIVOTAL - SPYRAL HTN -OFF MED Clinical Investigation Plan  
  
 Version  12 .0 Page 58 of 139  
 
Medtronic Confidential  
  056-F275, v3 .0 Clinical Investigation Plan Template  
  
21 CFR P art 56 (Institutional Review Boards), Part 50 (Protection of Human Subjects), and 
Part 812 (Investigational Device Exemptions ) only  apply to the US; not to other geographies ). 
21 CFR Part 54 (Financial Disclosure by Clinical I nvestigators) , and Part 11 (Electronic 
Records; Electronic Signatures)  apply to all geographies.  
All principles of the Declaration of Helsinki have been implemented in this  clinical study  by 
means of the informed consent process, EC/IRB  approval, study  training, preclinical testing, 
risk benefit assessment, publication policy, etc.  This clin ical study will also be registered on 
clinicaltrials.gov and study results posted based on the posting rules stipulated.  
The sponsor will avoid improper influence on, or inducement of the subject, monitor, and 
investigator(s) or other parties participating in, or contributing to, the clinical study  by 
implementing the informed consent process, Clinical Investigation Agreements, EC/IRB  
approval.  
In Japan, the planning and conduct of this clinical study are subject to Japanese laws. It will 
begin only when all the requirements of the appropriate regulatory authority have been fulfilled. The study  will also be conducted in accordance with the ethical principles of the Japan GCP 
Ordinance and the Pharmaceutical and Medical Device Act . 
In Canada,the study will be conducted under an Investigational Testing Authorization in 
compliance with Medical Devices Regulations, SOR/98- 282, Section 79- 88.  
E.4 Training  requirements  
Prior to investigational  site activation or subsequent involvement in clinical study  activities, 
Medtronic will provide clinical study  training relevant to the involvement of personnel 
conducting clinical study  activities . Medtronic will train site personnel on, but not limited to, the 
clinical investigation plan, relevant standards and regulations, informed consent, written clinical inv estigation agreements, data collection and reporting tools,  investigator 
responsibilities, as well as device/product training. Study specific training will be documented 
prior to investigational  site activation.  
Training will occur prior to site activation at each site, and will include at a minimum the 
following topics  (as applicable to the role at the site) : 
• Technical overview of device(s)  
• Procedural training for proceduralist  
• CIP overview and study  procedures  
• Investigational device disposition and accountability procedures  
• Procedures for returning unused/explanted devices  
• Case report form (CRF) completion and management, including electronic data entry  
• Investigator and sponsor responsibilities  
• Procedures for obtaining informed consent 
• Investigational Review Board (IRB)/ Ethics Committee (EC) requirements  
• Adverse event/device deficiency reporting procedures  and timelines  
• Deviation reporting procedures  
• Monitoring requirements and expectations  
• Potential regulatory inspections and audits  by the sponsor or sponsor 
representative  
SPYRAL PIVOTAL - SPYRAL HTN -OFF MED Clinical Investigation Plan  
  
 Version  12 .0 Page 59 of 139  
 
Medtronic Confidential  
  056-F275, v3 .0 Clinical Investigation Plan Template  
  
• Site record maintenance and retention  
• Regulatory requirements for commercially approved devices in a clinical study , 
including timely adverse event and complaint reporting  
• Any additional regulatory requirements  
E.5 Clinical study  materials and clinical study -specific equipment  
The sponsor will supply all required study  materials for appropriate data collection before study  
start. Data collected on each patient will be recorded on a web -based electronic Case Report 
Form (eCRF). The passwords for the electronic CRF and for randomization will only be 
distributed to investigational centers where the sponsor has written document ation of site 
readiness.  
Medtronic will control the supply of devices and study  materials. Investigational devices will 
not be sent to the site until receipt of or completion of the following:  
• Curriculum vitae of the principal investigator, (if applicable) co- investigators and 
all key site staff.  
• A signed Clinical Trial Agreement  
• Financial disclosure from the investigators  
• Competent Authority/FDA approval (as applicable to the geography)  
• A copy of the IRB/EC approval letter, along with the voting roster  
• The IRB/EC approved Patient Information and I nformed Consent Form  
• Documented training of the Principal Investigator, at a minimum  
• Delegated Task List  
• Lab certificate and lab normal values/ranges  
• Confirmation of adequacy of equipment/facilities  (e.g. a quiet room to perform 
the blood pressure measurements)  
E.6 Study device/product  handling and traceability 
The Symplicity SpyralTM catheter and Symplicity G3TM generator must be stored as labeled at 
all sites. In countries where the product is investigational (Canada, the US, and Japan) and 
in countries where product is provided by Medtronic for purposes of the study  and 
commercially available, product must be placed in a secure/locked location that meets the 
labeling requirements for device storage. Sites are required to maintain investigational device records that contain the following information on all components shipped to the site for the 
study : 
• Investigational device name  
• Device serial/model number  
• Date of receipt of device 
• Name of person receiving the device  
• Name of person using/opening the device (if applicable)  
• Date of use (if applicable)  
• Subject Identification Number (SID) of subject receiving or using the device (if 
applicable)  
• Disposition (implanted, disposed of, or returned to Medtronic)  
For devices that are returned to Medtronic or disposed of, sites are required to document the following additional information: 
SPYRAL PIVOTAL - SPYRAL HTN -OFF MED Clinical Investigation Plan  
  
 Version  12 .0 Page 60 of 139  
 
Medtronic Confidential  
  056-F275, v3 .0 Clinical Investigation Plan Template  
  
• The reason for the device being returned to Medtronic or disposed of  
• Name of the person who returned or disposed of each device  
• Date shipped to Medtronic, if returned  
• If device is disposed of, the method of disposal  
At the end of the study  enrollment  and crossover  period,  and all remaining investigational 
devices must be returned to  Medtronic.  
The Symplicity SpyralTM catheter and Symplicity G3TM RF generator are commercially 
available in Europe and Australia and will be used within approved labelling for this study .  
 Supply  of investigational devices /products  
 Storage and handling of investigational devices/products  
Investigational devices /products  or products provided by Medtronic free of charge must be 
stored in a secured area. The method of storage shall prevent the use of investigational 
devices/products  for other appli cations than mentioned in this Clinical Investigation Plan. In 
addition, all information for the use, storage and handling of the investigational device/product  
as indicated in the Instructions for Use and User Manual  must be taken into account.  
 Device return procedures /products  
Non-functioning investigational devices must be returned to Medtronic as soon as possible for 
investigation.   
In case a Symplicity G3TM generator or Symplicity SpyralTM catheter needs to be returned, it 
will be returned to the address below, following local procedures:  
 
Symplicity G3TM generator:  
Medtronic CardioVascular  
Attn: Service and Repair  
 7611 Northland Drive  
Brooklyn Park, MN 55428 
Tel: +1 800- 433-4311  
 Symplicity Spyral
TM catheter:  
Medtronic PXM RGI Lab Building 4 
Parkmore Business Park West  
Ballybrit  
Galway  
H91 A2Y5 
Ireland  
 
Symplicity G3TM generator (Japan only)  
Plexus Manufacturing Sdn Bhd (Hillside)  
Bayan Lepas Free Industrial Zone  
Phase II, 11900 Bayan Lepas  
Pulau Pin ang, Malaysia  
SPYRAL PIVOTAL - SPYRAL HTN -OFF MED Clinical Investigation Plan  
  
 Version  12 .0 Page 61 of 139  
 
Medtronic Confidential  
  056-F275, v3 .0 Clinical Investigation Plan Template  
  
At the end of the clinical study , all remaining investigational devices /products  must be returned 
to Medtronic  in the applicable region. 
 Device/product disposition requirements  
Investigational devices/products will be traced during the clinical study  by assigning specific 
serial numbers  to each device/product. The investigator is responsible for maintenance of a 
Device Tracking Log in the Investigator Site File. On this log, the receipt, use, return and 
disposal of the investigational devices/products shall be documented. At the end of the clinical 
study  the principal investigator must sign and date the original Device Tracking Log.  
F STUDY  METHODS  
F.1 Point of enrollment  
Patients will be pre -screened for potential enrollment in the clinical study  based on prior 
medical history and records of office SBP . A pre-screening log will be maintained to determine 
the number of patients that do not meet study  eligibility criteria and who will not be approached 
for participation in the study . 
A subject is  considered enrolled in this  clinical study  at the time at which the subject and 
investigator or authorized designee have personally signed and dated the Patie nt Information 
and Informed Consent Form. Written consent must have been obtained prior to Screening 
Visit 1  (SV1) . 
Investigational  sites will maintain a subject identification log. H owever , this document will not 
be submitted to the sponsor.  
A schedule outlining protocol required visits and assessments for subjects enrolled in the study  
is displayed in Table 4. A flowchart depicting the study design  overview is provided in  
Figure 12. The following procedures will be followed for all subjects , excluding crossovers,  
enrolled in this study  until study  exit. 
SPYRAL PIVOTAL - SPYRAL HTN -OFF MED Clinical Investigation Plan  
  
 Version  12 .0 Page 62 of 139  
 
Medtronic Confidential  
  056-F275, v3 .0 Clinical Investigation Plan Template  
  
 
Figure 12 : Study Design Overview  
 Screen Failure
Does NOT Meet 
All Eligibility CriteriaInformed 
Consent
Screening Visit 1
(1) Medical History
(2) Office blood pressure and heart rate measurements(3) Record Medications and AEs, if applicable
Two Week Screening Visit
(Not required for drug naïve subjects)
(1) Office blood pressure and heart rate measurements(2) Record Medications and AEs, if applicable(3) Clinical Assessment
Screening Visit 2
(1) EQ-5D and SF-36(2) Clinical Assessment(3) Confirm Office SBP ≥ 150 mmHg and <180 mmHg and Office DBP ≥ 90 mmHg (4) Laboratory testing (blood and urine) including drug testing, lipids, uric acid, hsCRP, and renin/aldosterone(5) Subject fitted with 24-Hour ABPM(6) Record Medications and AEs, if applicable
24-Hour ABPM completed
Confirm 21 daytime and 12 
nighttime readings and 24-Hour 
Average ≥140 and <170 mmHg 1:1 
Randomization
Renal Angiography
(1) Reconfirm inclusion/exclusion criteria, including anatomy(2) Subject blinding implemented(3) Record Medications and AEs, if applicable
Denervation Group
Denervation 
Procedure
Control Group
Sham ProcedureDischarge
(1) Blinding Assessment(2) Office Blood Pressure(3) Laboratory testing (blood)(4) Record Medications and AEs, if 
applicable
Study ExitMeets all 
SV2
 Eligibility CriteriaDoes NOT meet 
eligibility criteria
Does NOT Meet 
All eligibility criteria 
Crossover 
evaluation 
6M
Anti-hypertensive 
Medication Washout
 (3-4 weeks)
6 weeks, 8 weeks, 10 weeks
(1) Clinical Assessment (via telephone at 6 and 
10 weeks; or clinic visit if medically necessary)(2) Office Blood Pressure, required at 8 weeks;  only at 6 and 10 weeks if investigator determines clinic visit is necessary
(4) Record Medications and AEs, if applicable2 weeks, 4 weeks
(1) Clinical Assessment
(2) Office Blood Pressure(3) Laboratory testing (4 weeks only)(4) Record Medications and AEs, if 
applicable
3 Months
(1) EQ-5D and SF-36
(2) Clinical Assessment(3) Office Blood Pressure (4) Laboratory testing including drug testing (blood and urine), and renin/aldosterone (blood)(5) Subject fitted with 24-Hour ABPM(6) Blinding Assessment
(7) Record Medications and AEs, if applicableDischarge
(1) Blinding Assessment
(2) Office Blood Pressure(3) Laboratory testing (blood)(4) Record Medications and AEs, if 
applicable
Follow-Up Visits at 6M, 12M, 24M, 36M
(1) EQ-5D and SF-36
(2) Clinical Assessment(3) Office Blood Pressure(4) Laboratory testing including drug testing (blood and urine)(5) Subject fitted with 24-Hour ABPM(6) Renal Artery Imaging (6M, 12M only)(7) Blinding Assessment (6M only)
(8) Record Medications and AEs, if applicable6 weeks, 8 weeks, 10 weeks
(1) Clinical Assessment (via telephone at 6 and 
10 weeks; or clinic visit if medically necessary)(2) Office Blood Pressure, required at 8 weeks;   only at 6 and 10 weeks if investigator determines clinic visit is necessary
(4) Record Medications and AEs, if applicable2 weeks, 4 weeks
(1) Clinical Assessment
(2) Office Blood Pressure(3) Laboratory testing (4 weeks only)(4) Record Medications and AEs, if 
applicable
3 Months
(1) EQ-5D and SF-36
(2) Clinical Assessment(3) Office Blood Pressure (4) Laboratory testing including drug testing (blood and urine), and renin/aldosterone (blood)(5) Subject fitted with 24-Hour ABPM(6) Blinding Assessment
(7) Record Medications and AEs, if applicableOffice SBP ≥ 180 mmHg
Office DBP < 90 mmHg
(drug naïve subjects only)Office SBP ≥ 180 mmHg
Drug naïve subjects with 
Office DBP < 90 mmHg 
Follow-Up Visits at 6M, 12M, 24M, 36M
(1) EQ-5D and SF-36
(2) Clinical Assessment(3) Office Blood Pressure(4) Laboratory testing including drug testing (blood and urine)(5) Subject fitted with 24-Hour ABPM(6) Renal Artery Imaging (6M, 12M only)(7) Blinding Assessment (6M only)
(8) Record Medications and AEs, if applicableMedication Re-Introduction: 
Subjects with OSBP ≥ 140 mmHg 
at 3M
4 Month Visit: 
 (1) Office Blood Pressure
 (2) Clinical Assessment (3) Drug testing (blood and urine) (4) Record Medications and AEs, if applicable
SPYRAL PIVOTAL - SPYRAL HTN -OFF MED Clinical Investigation Plan  
  
 Version  12 .0 Page 63 of 139  
 
Medtronic Confidential  
  056-F275, v3 .0 Clinical Investigation Plan Template  
  
F.2 Screening Visit 1  
After confirmation that the investigator or authorized designee and subject have personally  
signed and dated Patient Information and I nformed Consent  Form , the following assessments 
will be performed at Screening Visit 1:  
a) Medical History will be documented from the study  subject to evaluate for prior 
or existing medical conditions and/or procedures that would exclude subjects 
from participation in the study . 
b) Office Blood Pressure measurements will be obtained in accordance with 
Appendix L.7. This blood pressure measurement will not be used as the 
baseline BP measurement but will be used, in conjunction with the subject’s 
medical history, to determine if, in the investigator’s judgment, the subject’s BP 
at Screening Visit 2 will qualify for inclusion in the study following the 
antihypertensive drug washout period. However, if the subject’s SBP is ≥ 180 
mmHg, the subject will be excluded at Screening Visit 1.  
c) Medication & Adverse Event Reviews will be completed to document baseline 
medication use  and adverse events that occur after enrollment.  
Notification to the subject’s family physician (i.e., the primary physician caring for the patient) of the subject’s participation in the study will be made by mail  prior to the next screening visit . 
The letter should include a brief description of the study , indicate that the subject has given 
permission for the communication, and provide notification that medications that affect blood 
pressure should not be changed without consulting the Principal Investigator from the time of 
randomization until after the 6 month follow -up visit as this would impact the major  endpoint 
of the study.  
F.3 Medication Washout Period  
Subjects not on antihypertensive medication(s) for a minimum of 4 weeks prior to SV1  are 
considered drug
 naïve and can proceed directly to SV2, within 3 -4 weeks.  
Following completion of Screening Visit 1, subjects  on antihypertensive medication must  be 
titrated off all antihypertensive medications over a 3- week washout period in a manner 
specified by the investigator . The washout period may be extended 1 additional week per 
investigator’s discretion if it is judged necessary to allow the subject’s blood pressure to 
stabilize off medications . Subjects with an office systolic blood pressure of <180 mmHg  after 
the minimum  3-week washout period will continue to Screening Visit 2 (SV2) . Subjects with 
an office systolic blood pressure of ≥180 mmHg  at any point  during and after  the washout 
period until procedure will be considered Screen Failures and will be exited from the study , as 
described in the Subject Exit from Study  section of this  Clinical Investigation Plan.  
F.4 Two Week Screening Visit  
The purpose of this visit is to assess the subject’s office blood pressure two weeks after the 
antihypertensive medication washout period has been started. D rug-naïve patients do not 
need this visit . The target date is 2 weeks from the Screening 1 visit ± 3 days. 
SPYRAL PIVOTAL - SPYRAL HTN -OFF MED Clinical Investigation Plan  
  
 Version  12 .0 Page 64 of 139  
 
Medtronic Confidential  
  056-F275, v3 .0 Clinical Investigation Plan Template  
  
a. Office Blood Pressure measurements will be obtained in accordance with 
Appendix L.7. This blood pressure measurement will not be used as the 
baseline BP measurement but will be used, in conjunction with the subject’s 
medical history, to determine if, in the investigator’s judgment, the subject’s BP 
at Screening Visit 2 will qualify for inclusion in the study following the 
antihypertensive drug washout period.  If the systolic OBP ≥180 mmHg, the 
subject must be exited from the trial. A subject who is drug naïve but still has a two week screening visit conducted, should  be considered a screen failure if 
their office diastolic blood pressure is <90 mmHg when the subject is drug naïve 
at SV1 through the 2 week screening visit.  
b. Clinical Assessment will be conducted to further evaluate for prior or existing 
medical conditions that would exclude subjects from participation in the study and to establish the subject’s baseline medical condition. An individual experienced in performing histories and physical exams is required to assess 
subjects for safety assessment during the period of time that study subjects are 
not on antihypertensive medications. 
c. Medication & Adverse Event Reviews will be completed to document baseline 
medication use and adverse events that occur after enrollment. 
F.5 Screening Visit 2  
Screeni ng Visit 2 must  occur within 3-4 weeks of completion of SV1. The following 
assessments will be performed at Screening Visit 2: 
a. EQ-5D: The EuroQol (EQ -5D) instrument will be administered to measure 
baseline health outcomes.  
b. SF-36: The 36- Item Short Form Survey (SF -36) instrument will be administered 
to measure baseline health outcomes. 
c. Clinical Assessment  will be conducted to further evaluate for prior or existing 
medical conditions that would exclude subjects from participation in the study  
and to establish the subject’s baseline medical condition.  An individual 
experienced in performing histories and physical exams is required to assess subjects for safety assessment during the period of time that study subjects are 
not on antihypertensive medications. 
d. Office Blood Pressure measurements will be obtained in accordance with 
Appendix L.7. The average office blood pressure value will be used as the 
baseline value for comparison with follow -up visit office blood pressure values. 
Subjects with an office systolic blood pressure ≥150 and <180 mmHg  and an 
office DBP ≥ 90 mmHg  are eligible to continue the screening process . 
e. Laboratory Tests:  
• Basic metabolic panel Chem -7 (blood ): serum -creatinine, sodium, 
potassium, blood urea nitrogen (BUN), bicarbonate, chloride and 
glucose. Bicarbonate will not be measured for subjects enrolled in Japan  
and Europe. 
SPYRAL PIVOTAL - SPYRAL HTN -OFF MED Clinical Investigation Plan  
  
 Version  12 .0 Page 65 of 139  
 
Medtronic Confidential  
  056-F275, v3 .0 Clinical Investigation Plan Template  
  
• Lipid Panel and hs- CRP (blood) : total cholesterol, HDL, LDL, and 
triglycerides, as well as high sensitive- C reactive protein test are intended 
to evaluate a subject’s cardiovascular risk profile.  High-sensitivity CRP is 
not required to be measured for subjects enrolled at sites where high-
sensitivity CRP test cannot be locally performed.  
• Uric Acid (blood):  This test is intended to potentially identify a marker 
for the renal denerv ation therapy responders. 
• eGFR will be calculated from the serum -creatinine in the Chem -7 panel 
for eligibility criteria by using the  4 variable Modification of Diet in Renal 
Disease (MDRD) Formula or the local Japanese criteria for subjects enrolled in Japan The equation for estimated Glomerular Filtration Rate 
(eGFR) calculation method for Japanese is as follows:    
eGFR (mL/min/1.73 m
2) = 194 x (sCr)－1.094× (Age)－0.287  x (0.739 if 
female)  
Japanese Society of Hypertension Guidelines (JSH 2014), Hypertension 
Research (2014) 37, 266 –278. 
Note:  If eGFR ≥42 and <45 mL/min/1.73m² then patient can be retested 
after hydration with a single, repeat test within two weeks.  
• hCG pregnancy test in blood/urine for female subjects who are not post -
menopausal  
• Renin and Aldosterone (blood) : Samples should be collected in the  
morning after the patient has been out of bed for ≥2 hours and after  
resting quietly  sitting  for a minimum of 5 minutes but preferably  30 
minutes . The time of day and subject’s  position (standing, sitting, or lying 
down) when  the blood sample is collected  should be documented and 
the same time of day  (± 2 hours)  and subject position should be used for 
collection of blood samples for determination of renin and aldosterone at 
later time points in the study.  
• Drug testing  (urine/ blood ) to ensure medications are no longer present 
in the subject’s system. A urine sample will be collected, preferably using 
the subject’s first morning urine. A blood sample will be collected at the 
time of the visit.  
f. 24-hour Ambulatory Blood Pressure Monitoring will be applied at the 
conclusion of Screening Visit  2 to confirm subject’s baseline blood pressure. This 
value will be utilized  as the baseline value for calculating change in 24- hour 
ABPM at various time points post -procedure. Subjects with a 24 -hour systolic 
ABPM of <140 or ≥170 mmHg  after completion of the screening visit will be exited 
from the study . Subjects with a 24- hr systolic ABPM of ≥ 140 an d < 170 mmHg  
are eligible to continue to the randomization (procedure or control ) visit.  A single 
repeat measurement is allowed in case of the following: 1.) a technical issue with 
the blood pressure monitor  or failure to follow ABPM instructions , or 2.) if a valid 
number of readings is not obtained, or 3.) i f the 24 -hr systolic ABPM measured 
SPYRAL PIVOTAL - SPYRAL HTN -OFF MED Clinical Investigation Plan  
  
 Version  12 .0 Page 66 of 139  
 
Medtronic Confidential  
  056-F275, v3 .0 Clinical Investigation Plan Template  
  
135 - <140 mmHg or 170- 175 mmHg. ABPM must be conducted according to 
the guidelines in Appendix L.7.  If ABPM is repeated office blood pressure and 
drug testing must be repeated on day the ABPM is applied.  
g. Adverse Event Reviews will be completed to document adverse events that 
occur after enrollment.  
h. Baseline Renal Imaging  Submit  a baseline Duplex Ultrasound, CT, or MRA  if 
obtained per standard of care prior to procedure  within one year from the date of 
the screening visit 1 and upload via Intelemage or send via courier.  
Subjects determined to not be eligible for randomization will be exited from the study , as 
described in the Subject Exit from Study  section of this  Clinical Investigation Plan.  
It is expected that subjects  who are eligible to continue to randomization will be scheduled for 
a procedure date within 14 calendar days  of completion of Screening Visit 2.. Completion of 
Screening Visit 2 is defined as the day the 24 hour ABPM is completed or date of lab results, 
whichever is later. No subjects will be eligible for  the renal angiogram  more than 2 weeks 
following Screening Visit 2. Randomization confirmation and the control or denervation 
procedure  will occur once all eligibility criteria have been met as evaluated at Screening Visit 
2 and the renal angiogram . 
F.6 Procedure  
Renal Angiography and Randomization Visit  
Reconfirm Key Inclusion/Exclusion Criteria: To re- confirm that subjects still meet 
previously assessed eligibility criteria.   
Renal Angiography and Blinding  
All medication used should be commercially available in the respective geographies and compliant w ith local labeling. When scheduled, subjects will be prepared for a renal 
angiography according to standard procedures. For subjects with chronic kidney disease and/or other risk factors for contrast -induced nephropathy (CIN), the hospital’s standard- of-
care protocol for CIN prevention will be used. Prior to this procedure, appropriate systemic 
anticoagulation ( e.g., heparin  or heparin analog  in case of a documented heprin allergy  should 
be initiated  to maintain an ACT ≥ 250 sec  during the procedure for control and treatment 
groups ). While these subjects are not to be taking antihypertensive medications following SV1 
until 3 months following randomization, either hospital protocol driven or physician discretion 
driven use of short acting antihypertensive medications are permitted to control hypertension 
in order to mitigate bleeding from the arterial access site during the periprocedural period. An 
aortogram and selective renal angiography  will be performed with subjects blinded to 
treatment allocation according to methods outlined in section C. 5 to confirm eligible renal 
artery anatomy . Ensure subject received a minimum aspirin dose of 250 mg intravenous  (per 
local drug dose labelling)  or up to 325 mg oral (per local drug dose labelling) prior to procedure  
unless patient was already taking aspirin on a regular basis . If the patient is already taking 
aspirin daily then at least the usual daily dose should be given on the day of the procedure . If 
the subject has a documented allergy to aspirin, 75 mg per day of clopidogrel can be 
substituted (per local drug dose labelling); under these circumstances, a loading dose of at 
least 150  mg clopidogrel may be administered prior to the procedure  per phy sician discretion . 
SPYRAL PIVOTAL - SPYRAL HTN -OFF MED Clinical Investigation Plan  
  
 Version  12 .0 Page 67 of 139  
 
Medtronic Confidential  
  056-F275, v3 .0 Clinical Investigation Plan Template  
  
In Japan, Canada, and Australia, use of  antiplatelet agents should follow the hospital’s 
protocol for  renal angiography.  
 
Control Group  
Subjects will be blinded during the renal angiogram by a combination of conscious sedation, sensory isolation (e.g., blindfold and music), and lack of familiarity the procedural details and 
duration (i.e., subjects will not know the difference between the renal angiography procedure 
alone and the renal angiography and denervation procedure). If randomized to the Control Group, subjects will remain blinded and remain on the catheterization lab table for at least 20 
minutes prior to introducer sheath removal.  Details of blinding procedure are described in C.5.  
Denervation Procedure  
If randomized to treatment, the renal artery denervation procedure will be performed according 
to the supplied Symplicity Spyral ™ catheter Instructions for Use , Symplicity G3 ™ generator 
User Manual and associated training provided by Medtronic.  
Consider pre -treatment with both anxiolytic medications and analgesic medications, such as 
morphine sulfate or fentanyl (with additional doses timed with ablation treatments as 
appropriate). Blood pressure, O
2 saturation, and heart rate should be closely monitored both 
during the procedure and throughout the recovery phase from the conscious sedation 
administered. Investigators  should make an attempt  to apply treatment to any renal artery that 
meets the anatomy eligibility criteria. The Symplicity Spyral ™ catheter will be inserted into the 
renal artery and the ablation treatments at multiple positions along the renal artery will be 
performed .  
Medtronic recommends performing ablations in all accessible renal arterial vessels between 
3 and 8 mm   in diameter including accessory, branch and main renal arteries  that are outside 
the kidney parenchyma . 
Note: Initial placement of the Symplicity SpyralTM catheter should be just proximal to the renal 
parenchyma as identified on fluoroscopic imaging. Perform as many ablations within a 
segment as anatomy permits starting distally and working proximally without overlapping 
treatment zones. Avoid ablations in a bifurcat ion and within 5mm of areas with calcification  
atheroma or stented lesions .  If the vessel segment cannot accommodate all 4 electrodes, 
then it is suggested to  either 1) position a smaller number of electrodes and deselect 
electrodes, or 2) advance all electrodes within the renal artery vessel segment and deselect the distal electrodes.   
Upon completion of denervation procedure for the Denervation group subjects, or renal 
angiogram for Control subjects, either manual compression or commercialized closure devices can be used to achieve hemostasis at the puncture site. As per usual clinical practice, 
consider use of short acting antihypertensive medications for BP control in the cath lab and 
prior to removing arterial access.  Strict adherence to anticoagulation parameters prior to 
sheath withdrawal following either hospital protocol or standard of care practices are strongly 
recommended . 
Post -procedure data collection requirements  
SPYRAL PIVOTAL - SPYRAL HTN -OFF MED Clinical Investigation Plan  
  
 Version  12 .0 Page 68 of 139  
 
Medtronic Confidential  
  056-F275, v3 .0 Clinical Investigation Plan Template  
  
A copy of the renal angiogram cine procedure will be submitted to the Angiographic Core 
Laboratory. Sedation type, procedure information, fluoroscopy time and contrast dye amount 
will be collected.  
Symplicity G3 ™ generator data will be downloaded by Medtronic, loaded into the Case Report 
Form and submitted to Medtronic Resea rch and Development Department . 
Post -procedure care  
All randomized subjects will be hospitalized overnight following the renal angiogram and 
standard -of-care post -intervention monitoring procedures will be followed, while ensuring 
blinding is maintained.  
Prior to discharge, the subject and BP assessor will complete a blinding assessment form and 
the research staff will collect blood samples, assess for adverse events, and review study  
requirements with the subject to help ensure compliance with the follow -up schedule. An office 
blood pressure will also be obtained by blinded study  personnel. In case of a crossover, anti-
HTN meds, if applicable,  will not be required to be withheld prior to this office blood pressure  
assessment . Various contact details (including telephone numbers and email address)  should 
be obtained from the participant (not supplied to the sponsor) to ensure the ability to contact him/her at the required follow- up times (e.g., home, work, cell, and primary physician).  
Patients shall be prescribed a minimum of 75 mg aspirin for 1 month post -procedure.  All 
medication used should be commercially available in the respective geographies and 
compliant with local labeling. If the subject has a documented allergy to aspirin, at least 75 mg 
clopidogrel per day for 1 month post- procedure may be prescribed. Use of antiplatelet agent s 
in Japan, Canada , and Australia should follow the hospital’s protocol for renal angiography . 
F.7 Follow-Up Procedures  
Subjects will return for in-office follow- up visits at week 2, 4 and 8 (±3 days ) post-procedure. 
A phone call follow- up will be conducted at week 6 and 10 (± 3 days) post -procedure. There 
will additionally be follow- up visits at  3 and 6 months  (±14 days)  post-procedure. Upon 
completion of the 3 month follow -up visit, a Medication Re- Introduction protocol to resume 
antihypertensive medications must be followed, if required. See instructions in  Section F. 9 for 
Medication Re-Introduction for Subjects with  Systolic OBP ≥ 140 mmHg at 3M follow- up visit . 
Subjects  will then return at 6 months ( ± 14 days)  ,12, 24, and 36 months post -procedure with 
visits conducted ± 30 days , from the procedure date. In case of a crossover ,
 subjects  will return 
for in -office visits at 1, 3, 6, 12 and 24 months post -crossover procedure.  
Alternative methods of data collection may be necessary in the case of extenuating 
circumstances, such as a global pandemic, when subjects are prohibited from coming into the 
office for required assessments. For all assessments completed via alternative methods in 
these circumstances, sites are not required to enter a protocol deviation for missing, and/or 
alternative  data collection.   Data unable to be collected remotely or via an alternative method 
should be collected at the next possible in- person visit.   In the event a subject is unable to 
return for a n in-office  follow- up visit, the alternative methods of obtaining follow -up 
assessments are listed below:  
SPYRAL PIVOTAL - SPYRAL HTN -OFF MED Clinical Investigation Plan  
  
 Version  12 .0 Page 69 of 139  
 
Medtronic Confidential  
  056-F275, v3 .0 Clinical Investigation Plan Template  
  
• In-home visit by trained and delegated site personnel or designee, i.e. home health 
care personnel. The following assessments maynot be completed with an in- home 
visit: 
o Renal Artery Imaging:  
 Make every effort to schedule in- person renal artery imaging as soon 
as possible.  
 When possible, the subjects may be referred to a local imaging center 
for assessment. Local imaging technicians would require study training 
and delegation prior to assessment.  
In the event an in- home visit is not possible, the alternate methods for obtaining follow -up 
assessments are listed below:  
• Virtual Visit, i.e. inclusive of video with study subject. The following assessments may 
not be completed with a virtual visit:  
o Clinical Assessment , limited review to be completed per physician discretion. 
o Laboratory Tests:  
 When possible, the subject should be referred to a local laboratory to 
collect samples. Laboratory Kits to be provided to subjects in advance of the visit  by the study site. 
o Renal Artery Imaging:  
 Make every effort to scheduled in- person renal artery imaging as soon 
as possible.  
 When possible, subjects may be referred to a local imaging center for 
assessment. Local imaging technicians would require study training 
and delegation prior to assessment.  
o Office Blood Pressure and ABPM measurements may be collected and 
designated as subject -reported in the case report form.  
 Office blood pressure and ABPM units to be provided to the subjects in 
advance of the visit  by the study site . 
o Witnessed pill intake prior to ABPM.  
 Documentation of pill intake will be assessed virtually.  
• Phone Visit, i.e. no video with the subject. The following assessments may not be 
completed with a phone visit:  
o Clinical Assessment , limited review to be completed per physician discretion. 
o Laboratory Tests:  
 When possible, the subject should be referred to a local laboratory to 
collect samples. Kits to be provided to subjects in advance of the visit  
by study site . 
o Renal Artery Imaging:  
 Make every effort to schedule in- person renal artery imaging as soon 
as possible.  
 When possible, the subjects could be referred to a local imaging center 
for assessment. Local imaging technicians would require study training 
and delegation prior to assessment.  
o Office Blood Pressure and ABPM measurements may be collected and designated as subject -reported in the case report form.  
 Office blood pressure and ABPM units to be provided to the subjects in 
advance of the visit  by study site . 
o Witnessed pill intake prior to ABPM.  
SPYRAL PIVOTAL - SPYRAL HTN -OFF MED Clinical Investigation Plan  
  
 Version  12 .0 Page 70 of 139  
 
Medtronic Confidential  
  056-F275, v3 .0 Clinical Investigation Plan Template  
  
 Documentation of pill intake will be assessed over the phone as 
confirmed verbally by subject . 
In  case the Symplicity  Spyral ™ catheter and Symplicity G3TM generator  receive commercial 
approval in the United States, Canada  and/or Japan during the course of this clinical study , 
the follow -up assessments will continue to be conducted as planned unless otherwise 
instructed.  
Follow -up procedures for all subjects are listed below. Follow -up procedures must be 
performed by blinded site personnel through 6 months follow -up for each subject.  
a) EQ-5D: The Euro- Qol 5D (EQ- 5D) will be administered at the 3, 6,  12, 24 and 
36 month post -procedure visits to measure health outcomes.  
b) SF-36: The 36-Item Short Form Survey (SF- 36) will be administered at the 3, 
6,12, 24  and 36  month post -procedure visits to measure health outcomes.  
c) Clinical Assessment will be conducted at all post-procedure  follow- up visits to 
evaluate the subject’s current medical c ondition.  An individual experienced in 
performing histories and physical exams is required to assess subjects for safety 
assessment during the period of time that study subjects are not on 
antihypertensive medications.   
d) Office Blood Pressure measurements will be obtained in accordance with 
Appendix L.7 at all post-procedure follow- up visits.  
e) Laboratory Tests:   
• Basic metabolic panel Chem -7 (blood) : serum -creatinine, sodium, 
potassium, blood urea nitrogen (BUN), bicarbonate, chloride and 
glucose. Bicarbonate will not be measured for subjects enrolled in Japan  
and Europe. 
• eGFR will be calculated from the serum -creatinine in the Chem -7 panel 
for eligibility criteria by using the 4 variable Modification of Diet in Renal 
Disease (MDRD) Formula or the local Japanese criteria for subjects enrolled in Japan.  
• Renin and Aldosterone test ing (blood; 3 month follow -up only) 
Samples should be collected in the morning after the patient has been 
out of bed for ≥2 hours and after resting quietly after a minimum of 5 
minutes but preferably 30 minutes. The time of day and subject’s position (standing, sitting, or lying down) before the blood sample is collected  
should be documented and the same time of day (± 2 hours) and subject 
position should be used for collection of blood samples for determination of renin and aldosterone at later time points in the study.  
• Drug testing (urine/ blood ) to ensure no medications are present in the 
subject’s system at  3 months follow -up and to ensure that prescribed 
medications are in the subject’s system at 6 , 12, 24, and 36  months . A 
SPYRAL PIVOTAL - SPYRAL HTN -OFF MED Clinical Investigation Plan  
  
 Version  12 .0 Page 71 of 139  
 
Medtronic Confidential  
  056-F275, v3 .0 Clinical Investigation Plan Template  
  
urine sample will be collected, preferably using the subject’s first morning 
urine. A blood sample will be collected at the time of the visit.  
f) Initiate Medication Re-Introduction for Subjects with  Systolic OBP ≥ 140 
mmHg  at 3M follow -up visit. Starting at 3 month follow- up after clinical 
assessment and a valid ABPM  are completed.  
g) Medication & Adverse Event Reviews will be completed at each follow -up visit 
to assess any changes in medication usage or medical condition:  
• Enrollment (consent) to 12- months post  procedure: all medications 
and all adverse events  
• 12 to 36 months post -procedure:  all medications and serious adverse 
events only. Previously reported adverse events will be followed up through resolution until the end of the study. 
h) Renal Artery Imaging will be performed at the 6- month post -procedure  visit to 
assess if a renal artery stenosis   is suspected. A renal duplex ultrasound (DUS) 
will be obtained at 6M and submitted to the DUS Core Laboratory. If the DUS is 
determined to be nondiagnostic  a repeat DUS, a MRA, CT or angiogram will be 
performed (repeat imaging is recommended to be completed within 30 days  after 
confirmation of non -diagnostic imaging) . If evidence of a clinically significant 
stenosis  is indicated by the DUS or MRA/CT Core Laboratories, an angiogram 
must be obtained and submitted to the Angiographic Core Laboratory.   
• A renal duplex ultrasound (DUS) at 6- month follow -up is not 
required for subjects randomized to the control group who are 
crossing over, if they are having the renal denervation procedure 
done within 30 days of their 6 month follow -up visit. If they are not 
having the renal denervation procedure done within the 30 days 
of their 6 month follow -up visit, a renal duplex ultrasound (DUS) 
is required.  
• The 12- month renal imaging  will be required for all randomized 
subjects . If the renal imaging is determined to be nondiagnostic, a 
repeat DUS, MRA, CT A or angiogram will be performed.   If repeat DUS, 
CTA, or MRA is nondiagnostic or evidence of a clinically significant 
stenosis (>60- 70%) is indicated, an angiogram must be obtained and 
submitted to the Angiographic Core Laboratory.  Subjects who have already completed their 12- month visit follow up at the time of protocol 
approval will be required to undergo renal imaging at their next 
scheduled follow -up visit unless they have a renal angiogram due to 
crossover.
For participating sites in Germany and the U K, only DUS 
or renal MRA imaging at the 12- month follow -up visit (or 24M or 
36M follow -up as applicable) will be performed. For these 
countries, if the initial DUS or initial renal MRA is non- diagnostic, 
a repeat DUS or repeat renal MRA should be performed . If the 
initial imaging modality or subsequent repeat(s) are non-
diagnostic, the investigator should choose the repeat imaging 
modality (DUS or MRA) that is expected to yield the required 
information for a diagnostic study.  
SPYRAL PIVOTAL - SPYRAL HTN -OFF MED Clinical Investigation Plan  
  
 Version  12 .0 Page 72 of 139  
 
Medtronic Confidential  
  056-F275, v3 .0 Clinical Investigation Plan Template  
  
i) 24-hour Ambulatory Blood Pressure Monitoring will be conducted at each 
visit from  the 3  month  to the 36 month follow -up visits post-procedure according 
to the guidelines in Appendix L.7. A r epeat ABPM will be required in the event of 
technical issues , failure to follow ABPM guidelines  or if the minimum required 
number of daytime and nighttime readings is not obtained.  If ABPM is repeated 
office blood pressure and drug testing must be repeated on day the ABPM is 
applied (). 
j) Blinding Assessment will be requested from  all study  subjects  and study staff 
assessing BP  at the 3- and 6-month follow -up visits to assess validity of the study  
blinding.  
k) Mortality Assessment will be completed by the investigati onal site when a 
subject cannot be reached after each of the protocol required follow -up visits .. 
F.8 Escape Medication Protocol during  Off Medication Period  
In the event a subject’s office SBP ≥180 mmHg  or there is a safety concern , from 
randomization up to and including the 3 month visit, the subject will be seen a second time 
within 72 hours for a repeat office BP. If the subject’s office SBP remains ≥180 mmHg , the 
subject will be put back on an antihypertensive medication regimen per the investigator’s 
discretion. All efforts should be made to obtain an ABPM and Chem 7 panel , and urine and 
blood for antihypertensive drug testing, prior to t he subject being put back on medications. If 
the subject already started medications, the subject and investigator should consider if it is safe to take the subject off medications for 2 weeks in order to obtain the requirements at the 
3 month visit to ensure endpoint data is collected. The subject will be exited from the off 
medications portion of the study  and will be followed according to  Table 6. If the subject’s 
office SBP< 180 mmHg , the subject will continue to be followed per  Table 4. At any time while  
the subject is not taking anti hypertensive medications, either the subject or the investigator 
may restart anti hypertensive medications if there is a safety concern  and the subject will be 
followed according to Table 8. All blood pressures must be taken according to the guidelines 
in Appendix L.7 with the exception of needing to be completed by 10:30 am . Visits for 
monitoring the subject’s BP for these purposes  must be documented on the eCRF.  Escape 
subjects  randomized to the Control (sham)  group  may be offered renal denervation therapy 
(crossover) after their 6- month follow -up visit. Refer to Section F.10 for crossover procedures.  
F.9 Medication Re-Introduction  for Subjects with 3M Systolic OBP ≥ 140 mmHg  
Upon completion of a valid ABPM at the 3 month follow -up visit, s ubjects with an office 
SBP< 140 mmHg do not need to be followed up for study purposes  until the 6 month follow- up 
visit. Subjects with a n office  SBP ≥ 140 mmHg will begin an antihypertensive medication  
regimen  of one  or more  of the following  classes individually or in a  combination pill  with dosing 
at the discretion of the study investigator : 
• ACE/ARB 
• Calcium Channel Blocker  
• Thiazide- Type Diuretic  
SPYRAL PIVOTAL - SPYRAL HTN -OFF MED Clinical Investigation Plan  
  
 Version  12 .0 Page 73 of 139  
 
Medtronic Confidential  
  056-F275, v3 .0 Clinical Investigation Plan Template  
  
Subject s will return at 4 months ( ± 7 days) to perform a clinical assessment and obtain an 
Office Blood Pressure according to  the guidelines in Appendix L.7.   
• The investigator may utilize his or her discretion in modifying the 
antihypertensive regimen.  
• Any modification to the antihypertensive medication regimen must be 
documented on the eCRFs.  
To provide the appropriate oversight for study subjects, the visit schedule  between the 
required 4- month and 6 -month visits may need to be adapted to account  for a subject's clinical 
status , complexity of the medication regimen, and/or  the subject’s  blood pressure.  If additional 
changes to the antihypertensive medication regimen are made between 3 and up to 6 months  
post-procedure , complete an unscheduled follow-up visit, and obtain an Office Blood Pressure 
according to the guidelines in Appendix L.7.  In addition, all medication changes are to be 
documented on the eCRF.  All medication used should be commercially available in the 
respective geographies and compliant with local labeling.  
 
F.10 Crossover Procedures  
Control subjects may crossover and receive renal denervation therapy at or after their 6 month 
follow- up visit. For the subjects who had already completed their 6 month visit, the decision to 
crossover  must take place at their next in person visit.  All subjects will have 30 days from the  
Crossover visit ( 6, 12, 24 , 36 month follow- up or Unscheduled visit )  to undergo the crossover 
procedure.  Subjects who are more than 30 days from their 6, 12, 24 or 36 month , must 
complete a crossover Baseline visit prior to crossing over. Control subjects who are coming in 
for their scheduled 6, 12, 24 and 36 month  follow- up visi t do not need to come in for a 
crossover Base line visit if all the required crossover Baseline procedures occurred, including 
lipid panel, hs -crp and uric acid blood tests.  To crossover, the subject cannot meet any of the 
anatomical and glomerular filtration rate (eGFR) exclusion criteria, and cannot be  pregnant, 
nursing or planning to become pregnant during the course of the study follow -up.Crossover 
subjects will undergo follow- up visits at 4 weeks, 3, and 6 months (± 14 days) post -procedure 
and annually at 12 and 24 months (± 30 days) post -procedure. Follow -up procedures post -
crossover procedure are listed below.  Subjects who do not meet required eligibility criteria for 
crossover on the day of the procedure will undergo follow -up visits according to their original 
follow- up schedule. Crossover will not be offered at a later time if it was declined by control 
subjects during the allowed 30- day window.     
 
Baseline Crossover Dat a:  
Control subjects who are coming in for their scheduled 6, 12, 24, 36-month or Unscheduled 
follow- up visits do not need to come in for a crossover baseline visit if all required crossover 
baseline procedures occurred during the respective follow -up visi t, as listed below. An in -office 
visit is required for the baseline crossover visit assessments.  Note, if the lipid panel, hs -CRP 
and uric acid were collected at SV2, these tests will not be required to be repeated.  If the lipid panel, hs -CRP and uric acid was not collected at SV2, they will need to be collected within 30 
days prior to the crossover procedure.  For subjects accepting crossover at their 6- month visit, 
the 6 -month DUS is not needed, if the subject has the crossover procedure within 30 days of 
the visit . 
 
SPYRAL PIVOTAL - SPYRAL HTN -OFF MED Clinical Investigation Plan  
  
 Version  12 .0 Page 74 of 139  
 
Medtronic Confidential  
  056-F275, v3 .0 Clinical Investigation Plan Template  
  
a) Clinical Assessment will be conducted.  
b) Office Blood Pressure measurements will be obtained in accordance with 
Appendix L.7.  
c) Laboratory Tests:  
• Basic metabolic panel Chem -7 (blood)): serum -creatinine, sodium, 
potassium, blood urea nitrogen (BUN), bicarbonate, chloride and 
glucose. Bicarbonate will not be measured for subjects enrolled in Japan 
and Europe.  
• Lipid Panel and hs- CRP (blood)  (prior to procedure,  If not already 
collected at SV2) : total cholesterol, HDL, LDL, and triglycerides, as well 
as high sensitive -C reactive protein test are intended to evaluate a 
subject’s cardiovascular risk profile.  High-sensitivity CRP is not required 
to be measured for subjects enrolled at sites where high- sens itivity CRP 
test cannot be locally performed. 
• Uric Acid (blood)  (prior to procedure,  If not already collected at 
SV2): This test is intended to potentially identify a marker for the renal 
denervation therapy responders . 
• eGFR will be calculated from the ser um-creatinine in the Chem -7 panel 
for eligibility criteria by using the 4 variable Modification of Diet in Renal Disease (MDRD) Formula or the local Japanese criteria for subjects 
enrolled in Japan.  
• hCG  (prior to procedure)  pregnancy test in blood/urine for female 
subjects who are not post -menopausal.  
• Drug testing (urine/blood) to ensure prescribed medications are 
present in the subject’s system. A urine sample will be collected, 
preferably using the subject’s first morning urine. A blood sample will be 
collected at the time of the visit.   
d) Medication & Adverse Event Reviews  will be completed to assess any 
changes in medication usage or medical condition,  
e) Witnessed pill taking prior to ABPM  will be undertaken, if applicable. Subjects 
will be instructed to not take their antihypertensive medications on the day of the office visit and to bring their medications with them. Visits will start prior to 
10:30am for all patients who take their antihypertensive medications in the morning. Afternoon visits will be allowed for subjects that take their 
antihypertensive medications in the afternoon. Study personnel should document pill identity and observe the subject swallowing the antihypertensive 
medication(s). Once this is completed and documented, the ABPM device should 
be applied to the subject and the recording started before leaving the office . 
f) 24-hour Ambulatory Blood Pressure Monitoring will be conducted at the 3, 6, 
12, and 24- month post -procedure follow- up visits to evaluate the subject’s 
SPYRAL PIVOTAL - SPYRAL HTN -OFF MED Clinical Investigation Plan  
  
 Version  12 .0 Page 75 of 139  
 
Medtronic Confidential  
  056-F275, v3 .0 Clinical Investigation Plan Template  
  
ambulatory blood pressure according to the guidelines in Appendix L.7. Repeat 
ABPM will be required  in the event of technical issues , failure to follow ABPM 
guidelines  or if the minimum required number of daytime and nighttime readings 
is not obtained.  If ABPM is repeated office blood pressure and drug testing must 
be repeated on day the ABPM is applied.  
 
Crossover Follow -Up Data:  
Crossover subjects will undergo follow -up visits at 1, 3, and 6- months ( ± 14 days) post -
procedure and annually at 12 and 24-months ( ± 30 days) post -procedure. Follow -up 
procedures post -crossover procedure are listed below. Subjects who do not meet required 
eligibility criteria for crossover on the day of the procedure will undergo follow -up visits 
according to their original follow -up schedule.  
 
a) EQ-5D: The Euro- Qol 5D (EQ -5D) will be requested at the 3, 6,  12  and 24 month 
post-procedure visits to measure health outcomes . 
b) SF-36: The 36 -Item Short Form Survey (SF -36) will be administered at the 3, 
6,12  and 24  month post -procedure visits to measure health outcomes. 
c) Clinical Assessment will be conducted at all post -procedure  follow- up visits to 
evaluate the subject’s current medical condition. 
d) Office Blood Pressure measurements will be obtained in accordance with 
Appendix L.7 at all post -procedure  follow- up visits.  
e) Laboratory Tests:  
• Basic metabolic panel Chem -7 (blood)) : ser um-creatinine, sodium, 
potassium, blood urea nitrogen (BUN), bicarbonate, chloride and 
glucose. Bicarbonate will not be measured for subjects enrolled in Japan  
and Europe. 
• eGFR will be calculated from the serum -creatinine in the Chem -7 panel 
for eligibility criteria by using the 4 variable Modification of Diet in Renal 
Disease (MDRD) Formula or the local Japanese criteria for subjects 
enrolled in Japan.  
f) Medication & Adverse Event Reviews will be completed at each follow -up visit 
to assess any changes in medication usage or medical condition:  
• Procedure to 12 -months post -procedure: all medications and all 
adverse events  
• After the 12 -month visit through 24 months post -procedure:  all 
medications and serious adverse events only. Previously reported adverse events will be followed up through resolution until the end of the 
study . 
SPYRAL PIVOTAL - SPYRAL HTN -OFF MED Clinical Investigation Plan  
  
 Version  12 .0 Page 76 of 139  
 
Medtronic Confidential  
  056-F275, v3 .0 Clinical Investigation Plan Template  
  
g) Renal Artery Imaging will be performed at the 6- month post -crossover 
procedure visit to assess if a renal artery stenosis is suspected. A renal duplex 
ultrasound (DUS) will be obtained and submitted to the DUS Core Laboratory. If 
the DUS is determined to be nondiagnostic (not evaluable), a repeat DUS, a 
MRA, CT or angiogram will be perform ed. If evidence of a clinically significant 
stenosis is indicated by the DUS or MRA/CT Core Laboratories, an angiogram must be obtained and submitted to the Angiographic Core Laboratory.  
• The 12- month post -crossover renal DUS, CTA or MRA will be required. 
If the DUS, CTA or MRA is determined to be nondiagnostic, a repeat 
DUS, CTA,  MRA or angiogram will be performed. If repeat DUS/CTA/MRA is nondiagnostic or evidence of a clinically significant 
stenosis (>60- 70%) is indicated, an angiogram must be obtained and 
submitted to the Angiographic Core Laboratory.  Subjects who have already completed their 12- month visit follow up at the time of protocol 
approval will be required to undergo renal imaging at their next scheduled 
follow- up unless they have a renal angiogram due to crossover.  
i. For the participating sites in Germany and the UK, only renal MRA imaging at the 12- month follow -up visit (or 24 or 36M follow -up as 
applicable) will be performed. For these countries, if the initial MRA is non -diagnostic, a repeat MRA should be performed. If the 
initial MRA or repeat renal MRAs are non- diagnostic and an 
additional repeat MRA is not expected to yield the required information for a diagnostic study, a DUS can be completed.  
h) 24-hour Ambulatory Blood Pressure Monitori ng will be conducted at the 3, 6, 
12, and 24- month post -procedure follow- up visits to evaluate the subject’s 
ambulatory blood pressure according to the guidelines in Appendix L.7. Repeat 
ABPM will be required in the event of technical issues , failure to follow ABPM 
guidelines  or if the minimum required number of daytime and nighttime readings 
is not obtained.  If ABPM is repeated office blood pressure and drug testing must 
be repeated on day the ABPM is applied.   
i) Mortality Assessment will be com pleted by the investigational site when a 
subject cannot be reached after each of the protocol required follow -up visits.  
F.11 Confirmatory Blood Draws to Assess Renal Function  
Serum creatinine values will be assessed throughout the study . A second  blood draw will be 
required to confirm a sustained change in renal function in the event of one of the following:  
• >50% increase in serum creatinine from baseline (S creening Visit 2)  
• eGFR <15 mL/min/1.73m2 using the 4 variable MDRD calculation 
The additional blood draw must be taken at least 21 days from the date of the event noted above and documented on an Unscheduled Follow -up CRF. In the event the second blood 
draw results in the sam e event ( e.g., >50% increase in serum creatinine from baseline), an 
adverse event must be reported. If the event is a continuation of an already -identified 
SPYRAL PIVOTAL - SPYRAL HTN -OFF MED Clinical Investigation Plan  
  
 Version  12 .0 Page 77 of 139  
 
Medtronic Confidential  
  056-F275, v3 .0 Clinical Investigation Plan Template  
  
sustained elevation that did not return to <50% of baseline value, another blood draw is not 
necessary.  
F.12 Drug testing for  Emergency Room visit or Hospital ization  for Elevated Blood 
Pressure  
In the event a study subject is  hospitalized or presents to the emergency room for elevated 
BP, the subject should be instructed to have site personnel notified and site personnel should 
attempt to obtain a urine and blood sample for antihypertensive drug testing to confirm if 
subject was complying with medication requirements as per the protocol. This can be obtained 
up to 24 hours after the subject has been discharged 
F.13 Data collection requirements  
All study  data will be entered into electronic Case Report Forms (eCRFs) in a database 
provided by the Sponsor. All eCRFs will be completed using de- identi fied data.  
eCRF completion may be delegated by the Principal Investigator (documented on the 
Delegated Task List) to other study  personnel but the Principal Investigator remains 
responsible for the accuracy and integrity of all data entered in eCRFs.  
Additional details regarding procedures used for data review, database cleaning, issuing and 
resolving data queries, and identification of steps for creation, modification, maintenance, 
archiving retrieval or transmission of source data via any computerize d systems will be 
provided in the study  specific Data Management Plan (DMP).  
The following equipment will be provided to the sites and utilized for assessing the endpoints of the study : 
• Office Blood Pressure Monitors  
• 24-hour Ambulatory Blood Pressure Monitors (ABPM)  
Medtronic will provide automated blood pressure monitors to participating centers for recording office based systolic and diastolic blood pressure through the course of the study . 
Blood pressure monitors will be provided to the sites for use with subjects to record ambulatory systolic and diastolic blood pressure at baseline and through subsequent follow -ups. 
Medtronic will be responsible for the timely calibration of the monitors and replacement of 
monitors, in case of malfunction or failure to record accurate and reliable blood pressure data.  
Medtronic will be responsible for annual maintenance of the Symplicity G3
TM generator  and 
calibration of the Office Blood Pressure and ABPMs according to the manufacturer’s 
requirements . Docu mentation of the routine maintenance will be provided to the study site 
upon completion.  
  
SPYRAL PIVOTAL - SPYRAL HTN -OFF MED Clinical Investigation Plan  
  
 Version  12 .0 Page 78 of 139  
 
Medtronic Confidential  
  056-F275, v3 .0 Clinical Investigation Plan Template  
  
Table 4: Schedule of Testi ng for All Subjects (See 5 for Crossover Subjects’ Testing)  
3 Months  (90 days) : 76-104 days       24 Months  (720 days) : 690 -750 days  
4Months (120 days):113 -127 days  
6 Months  (180 days) : 166 -194 days     36 Months  (1080 days) : 1050- 1110 days  
12 Months  (360 days) : 330- 390 days  
 
 Post-Procedure 
(Wk= ± 3 days) (M=months ± 14 days for 3M and 6M visits; ± 30 days for 12M -36M 
visits)  
Required 
Assessments  SV1 3 Wk Washout 
(minimum) with 
screening visit 
at Wk 2 (see 
next column)  2 Wk visit 
(Screening)  
± 3 days  SV2 
(within 
3-4 Wk 
of SV2)  Procedure Prior to 
Discharge 2Wk 4Wk 6Wk 8Wk 10Wk  3M 4m visit 
for BP≥ 
140 
mmHg  
at 3m 
(±7days)  
 6M 12M  24M  36M  
Medical History  X 
                
Clinical 
Assessment   X X   X X X3 X X3 X X X X X X 
Prescribe 
Medications according to section  F.9)            X X     
Witnessed pill intake (if subject is taking  
antihypertensive medications), Complete after OBP measurements.             X X X X 
SPYRAL PIVOTAL - SPYRAL HTN -OFF MED Clinical Investigation Plan  
  
 Version  12 .0 Page 79 of 139  
 
Medtronic Confidential  
  056-F275, v3 .0 Clinical Investigation Plan Template  
  3 Months  (90 days) : 76-104 days       24 Months  (720 days) : 690 -750 days  
4Months (120 days):113 -127 days  
6 Months  (180 days) : 166 -194 days     36 Months  (1080 days) : 1050- 1110 days  
12 Months  (360 days) : 330- 390 days  
 
 Post-Procedure 
(Wk= ± 3 days) (M=months ± 14 days for 3M and 6M visits; ± 30 days for 12M -36M 
visits)  
Required 
Assessments  SV1 3 Wk Washout 
(minimum) with 
screening visit 
at Wk 2 (see 
next column)  2 Wk visit 
(Screening)  
± 3 days  SV2 
(within 
3-4 Wk 
of SV2)  Procedure Prior to 
Discharge 2Wk 4Wk 6Wk 8Wk 10Wk  3M 4m visit 
for BP≥ 
140 
mmHg  
at 3m 
(±7days)  
 6M 12M  24M  36M  
Renal 
Denervation or Sham Procedure   
  X         
    
Office Blood Pressure according to guidelines in Appendix L.7  X 
X X  X X X X3 X X3 X 
X 
 X X X X 
24-Hour ABPM 
according to guidelines in Appendix L.7    
X        X  
X X X X 
Blood Test s 
(uric acid , lipid 
panel and high -
sensitivity CRP7 
(hs-CRP) )   
X          
    
SPYRAL PIVOTAL - SPYRAL HTN -OFF MED Clinical Investigation Plan  
  
 Version  12 .0 Page 80 of 139  
 
Medtronic Confidential  
  056-F275, v3 .0 Clinical Investigation Plan Template  
  3 Months  (90 days) : 76-104 days       24 Months  (720 days) : 690 -750 days  
4Months (120 days):113 -127 days  
6 Months  (180 days) : 166 -194 days     36 Months  (1080 days) : 1050- 1110 days  
12 Months  (360 days) : 330- 390 days  
 
 Post-Procedure 
(Wk= ± 3 days) (M=months ± 14 days for 3M and 6M visits; ± 30 days for 12M -36M 
visits)  
Required 
Assessments  SV1 3 Wk Washout 
(minimum) with 
screening visit 
at Wk 2 (see 
next column)  2 Wk visit 
(Screening)  
± 3 days  SV2 
(within 
3-4 Wk 
of SV2)  Procedure Prior to 
Discharge 2Wk 4Wk 6Wk 8Wk 10Wk  3M 4m visit 
for BP≥ 
140 
mmHg  
at 3m 
(±7days)  
 6M 12M  24M  36M  
Blood Tests 
(Chem -7) 4   
X  X  X    X  
X X X X 
Blood Tests (renin and aldosterone)   
 
X        X  
    
Serum or Urine Pregnancy Test    X              
Drug testing    X        X X X X X X 
Renal Artery Imaging - 
Angiogram    
 X         
    
Renal Artery 
Imaging    X5          X1 X6 (X)6 (X)6 
Blinding Assessment      X      X  X    
EQ-5D and SF -
36   X        X  X X X X 
SPYRAL PIVOTAL - SPYRAL HTN -OFF MED Clinical Investigation Plan  
  
 Version  12 .0 Page 81 of 139  
 
Medtronic Confidential  
  056-F275, v3 .0 Clinical Investigation Plan Template  
  3 Months  (90 days) : 76-104 days       24 Months  (720 days) : 690 -750 days  
4Months (120 days):113 -127 days  
6 Months  (180 days) : 166 -194 days     36 Months  (1080 days) : 1050- 1110 days  
12 Months  (360 days) : 330- 390 days  
 
 Post-Procedure 
(Wk= ± 3 days) (M=months ± 14 days for 3M and 6M visits; ± 30 days for 12M -36M 
visits)  
Required 
Assessments  SV1 3 Wk Washout 
(minimum) with 
screening visit 
at Wk 2 (see 
next column)  2 Wk visit 
(Screening)  
± 3 days  SV2 
(within 
3-4 Wk 
of SV2)  Procedure Prior to 
Discharge 2Wk 4Wk 6Wk 8Wk 10Wk  3M 4m visit 
for BP≥ 
140 
mmHg  
at 3m 
(±7days)  
 6M 12M  24M  36M  
Mortality 
Assessment *2      X X  X  X  X X X X 
Medication 
Review, Event 
Review  All adverse events (AE) and medication review . 
After 12 months, previously reported AEs will need to be reviewed and updated as needed  Serious AE 
and all 
medication 
review  
1 DUS is required as first line imaging modality. Repeat DUS, MRA, CT,  or angiogram  to be used if DUS is nondiagnostic.  Renal angiography must be used if  repeat  DUS/CTA/MRA is nondiagnostic or stenosis 
>60-70% is suspected.  The 6M DUS w ill not be required for subjects crossing over at 6M.  
2 Conduct if follow -up missed.  
3 If medically necessary, phone contact may be replaced with office visit. Office blood pressur e (according to guidelines in Appendix L.7), only needs to be obtained if an office visit occurs.   
4 Bicarbonate will not be measured for subjects enrolled in Japan and Europe.  
5 Submit baseline duplex ultrasound, CT, or MRA  if obtained per standard of car e within one year from the date of Screening visit 1.  
6 DUS/ CTA/MRA  required as first line imaging modality at 12M (and 24M and 36M as applicable).  Repeat DUS, MRA, or CTA to be used if prior imaging modality is nondiagnostic. If repeat DUS/CTA/MRA is nondiagnostic or evidence 
of a clinically significant stenosis (>60 -70%) is indicated, an angiogram must be obtained and submitted to the Angiographic Core Laboratory.  Subjects who have already completed their 12 -month without renal imaging  will be required to 
undergo renal imaging at their next scheduled follow -up unless they have a renal angiogram due to crossover. For participating sites in Germany and the UK, only DUS or renal MRA imaging at the 12 -month follow -up visit (or 24 or 36M 
follow-up as applicable) will be performed. For these countries, if the initial DUS or initial renal MRA is non -diagnostic, a repeat DUS or repeat renal MRA should be performed. If the initial imaging modality or subsequent repeat(s) are  non-
diagnostic, the investigator should choose the repeat imaging modality (DUS or MRA) that is expected to yield the required information for a d iagnostic study.  
 
7 High -sensitivity CRP is not required to be measured for subjects enrolled at sites where high-sensitivity CRP test cannot be locally performed  
 
 
  
SPYRAL PIVOTAL - SPYRAL HTN -OFF MED Clinical Investigation Plan  
  
 Version  12 .0 Page 82 of 139  
 
Medtronic Confidential  
  056-F275, v3 .0 Clinical Investigation Plan Template  
  Table 5: Schedule of Testing for Crossover Subjects   
1 Month (30 days): 14 -44 days  
3 Months  (90 days) : 76-104 days       24 Months  (720 days): 690- 750 days  
6 Months  (180 days) : 166 -194 days      
12 Months  (360 days) : 330- 390 days  
 Post-Procedure 
 (M=months ± 14 days for 3M and 6M visits; ± 30 days for 12M -24M 
visits)  
Required Assessments   
Baseline  Renal 
Denervation  Prior to 
Discharge 1M  
3M 6M 12M  24M  
Clinical Assessment  X   X X X X X 
Blood test s (uric acid , lipid panel and high -
sensitivity CRP (hs -CRP) )******  X (prior to 
procedure) *****        
Blood Tests (Chem -7)***  
X  X X X X X X 
Office Blood Pressure  according to guidelines in 
Appendix L.7   
X  X X X X X X 
Serum or Urine Pregnancy Test   X (prior to 
procedure)        
Witnessed pill intake (if subject is taking  
antihypertensive medications), Complete after 
OBP measurements.  X    X X X X 
24-Hour ABPM according to guidelines in 
Appendix L.7   
X    X X X X 
EQ-5D and SF -36     X X X X 
Renal Denervation   X       
Renal Artery Imaging - Angiogram   X       
Drug Testing  X    X X X X 
SPYRAL PIVOTAL - SPYRAL HTN -OFF MED Clinical Investigation Plan  
  
 Version  12 .0 Page 83 of 139  
 
Medtronic Confidential  
  056-F275, v3 .0 Clinical Investigation Plan Template  
  1 Month (30 days): 14 -44 days  
3 Months  (90 days) : 76-104 days       24 Months  (720 days): 690- 750 days  
6 Months  (180 days) : 166 -194 days      
12 Months  (360 days) : 330- 390 days  
 Post-Procedure 
 (M=months ± 14 days for 3M and 6M visits; ± 30 days for 12M -24M 
visits)  
Required Assessments   
Baseline  Renal 
Denervation  Prior to 
Discharge 1M  
3M 6M 12M  24M  
Renal Artery Imaging       X* X**** (X)**** 
Mortality Assessment**     X X X X X 
Medication Review, Event Review  All adverse events (AE) and medication review  
After 12 months, previously reported AEs will need to be reviewed and updated as needed  
 Serious AE 
and all 
medication 
review   
  *DUS is required as first line imaging modality. Repeat DUS, MRA, CT or angiogram to be used if DUS is non- diagnostic . Renal angiography must be used if repeat DUS/CTA/MRA is nondiagnostic or stenosis 
>60-70% is suspected.  
  **Conduct if follow -up visit mis sed  
  *** Bicarbonate will not be measured for subjects enrolled Japan  and Europe.  
**** DUS/ CTA/MRA  required as first line imaging modality at 12M (and 24M as applicable).  Repeat DUS, MRA, or CTA to be used if prior imaging modality is nondiagnostic. If repeat DUS/CTA/MRA is nondiagnostic or evidence of a 
clinically significant stenosis (>60 -70%) is indicated, an angiogram must be obtained and submitted to the Angiographic Core Laboratory.  Subjects who have already completed their 12 -month without renal imaging will be required to 
undergo renal imaging at their next scheduled follow- up. For participating sites in Germany and the UK, only DUS or renal MRA imaging at the 12 -month follow -up visit (or 24 M follow -up as applicable) will be performed. For these countries, 
if the initial DUS or initial renal MRA is non -diagnostic, a repeat DUS or repeat renal MRA should be performed. If the initial imaging modality or subsequent repeat(s) are  non-diagnostic, the investigator should choose the repeat imaging 
modality (DUS or MRA) that is expected to yield the required information for a diagnostic study.  
 
*****If not already collected at SV2  
******  High -sensitivity CRP is not required to be measured for subjects enrolled at sites where high -sensitivity CRP test cannot be locally performed  
  
SPYRAL PIVOTAL - SPYRAL HTN -OFF MED Clinical Investigation Plan  
  
 Version  12 .0 Page 84 of 139  
 
Medtronic Confidential  
  056-F275, v3 .0 Clinical Investigation Plan Template  
   
Table 6: Schedule of Testing through 36 Months for Subjects with office SBP ≥180 mmHg (confirmed via 2 measurements) or Escape via 
Investigator Discretion during Off -Medication Period Post -randomization  
 
   Post-Procedure 
 (Wk= ± 3 days, M=months ± 14 days for 3M and 6M visits; ± 30 days for 12M -36M visits)  
Required Assessments  Procedure Prior to 
Discharge  2Wk 4Wk 6Wk 8Wk 10Wk  3M 6M 12M  24M  36M  
Office Blood Pressure according 
to guidelines in Appendix L.7   X X X X X X X X X X X 
Renal Artery Imaging          X1 X3 (X)3 (X)3 
Mortality Assessment2   X X X X X X X X X X 
Medication Review, Event 
Review  All adverse events (AE) and medication review  
After 12 months, previously reported AEs will need to be reviewed and updated as needed  Serious AE and all 
medication review  
1 DUS required as first line imaging modality. Repeat DUS, MRA, CT, or angiogram to be used if DUS is nondiagnostic.  Renal angiography must be used if  repeat  DUS/CTA/MRA is nondiagnostic or stenosis >60 -
70% is suspected.  
2 Conduct if follow -up visit missed  
3 DUS/ CTA/MRA  required as first line imaging modality at 12M (and 24M and 36M as applicable).  Repeat  DUS, MRA, or CTA to be used if prior imaging modality is nondiagnostic. If repeat DUS/CTA/MRA is nondiagnostic or evidence 
of a clinically significant stenosis (>60 -70%) is indicated, an angiogram must be obtained and submitted to the Angiographic Core La boratory.  Subjects who have already completed their 12 -month without renal imaging will be required to 
undergo renal imaging at their next scheduled follow -up. For participating sites in Germany and the UK, only DUS or renal MRA imaging at the 12 -month fo llow-up visit (or 24 or 36M follow -up as applicable) will be performed. For these 
countries, if the initial DUS or initial renal MRA is non -diagnostic, a repeat DUS or repeat renal MRA should be performed. If the initial imaging modality or subsequent repe at(s) are non -diagnostic, the investigator should choose the repeat 
imaging modality (DUS or MRA) that is expected to yield the required information for a diagnostic study.  
  
SPYRAL PIVOTAL - SPYRAL HTN -OFF MED Clinical Investigation Plan  
  
 Version  12 .0 Page 85 of 139  
 
Medtronic Confidential  
  056-F275, v3 .0 Clinical Investigation Plan Template  
  F.14 Role of sponsor’s representatives  
Sponsor’s representatives will provide support as required for the clinical study , including but 
not limited to technical support during the procedure and/or technical support during follow -up 
in order to ensure that all study  requirements are met  and the procedure is performed 
according to the Instructions for Use. The sponsor’s representatives providing technical 
support may be listed on the sponsor technical support list.  
F.15 Source documents  
Data entered in the eCRF must be traceable to source documents. Source documentation is 
defined as the first time data appear, and may include original documents, data and records 
(e.g., hospital records, clinical and office charts, procedure reports, laboratory notes, 
memoranda, pharmacy dispensing records, recorded data from automated instruments, 
copies or transcriptions certified after verification as being accurate copies, subject files, and 
records kept at the pharmacy, at the laboratories and at medico- technical departments 
involved in the clinical study ). Information in s ource documents  (i.e., medical history/physical 
condition)  dated prior to the Patient Information and Informed Consent Form signature date 
may be used to verify patient eligibility  criteria. 
Clinical records must be marked to indicate a subject has been enrolled into the clinical study . 
The eCRFs (or paper copies) may not serve as source documents. Source documentation for 
data elements not routinely captured in medical records may vary from site to site; the site may use source document worksheets if identified as source documents.  
The Investigator must ensure the availability of source documents from which the information on the eCRFs was derived. Where printouts of electronic medical records are provided as 
source documents, or where copies of source documents are retained as source documents, 
they should be signed and dated by a member of the investigational site team indicating they are a true reproduction of the original source document.  
The source documents must be made available for monitoring or auditing by the sponsor’s 
representative or representatives of the competent authorities and other applicable regulatory 
agencies.  
Copies of source documents will be requested to support event adjudication by the Clinical 
Events Committee. In Japan, availability of source documentation may be limited due to 
hospital policies. If a specific source document is not available, necessary information may be 
transcribed onto the relevant CRF page . 
F.16 Adverse events  and device deficiencies  
 Definition/classification  
For each reported adverse event, the Investigator will assess the events in terms of relationship to the device, relationship to the procedure, relationship to the renal denervation therapy (if applicable) as defined below. 
SPYRAL PIVOTAL - SPYRAL HTN -OFF MED Clinical Investigation Plan  
  
 Version  12 .0 Page 86 of 139  
 
Medtronic Confidential  
  056-F275, v3 .0 Clinical Investigation Plan Template  
  • Device : A device related AE is defined as any AE for which a causal relationship 
between the event and the Symplicity  SpyralTM catheter or Symplicity  G3TM 
generator can be established.  
• Procedure : A procedure related AE is defined as any  AE occurring within 7 days 
post-procedure (or post -denervation in the case of a control group subject being 
denervated at cross over) associated with the renal angiogram and intervention 
techniques involved in preparing for the actual renal denervation tr eatment.  
• Therapy : A therapy related AE is a defined as any AE associated with a subject’s 
physiological response to the renal denervation procedure.  
For the purposes of the clinical report, Medtronic will classify each Adverse Event according 
to the latest  version of International Organization of Standardization (ISO) ISO 14155.  
Where the definition indicates “device”, it refers to any device used in the study . This might be 
the device under investigation, or any market released component of the system. 
Adverse Event (AE): (ISO14155 3.2)  
Untoward medical occurrence , unintended disease or injury, or untoward clinical signs 
(including abnormal laboratory findings) in subjects, users or other persons, whether or not 
related to the investigational medical device and whether anticipated or unanticipated. 
NOTE 1: This definition includes events related to the investigational medical device or the comparator.  
NOTE 2: This definition includes events related to the procedures involved.  
NOTE 3: For users or other persons, this definition is restricted to events related to investigational medical devices. 
Adverse Device Effect (ADE): (ISO14155 3.1) 
Adverse event related to the use of an investigational medical device  
NOTE 1: This definition includes adverse events resulting from insufficient or inadequate 
instructions for use, deployment, implantation, installation, or operation, or any malfunction of 
the investigational medical device. 
NOTE 2: This definition includes any event resulting from use error or from intentional misuse 
of the investigational medical device 
Note 3:  This includes a “comparator” if the comparator is a medical device  
Device Deficiency (DD): ( ISO14155 3.19)  
Inadequacy of a medical device with respect to its identity, quality, durability, reliability, usability, safety 
or performance.  
NOTE 1: DD include malfunctions, use errors and inadequacy in the information supplied by 
the manufacturer including labeling.   
NOTE2: This definition includes device deficiencies related to the investigational medical device or the comparator.  
SPYRAL PIVOTAL - SPYRAL HTN -OFF MED Clinical Investigation Plan  
  
 Version  12 .0 Page 87 of 139  
 
Medtronic Confidential  
  056-F275, v3 .0 Clinical Investigation Plan Template  
   
Serious Adverse Event (SAE): (ISO 14155  3.37)  
Adverse event that led to any of the following:  
a) death,  
b) serious deterioration in the health of the subject , users, or other persons as defined 
by one or more of the following:    
1) a life -threatening illness or injury, or  
2) a permanent impairment of a body structure or a body function, including 
chronic diseases, or  
3) in-patient or prolonged hospitalization, or  
4) medical or surgical intervention to prevent life- threatening illness or injury or 
permanent impairment to a body structure or a body function  including 
chronic diseases, or  
c) foetal distress, foetal death or a congenital abnormality or birth defect  including 
physical or mental impairment .  
NOTE: Planned hospitalization for a pre- existing condition, or a procedure 
required by the CIP, without serious deterioration in health, is not considered a 
serious adverse event.  
Serious Adverse Device Effect (SADE): (ISO 14155 3.36)  
Adverse device effect that has resulted in any of the consequences characteristic of a Serious Adverse Event  
Unanticipated Serious Adverse Device Effect (USADE): (ISO 14155 3.42)  
Serious adverse device effect which by its nature, incidence, severity or outcome has not been identified in the current version of the risk analysis report  
NOTE: Anticipated serious adverse device effect (ASADE) is an effect which by its nature, incidence, severity or outcome has been identified in the risk analysis report.  
Serious Health Threat:
 (ISO 14155 3.46)  
Signal from any adverse event or device deficiency that indicates an imminent risk of death or a serious deterioration in the health in subjects, users or other persons, and that requires 
prompt remedial action for other subjects, users or other persons.  
NOTE 1: This would include events that are of significant and unexpected nature such that they become alarming 
as a potential serious health hazard or possibility  of multiple deaths occurring at short intervals  
As this study  will be conducted in compliance to US Code of Federal Regulations (CFR) CRF 
21 Part 11 the following definitions will apply:  
Unanticipated Adverse Device Effect (UADE): (CFR 21 -812.3)  
Any serious adverse effect on health or safety or any life- threatening problem or death caused 
by, or associated with, a device, if that effect, problem, or death, was not previously identified 
in nature, severity, or degree of incidence in the Clinical Investigation Plan or application (or a 
supplementary plan or application), or any other unanticipated problem associated with a 
device that relates to the rights, safety, or welfare of subjects.  
SPYRAL PIVOTAL - SPYRAL HTN -OFF MED Clinical Investigation Plan  
  
 Version  12 .0 Page 88 of 139  
 
Medtronic Confidential  
  056-F275, v3 .0 Clinical Investigation Plan Template  
  Serious Adverse Health Consequences: (CFR 21 -814) 
Any significant adverse experience, including those which may be either life- threatening or 
involve permanent or long term injuries, but excluding injuries that are non -life-threatening and 
that are temporary and reasonably reversible.  
 
 Recording, reporting, and review of Adv erse Events  
Adverse Event (AE) information will be collected by the site from subject enrollment (consent) 
through study  termination  or study exit  per table 8 reporting requirements . AEs will be followed 
until the event has resolved or study completion, which ever comes later (in the case of 
permanent impairment, the event will be followed until it stabilizes and the overall clinical outcome has been ascertained).  
The Investigator will report any adverse events that may occur to the Sponsor, and  will indicate  
the date of the event, and will assess  seriousness,  relationship (to the device, procedure and 
renal denervation therapy where applicable), subsequent treatment or intervention r equired, 
resolution status and whether or not the adverse event resulted in the subject’s discontinuation 
from the study . The Investigator will provide further information regarding adverse events as 
requested by the Sponsor. In the event of an unexpected death, an autopsy should be 
requested.  
A list of AEs that may be associated with the use of the investigational device and/or the 
interventional procedure is provided in the Risks section (Section J.2).  
Events that do not qualify as AEs:  
• Documented pre- existing conditions without a change in the nature or severity of 
the condition  
• Pre-planned hospitalizations for device change out (e.g. CRT, ICD, IPG)  
• Appropriate cardiac device therapies received as a result of pre- existing 
arrhythmias  
• SBP below 100 mmHg  without producing symptoms suggestive of hypotension 
• Unavoidable AEs (see Table 7)  
 
Table 7: Unavoidable Adverse Events  
Event Description  Time Frame (hours) from the Renal 
Denervation Procedure  
Anesthesia related nausea/vomiting  24 
Low grade fever (<100 ᴼF or <37.8 ᴼC) 48 
Mild to moderate bruising/ecchymosis (at insertion site)  168 
Sleep problems (insomnia)  72 
Back pain related to laying on table  72 
SPYRAL PIVOTAL - SPYRAL HTN -OFF MED Clinical Investigation Plan  
  
 Version  12 .0 Page 89 of 139  
 
Medtronic Confidential  
  056-F275, v3 .0 Clinical Investigation Plan Template  
  Event Description  Time Frame (hours) from the Renal 
Denervation Procedure  
Elevated blood pressure  During the procedure  
 
In Japan, all adverse event information (including Unavoidable AEs) will be collected by the 
site. 
Onset of any events listed in Table 7 after the specified timeframes and/or events lasting 
longer than the specified timeframe (if onset is at the time of procedure) should be reported 
as an AE.  
All Adverse Events, regardless of relatedness or outcome, must be reported up until 12 
months.  After 12 months, only SAEs are to be reported. Adverse events will be documented 
on the appropriate case report form, reported by the investigational site to Medtronic, and to 
the EC/IRB  (if required) within the EC/IRB  required timeframe and local and national 
regulations, as applicable. Adverse Even ts shall be reported on the Adverse Event eCRF, one 
eCRF for each Adverse Event term. See the Adverse Event eCRF for the information to be 
reported for each Adverse Event and Table 8  for the event reporting timeframe requirements.  
For Adverse Events that require immediate reporting ( Table 8 ), initia l reporting will be done  
on the eCRF by completing as much information as is available. The AE eCRF must be “saved 
as Complete” in the Remote Data Capture (RDC) system to ensure it is reported to Medtronic 
as soon as possible.  
All Adverse Events and Device Deficiencies will be reviewed by the Medtronic Safety Department. This review will include the determination whether the Adverse Event meets 
regulatory reporting requirements (seeTable 8). The Sponsor will ensure timely Adverse 
Event/ reporting to meet global regulatory requirements.  In case the Adverse Event/Device 
Deficiency is related to a Medtronic market released devic e used during the study , the 
Medtronic employee who first becomes aware will promptly  report this device related Adverse 
Event/Device Deficiency to the Medtronic Product Experience Management (PXM) Galway, 
Ireland. The Medtronic Product Experience Management (PXM) Galway, Ireland will ensure 
prompt review, and appropriate reporting.  
UADE Evaluation and Reporting:  
Medtronic will conduct an evaluation of the UADE in accordance with CFR 812.46(b) and shall 
report the results of such evaluation to FDA and to all reviewing ethics committees and 
participating investigators within 10 working days after Medtronic first receives notice of the 
effect. Thereafter, Medtronic shall submit such additional reports concerning the effect as FDA 
requests. Events reported for this study from all geographies will be reviewed and assessed 
for UADE reporting to the FDA. Events deemed to be UADEs will be submitted per local reporting requirements.  
 Recording, reporting, and review of Device Deficiencies  
Device deficiencies are defined as inadequacy of a medical device with respect to its identity, quality, durability, reliability, safety or performance (ISO 14155  3.19) . Device deficiencies 
SPYRAL PIVOTAL - SPYRAL HTN -OFF MED Clinical Investigation Plan  
  
 Version  12 .0 Page 90 of 139  
 
Medtronic Confidential  
  056-F275, v3 .0 Clinical Investigation Plan Template  
  include malfunctions, use errors, and inadequacy in the information supplied by the 
manufacturer including labeling.  
Malfunction is defined as the failure of a device to meet its performance specifications or 
otherwise perform as intended. Performance specifications include all claims made in the 
labeling for the device. The intended performance of a device refers to the intended use for 
which the device is labeled or marketed [Ref. 21 CFR 803.3(m)]. Product labels, Instructions 
for Use, and User Manuals for this study  are provided sepa rately . 
All device deficiencies and malfunctions will be documented on the appropriate case report 
form, reported to Medtronic, and reported to the ethics committee (if required) within the ethics 
committee required timeframe and local and national regulations.  Device Deficiencies that did 
not lead to an Adverse Event should be reported on a Device Deficiency Form,  one for each 
Device Deficiency. Please refer the Device Deficiency eCRF for the information to be reported 
for each Device Deficiency that did not lead to an Adverse Event.  
Device  deficiencies that did not lead to an Adverse Event but could have led to an SADE  (ISO 
14155 6.4.2)  
a) if either suitable action had not been taken,  
b) if intervention had not been made, or  
c) if circumstances had been less fortunate,  
require immediate reporting (see Table 8). Initial reporting may be done by will be done on the 
eCRF by completing as much information as is available. The Device Deficiency (e)CRF must be “saved as Complete” in the Remote Data Capture (RDC) system to ensure it is reported to 
Medtronic as soon as possible.  
 Adverse Event Reporting Requirements  
Investigator and Sponsor reporting requirements of events and device deficiencies are outlined in Table 8.   
SPYRAL PIVOTAL - SPYRAL HTN -OFF MED Clinical Investigation Plan  
  
 Version  12 .0 Page 91 of 139  
 
Medtronic Confidential  
  056-F275, v3 .0 Clinical Investigation Plan Template  
   
Table 8: Adverse Event Reporting Requirements  
Serious Adverse Device Effects (SADE), including Unanticipated Serious Adverse Device Effect  
(USADE) and Unanticipated Adverse Device Effects (UADE):  
Investigator submit to:  Sponsor submit to:  
Medtronic:  Submit as soon as possible  as per local reporting 
requirement , but not later than within 10 working days after the 
investigator first learns of the event.  
Canada: USADEs/SADEs on the patient, the user or any other 
person must be reported to the Sponsor within 72 hours after it 
comes to the attention of the qualified investigator. Incidents that could lead to USADEs/SADEs, were it to reoccur, must  also be reported within 72 hours.  
In Europe:  Submit immediately  (but no later than 10 working 
days)  after the investigator learns of the event or of new 
information in relation with an already reported event.  
In Japan:  Submit as soon as possible but no later than 3 business 
days after the designated study site personnel first learns of the event and to the IRB within the IRB required timeframe.  
 Regulatory authorities  (other than 
Australia) : Submit as soon as possible, but 
not later than within 10 working days after 
the Sponsor first receives notice of the 
event  as per local reporting requirement .  
In Australia : Medtronic will adhere to the 
adverse event reporting requirements for Post Market  Release ( PMR ) studies as per 
the requirements of the Therapeutic Goods 
(Medical devices) Regulations 2002.  
In Canada : Medtronic will adhere to the 
Medical Devices Regula- tions, SOR/98 -
282, Mandatory Problem Reporting 
Sections 59- 61. 
 
EC/IRB:  Reporting ti meframe as per local EC/IRB requirement.  
 EC/IRB:  Reporting timeframe as per local 
EC/IRB requirement.  
Serious Adverse Events (SAE)  
Investigator submit to:  Sponsor submit to:  
Medtronic:  Submit as soon as possible as per local reporting 
requirement, but not later than within 10 working days after the 
investigator first learns of the event.  
Canada: As required by Clinical Investigation Plan.  
In Europe:  Submit immediately  (but no later than  10 working 
days)  after the investigator learns of the event or of new 
information in relation with an already reported event.  
In Japan: SAE m ust be reported by the investigator or delegated  
study staff to Medtronic within 24 hours after the investigator 
first learns of the event by completion of an AE eCRF page . If 
the eCRF database is not available or the site is unable to 
complete the eCRF due to technical reasons, the Sponsor should be notified of the event using a faxed SAE Rush Form. If the SAE 
is reported using a SAE Rush Form, an AE page of the eCRF 
should be completed within 3 business days after the designated 
investigational site personnel first learns of the event if possible.  Regulatory authorities:  Reporting 
timeframe as per local  requirement  
In Japan: All SAEs classified by 
Medtronic Japan Safety as reportable 
events will follow the applicable 
Pharmaceutical s and Medical Devices 
Agency (PMDA) reporting requirements 
(Ordi nance for Enforcement of the 
Pharmaceutical and Medical Device Act, 
Article 274, paragraph 2).  
In Australia : Medtronic will adhere to the 
adverse event reporting requirements for PMR studies as per the requirements of the 
Therapeutic Goods (Medical devices) 
Regulations 2002.  
EC/IRB:  Reporting timeframe as per local EC/IRB requirement.  
In Japan: Upon reporting the SAE within 24 hours to Medtronic, 
the event must be reported to the site director (if required) by the investigator within the IRB required timeframe.  
In Australia:  Report to the sponsor per local reporting 
requirements and without unjustified delay, all serious adverse 
events   EC/IRB:  Reporting timeframe as per local 
EC/IRB requirement.  
Adverse Device Effects (ADE)  
Investigator submit to:  Sponsor submit to:  
Medtronic:  Submit as soon as possible as per local reporting Regulatory authorities  (other than 
SPYRAL PIVOTAL - SPYRAL HTN -OFF MED Clinical Investigation Plan  
  
 Version  12 .0 Page 92 of 139  
 
Medtronic Confidential  
  056-F275, v3 .0 Clinical Investigation Plan Template  
  Table 8: Adverse Event Reporting Requirements  
requirement, but not later than within 10 working days after the 
investigator first learns of the event.  
In Australia:  As required by Clinical Investigation Plan  
In Europe:  Submit immediately (but no later than 10 working 
days) after investigator learns about new event or of new 
information related to an already reported event.  
In Canada:  As required by the Clinical Inve stigation Plan  
 Australia) : Reporting timeframe as per 
local requirement  
In Australia : Medtronic will adhere to the 
adverse event reporting requirements for 
PMR studies as per the requirements of the 
Therapeutic Goods (Medical devices) 
Regulations 2002.  
EC/IRB:  Reporting timeframe as per local EC/IRB requirement.  
In Australia:  As required by EC . EC/IRB:  Reporting timeframe as per local 
EC/IRB requirement.  
All other AEs  
Investigator submit to:  Sponsor submit to:  
Medtronic:  Submit as soon as possible as per local reporting 
requirement after  the investigator first learns of the event.   
In Australia:  As required by Clinical Investigation Plan  
In Europe:  Submit in a timely manner after investigator learns 
about new event or of new information related to an already 
reported event.  Regulatory authorities  (other than 
Australia) : Reporting timeframe as per 
local requirement  
In Australia : Medtronic will adhere to the 
adverse event reporting requirements for PMR studies as per the requirements of the 
Therapeutic Goods (Medical devices) 
Regulations 2002.  
EC/IRB: Submit to EC/IRB per local reporting requirement.  
In Australia:  As required by EC  
In Canada:  As required by the Clinical Investigation Plan  
 EC/IRB:  Reporting timeframe as per local 
EC/IRB requirement.  
 
Regulatory Authority:  As per local reporting requirement .  
Device Deficiency with SADE potential  
Investigator submit to:  Sponsor submit to:  
Medtronic:  Submit as soon as possible as per local reporting 
requirement, but not later than 48 hours  after the investigator first 
learns of the event.  
In Europe:  Submit in a timely manner (but no later than 48 
hours) after investigator learns about new event or of new 
information related to an already reported event.  
In Canada:  DDs that have resulted in any of the consequences 
characteristic of an SADE on the patient, the user , or any other 
person, or could do so were it to reoccur, must be reported to the 
Sponsor w ithin 72 hours after it comes to the attention of the 
qualified investigator . 
 Regulatory authorities:  Reporting 
timeframe as per local requirement . 
In Australia : Medtronic will adhere to the 
adverse event reporting requirements for 
PMR studies as per the requirements of the 
Therapeutic Goods (Medical devices) 
Regulations 2002.  
In Canada: Medtronic will adhere to the 
Medical Devices Regulations, SOR/98 -
282, Mandatory Problem Reporting 
Sections 59- 61. 
EC/IRB:  Reporting timeframe as per local EC/IRB requ irement.  EC/IRB:  Reporting timeframe as per local 
EC/IRB requirement.  
All other Device Deficiencies  
Investigator submit to:   
Medtronic  Submit as soon as possible as per local reporting requirement, but not later 
than 48 hours  after the investigator first learns of the event.  
In Europe:  Submit in a timely manner (but no later than 48 hours) after 
investigator learns about new event or of new information related to an already 
reported event.  
In Canada:  As required by the Clinical Investigation Plan  
Regulatory Authority  As per local reporting requirement  
SPYRAL PIVOTAL - SPYRAL HTN -OFF MED Clinical Investigation Plan  
  
 Version  12 .0 Page 93 of 139  
 
Medtronic Confidential  
  056-F275, v3 .0 Clinical Investigation Plan Template  
  Table 8: Adverse Event Reporting Requirements  
EC/IRB  Submit to EC/IRB per local reporting requirement.  
 Data Safety Monitoring Board and Clinical Events Committee  
A Data Safety Monitoring Board (DSMB) will be established to monitor the health, safety and 
welfare of patients. Additionally, a Clinical Events Committee (CEC) will be established to 
adjudicate any safety end point events . See Section I.2 Advisory Committees.  
 Emergency contact details in case of serious AEs  
In the case a  Serious  Adverse Event  or Serious Adverse Device Effect  occurs and requires  
immediate consultation, the investigators can contact the sponsor (or designee)  as outlined in 
the Investigator Site File.  
F.17 Subject  accountability  
 Missed Follow -up Visits  
Every effort should be made to ensure subjects return to the investigational site for all protocol 
required follow- up visits. If the subject is unable to complete  an in- office, in -home, virtual, or 
phone visit, the Investigator (or designee) must document the reason the subject was unable 
to complete the visit and, if applicable, follow the requirements for deviation reporting as 
outlined in section F.17.  If a subject misses a follow -up visit, they will not be considered lost 
to follow up and all remaining follow -up visits will be scheduled per protocol.  The Investigator 
should also make every effort to contact the subject within the visit window,  to collect the 
subject’s vital status as well as information related to potential adverse events.  
At a minimum, four attempts must be made to contact the subject and documented in the subject’s study  records before a visit can become a missed visit:  
• 3 telephone attempts to the subject’s last known phone number, and if 
unsuccessful,  
• 1 letter from the PI to the subject’s last known address  sent by courier  with tracking 
information. 
 Unscheduled Follow -up Visits  
If a subject returns to the institution between the protocol -required screening or follow- up visits 
for one of the following reasons : an escape medication change, evaluating subjects during 
medication re -introduction, repeat procedures ( serum creatinine blood draw, ABPM, renal  
imaging), re-consenting , or drug testing for elevated blood pressure resulting in a 
hospitalization or emergency room visit, the visit will be treated as an unscheduled visit . The 
reason for the unscheduled visit, as well as any assessment data will be recorded on the Unscheduled Follow -up eCRF and AE data on the Unscheduled  AE eCRF  (if applicable) .
 If 
the subject returns for another reason, this will not need to be documented.  
SPYRAL PIVOTAL - SPYRAL HTN -OFF MED Clinical Investigation Plan  
  
 Version  12 .0 Page 94 of 139  
 
Medtronic Confidential  
  056-F275, v3 .0 Clinical Investigation Plan Template  
  
 Subject Withdrawal or Lost To Follow -up 
It is the subject’s right to withdraw from the study  at any time and for any reason without 
sanction, penalty or loss of benefits to which the subject is otherwise entitled, and without 
jeopardizing their future medical care. The investigator may withdraw the subject at any time 
to protect the health, safety  or welfare of the subject. The subject’s vital status should be 
recorded at the last point of contact (if outside a study -required visit) . Every effort should be 
made to collect the status of any ongoing adverse events , at a minimum . The subject will not  
be considered lost to follow- up during the course of this study .  
All subjects will be encouraged to remain in the study  through the last follow -up visit. Subjects 
who discontinue participation prematurely will be included in the analysis of results, but w ill 
not be replaced in the enrollment of total study  subjects. If the subject discontinues 
participating in the study  prior to completing the study  requirements, the reason for withdrawal 
will be recorded in the subject’s study  records . 
If withdrawal from the study  is due to problems related to the investigational device safety or 
performance, the investigator shall ask for the subject’s permission to follow his/her status 
outside the clinical study . 
 Subject Exit From Study  
There are many scenarios in which a subject may exit the study . Table 9 details how the data 
will be handled for each scenario.  
  
SPYRAL PIVOTAL - SPYRAL HTN -OFF MED Clinical Investigation Plan  
  
 Version  12 .0 Page 95 of 139  
 
Medtronic Confidential  
  056-F275, v3 .0 Clinical Investigation Plan Template  
  Table 9: Scenarios for Subject Exit from Study 
Scenario  Follow -up Required  
Subject enrolled (Patient Information and Informed Consent Form 
signed), but the procedure is never attempted (not randomized)  None  
Subject enrolled, randomized and exits the study  early due to any of 
the following:  
- Death  
- Withdrawal  Through point of death, withdrawal, or 
last visit completed ; consent to 
continue to allow data collection from 
their medical records is required  
Subject enrolled, randomized and completes the study  requirements  Through 3 year follow -up 
Subject enrolled, randomized but has an of fice SBP ≥180 mmHg  or 
is put back on medications before 3 months  post-procedure  Through 3 year follow -up 
Subject enrolled, randomized, completed  crossover  procedure  and 
completes the study requirements  Through 2 year follow -up 
F.18 Study deviations and CIP changes  
A study  deviation is an event where the investigator or investigational  site personnel did not 
conduct the clinical study  according to the Clinical I nvestigation Plan or Clinical Study  
Agreement. The investigator is not allowed to deviate from the above mentioned documents 
except with prior approval and under emergency circumstances. All deviations shall be 
documented and explained, regardless the reason for the deviation.  
Medtronic will assess the significance of all deviations and evaluate the need to amend the 
Clinical Investigation Plan or to early terminate the investigation, in accordance with Medtronic 
SOPs.  
 Request for approval of study deviations  
The investigator shall obtain documented approval from Medtronic, before implementation, for 
any change in - or deviation from the Clinical Investigation Plan.  In case of study deviations 
that can affect the subject’s rights, safety and well -being or the scientific integrity of the clinical 
study , approval from the EC/IRB and regulatory authority must also be obtained before 
implementation.  The investigator shall contact the Clinical Study Manager  for review of the 
proposed change/deviation. 
Prior approval is not always possible in situations where unforeseen circumstances are 
beyond the investigator’s control. However, also in these cases , the event is considered a 
deviation, and shall be reported.  
In any emergency situation the investigator shall exercise his/her judgment to safeguard the 
subject’s interest. Such deviations from the Clinical Investigation Plan do not require the prior approval of Medtronic. The investigator shall report the deviation as soon as possible to 
SPYRAL PIVOTAL - SPYRAL HTN -OFF MED Clinical Investigation Plan  
  
 Version  12 .0 Page 96 of 139  
 
Medtronic Confidential  
  056-F275, v3 .0 Clinical Investigation Plan Template  
  Medtronic and the reviewing EC/IRB, if applicable. Medtronic will inform the regulatory 
authorities, if required.  
 Reporting requirements for study deviations  
For reporting purposes Medtronic classifies deviations as major or minor protocol (Clinical 
Investigation Plan) deviations. Major protocol (Clinical Investigation Plan) deviations are deviations with respect to inclusion/ exclusion criteria and no patient informed consent prior to 
study procedures.   
Deviations will be recorded at the site and reported to Medtronic on the eCRF. The deviation 
document shall be signed and dated by the investigator or his authorized designee. At a 
minimum the following information will be recorded: 
• identification of the investigator and site  
• descri ption of deviation 
• date of occurrence  
• reason for the deviation  
• patient identifier, if associated with the event 
Deviations will be entered into a database to allow a comprehensive review on a regular basis for identifying trends that warrant additional preventive or corrective actions to mitigate further 
occurrence. Clinical study management at Medtronic shall conduct this review.  
Study deviations must be reported to Medtronic, regardless of whether medically justifiable, 
pre-approved by the study  leader (see contact details section), or taken to protect the subject 
in an emergency . In the case that the deviation involves a failure to obtain a subject’s informed 
consent or is made to protect the life or physical well -being of a subject in an emergency, the 
deviation must be reported to the EC/IRB  as well as the study  leader as soon as possible after 
the occurrence of the event. Reporting of all other study deviations should comply with EC /IRB 
policies and/or local laws.  
The investigator shall adhere to EC/IRB  requirements and procedures for reporting study 
deviations.  
The clinical study team shall provide regular site- specific reports to the investigator(s) 
summarizing information on deviations that occurred at the investigational site. The frequency of these reports will depend on the stage in the study  and number and details of protocol 
deviations.  
All deviations from the CIP shall be included in the final report.   
Specific examples of study deviations are, but not limited to:  
• failure to obtain  the Patient Information and Informed Consent Form prior to 
participation  
• incorrect version of the Patient Information and I nformed Consent Form used 
• no EC /IRB approval before the start of the study  
• enrolled patient did not meet inclusion/exclusion criteria  
• randomization processes not followed 
• CIP required testing and/or measurements not done or incorrectly done  
• patient did not attend follow up visit or follow up visit outside window  
SPYRAL PIVOTAL - SPYRAL HTN -OFF MED Clinical Investigation Plan  
  
 Version  12 .0 Page 97 of 139  
 
Medtronic Confidential  
  056-F275, v3 .0 Clinical Investigation Plan Template  
  • Adverse Events not reported by investigators in the required time frame as 
specified in the CIP  
• source data permanently lost  
• enrollment of patients during lapse of EC/IRB  approval  
Medtronic is responsible for analyzing deviations, assessing their significance, and identifying 
any additional corrective and/or preventive actions (e.g. amend the CIP, additional training, 
terminate the study , etc.). Repetitive or serious investigator compliance issues may result in 
the need to initiate a corrective action plan, and in some cases freeze enrol lment or ultimately 
terminate the investigator’s participation in the clinical study . The sponsor shall consider 
terminating or suspending the participation of a particular investigational center or investigator 
in in the clinical investigation if monitoring or auditing identifies serious or repeated deviations on the part of an investigator.  
Medtronic will provide investigational site-specific reports to the investigators on a periodic 
basis summarizing information on deviations that occurred at the investigation site.  
 Amendments to the Clinical Investigation Plan 
The investigator will propose any appropriate modification(s) of the Clinical Investigation Plan or investigational device /product  or investigational device/product  use. Medtronic will review 
this proposal and decide whether the modification(s) will be implemented.  
Medtronic will submit any significant amendment to the Clinical Investigation Plan, including a justification for this amendment, to the appropriate regulatory authorities and to the 
investigators to obtain approval from their EC/IRB. The investigator will only implement the 
amendment after approval of the EC/IRB, regulatory authority and sponsor. Administrative 
amendments to the Clinical Investigation Plan will be submitted to the EC/IRB for notification. Furthermore , investigators shall sign any approved amendment for agreement.   
G QUALITY CONTROL PROCEDURES  
G.1 Procedures for database management  
 Data collection  
The investigator must ensure accuracy, completeness and timeliness of the data reported in the CRFs  and in all other required reports. Data reported on the CRFs  which are derived from 
source documents must be consistent with the source documents and discrepancies need to 
be justified in a documented rationale, signed and dated by the (principal ) investigator, and 
filed in the patient medical file. 
Only authorized persons can complete CRFs . CRFs  shall be signed and dated by investigators 
(physicians only) as specified on the Delegated Tasks List  included in the Investigator Site 
File. 
The Electronic Data Capture (EDC) system  maintains an audit trail on entries, changes or 
corrections in CRFs . Upon completion of a CRF the investigator shall sign the CRF in a timely 
manner , if a change to an already signed CRF occurs , the investigator shall re- sign this CRF. 
SPYRAL PIVOTAL - SPYRAL HTN -OFF MED Clinical Investigation Plan  
  
 Version  12 .0 Page 98 of 139  
 
Medtronic Confidential  
  056-F275, v3 .0 Clinical Investigation Plan Template  
  Sites will be instructed to upload or transmit renal imaging media, source documents, raw 24 -
hour ABPM data, and other data required to be collected during the course of the study . The 
site should make every effort to de -identify personal subject information prior to transmission.  
 Source data to be directly recorded on the Case Report Forms  
Data entered must be traceable to source documents. Source documentation is defined as 
the first time data appear, and may include original documents, data and records (e.g., hospital 
records, clinical and office charts, procedure reports, laboratory notes, memoranda, subjects’ 
diaries or evaluation checklists, pharmacy dispensing records, recorded data from automated instruments, copies or transcriptions certified after verification as being accurate copies, 
microfiches, photographic negatives, microfilm or magnetic media, x -rays, subject files, and 
records kept at the pharmacy, at the laboratories and at medico- technical departments 
involved in the clinical study ). 
The eCRFs (or paper copies) may not serve as source documents. Source documentation for 
data elements not routinely captured in medical records (e.g. echocardiography variables) 
may vary from site to site; the site may use source document worksheets if identified as source 
documents  and are signed, and dated appropriately . 
 Time windows for completion and submission of Case Report Forms  
CRFs are recommended to be entered into the RDC system within 10 days of the completion 
of the protocol -specified follow -up visit  or sooner as requested by the sponsor.  
 Data review and processing 
Data management will be done according to Medtronic  SOPs and the Data Management Plan 
for this  clinical study . These documents will be made available on request.  All collected data 
will be reviewed for completeness, correctness and consistency. In case of issues, queries will be sent to the investigator to complete, correct or comment the data.  
G.2 Monitoring procedures  
Monitoring visits will be conducted at the start, during and at the closure of the clinical study  
in accordance with Medtronic SOPs and the Monitoring Plan.  Frequency and timing of 
monitoring visits shall be determined by the Sponsor for each site based on enrollment rate and volume, study  compliance, and findings from previous visits.  
A site initiation visit will be performed to prepare the site and it may include training and collection of the required documentation, such as Curricul a Vitae.   Monitors will verif y whether 
signed and dated patient Information, if applicable,  and informed consent forms have been 
obtained from each subject at the point of enrol lment before any study  procedure has been 
performed.  
Specific monitoring requirements are detailed in the monitoring plan. In order to ensure a high 
degree of data quality, all enrolling clinical centers will be monitored frequently. The aim is to 
monitor the source data of minimally 90% of data collected in the study . In addition, the aim, 
is to verify  all available informed consent  forms of  enrolled patients at the center during the 
monitoring visits . The principal investigator should be available during monitoring visits.  
SPYRAL PIVOTAL - SPYRAL HTN -OFF MED Clinical Investigation Plan  
  
 Version  12 .0 Page 99 of 139  
 
Medtronic Confidential  
  056-F275, v3 .0 Clinical Investigation Plan Template  
  The sponsor will provide updated contact  lists to the investigati onal sites.  
For the duration of the study, Medtronic or designee will conduct s ite monitoring visits to 
assess, A)  compliance with the protocol , clinical trial agreement , and applicable regulations , 
B) adherence to the data collection procedures, C) accuracy and completeness of  submitted 
clinical data, and D) proper maintenance of  records.  
Monitoring activities will be documented, including a summary of items  the monitor reviewed 
and the observations regarding the completion of previous action items, significant findings, 
facts, deviations, conclusions, and recommended actions to be taken to secure compliance.  
The monitor will confirm periodic testing, calibration and maintenance of equipment used for 
study  assessments such as the automated office blood pressure and ambulatory blood 
pressure monitors according to local standard of practice.  Furthermore , the calibration and 
maintenance of the Symplicity G3TM generator will be conducted by Medtronic’s technical 
support staff on an annual basis.  
In Japan, monitors follow the Japan GCP Ordinance to ensure  compliance with the study 
protocol and Good Clinical Practice for Medical Devices .  
 
 Accessibility of invest igational site staff and study materials  
The principal investigator(s), his/her delegate(s) and the study coordinator(s) shall be 
accessible to Medtronic field personnel  and the Clinical Study Manager . This accessibility is 
of particular importance for reviewing data in the Case Report Form (CRF). Direct  access to 
patient medical files  for source data verification will need to be granted and prepared prior to 
any monitoring visits.  
 Audits  and investig ation site inspections  
Medtronic may conduct audits at participating investigational  sites. The purpose of an audit is 
to verify the adequate performance of the clinical study  related activities. Independent of the 
employees involved in the clinical study . Regulatory bodies may also perform inspections at 
participating investigation sites.  Any regulatory authority inspection announcements shall be 
forwarded immediately to the Clinical S tudy Manager.  
The investigator and/or institution shall permit Medtronic and regulatory bodies direct access 
to source data and documents, taking into account any restrictions due to local law, to perform 
clinical study  -related monitoring, audits, EC/IRB review, and regulatory inspections.  
G.3 Study suspension or early termination  
Termination of the study  is discontinuance, by sponsor or by withdrawal of IRB/EC or local 
regulatory body approval, or of an investigation before completion. This is possible for the whole study , for all centers in a country, or for a single center.  
Study  suspension is a temporary postponement of study  activities related to enrollment and 
distribution of the investigational product(s). This is possible for the whole study , for all centers 
in a country or a single center.  In the case is study  suspension or early termination, it is up to 
SPYRAL PIVOTAL - SPYRAL HTN -OFF MED Clinical Investigation Plan  
  
 Version  12 .0 Page 100 of 139  
 
Medtronic Confidential  
  056-F275, v3 .0 Clinical Investigation Plan Template  
  the investigator’s discretion to assess whether or not to continue the clinical study  at the 
respective investigational site.  
 Early study  suspension or termination  
Possible reasons for considering study  suspension or termination of the study  for all centers 
include but are not limited to:  
• AEs and device deficiencies associated with the system or product under 
investigation which might endanger the safety or welfare of subjects  
• Observed/suspected performance different from the product’s design intent  
• Decision by Medtronic or regulatory body (medically/ethically justifiable) where the 
• study  is operating under regulatory body authority  
 Early  investigation site s uspension or termination  
Possible reasons for clinical investigator or center termination or suspension include but are not limited to:  
• Failure to obtain initial IRB/EC approval or annual renewal of the study  
• Consistent non -compliance to the CIP (e.g. failure to adhere to 
inclusion/exclusion criteria, failure to follow subjects per scheduled follow -ups, 
etc.) 
• Lack of enrollment  
• Noncompliance to regulations and the terms of the Clinical Trial Agreement 
(e.g. failure to submit data in a timely manner, failure to follow -up on data 
queries and monitoring findings in a timely manner, etc.)  
• IRB/EC  suspension of the center  
• Fraud or fraudulent misconduct (as defined by local law and regulations)  
• Investigator request (e.g. no longer able to support the study ) 
 Procedures for planned study  closure, termination or suspension  
Medtronic will promptly inform the clinical investigators of the reasons for a study termination or suspension and inform the regulatory authority(ies) (where required per regulatory requirements).  
G.3.3.1  Medtronic -initiated  
• In the case of study termination or suspension for reasons other than a temporary IRB/EC  approval lapse, the investigator will promptly inform the 
IRB/EC .  
• In the case of study termination, the investigator must inform the subjects and 
may inform the personal physician of the subjects to ensure appropriate care 
and follow -up is provided.  
• In the case of a study suspension, subject enrollment must stop until the 
suspension is lifted by Medtronic. Subjects already enrolled should continue to be followed out of consideration of their safety, rights, and welfare.  
G.3.3.2  Investigator -initiated  
• The investigator will promptly inform:  
SPYRAL PIVOTAL - SPYRAL HTN -OFF MED Clinical Investigation Plan  
  
 Version  12 .0 Page 101 of 139  
 
Medtronic Confidential  
  056-F275, v3 .0 Clinical Investigation Plan Template  
  o Medtronic and provide a detailed written explanation of the termination or 
suspension.  
o The institution (where required per regulatory requirements).  
o The IRB/EC . 
o The subjects and may inform the personal physicians of the subjects to ensure appropriate care and follow -up is provided.  
• In the case of a  study suspension:  
o Subject enrollment must stop until the suspension is lifted. 
o Subjects already enrolled should continue to be followed out of consideration of their safety, rights, and welfare.  
G.3.3.3  IRB/EC -initiated  
• The investigator will promptly inform:  
o Medt ronic and provide a detailed written explanation of the termination or 
suspension within 5 business days.  
o The institution (where required per regulatory requirements).  
o The subjects and may inform the personal physicians of the subjects, with the rationale for the study termination or suspension.  
• In the case of a study suspension:  
o Subject enrollment must stop until the IRB/EC  suspension is lifted.  
o Subjects already enrolled should continue to be followed in accordance with 
IRB/EC  policy or its determination that an overriding safety concern or ethical 
issue is involved.  
 Criteria for unblinding 
Reasons for unblinding are:  
• All randomized patients will be unblinded during the 6 month follow -up visit. 
The procedure will be offered to the randomized Control patient s that continue 
to meet eligibility criteria  after this visit. 
• All randomized patients will immediately be unblinded in case of study 
termination.  
• When a site is terminated, all randomized patients of this site will immediately be unblinded.  
Unblinding mus t be documented including the signature of site study personnel , date and 
reason for unblinding and must be reported to the Clinical Study Manager.  The unblinding will 
be documented on a separate file that can be found in the ISF.  
SPYRAL PIVOTAL - SPYRAL HTN -OFF MED Clinical Investigation Plan  
  
 Version  12 .0 Page 102 of 139  
 
Medtronic Confidential  
  056-F275, v3 .0 Clinical Investigation Plan Template  
  G.4 Study close out  
Upon study completion or termination Site Closeout Visits will be conducted, as outlined in the 
Monitoring Plan. After the study  has been completed or terminated, medical care will be 
provided to the subjects upon the discretion of the treating physician.  
In Japan, upon completion of the clinical study  (when enrollment of all prospective subjects 
has been completed, all follow -up visits have been completed and data queries resolved and 
all eCRFs have been approved), the investigator will notify the institution director of the site 
closeout. Medtronic Japan  will submit a  clinical study  notification to the regulatory authority  at 
the time of study  close- out. 
H DATA ANALYSIS  AND REPORTING  
Any deviations from this section and/or the Statistical Analysis Plan will be described and 
justified in the Final Clinica l Study Report, as appropriate  or justif ied in the CIP, if applicable.  
H.1 Analysis of clinical data  
General Analysis Overview  
Descriptive statistics of continuous outcomes will be presented by treatment arm and include 
sample size, mean, median, standard deviation, minimum and maximum. For categorical 
outcomes, the number and percentage of subjects in each category will be presented by 
treatment arm. Statistical comparisons between treatment arms will be made using t -tests for 
continuous outcomes and chi -square or Fisher’s exact test (depending on overall event rates) 
for categorical outcomes. Paired t -tests will be used to compare changes from baseline to 
follow- up within each treatment arm. All statistical analyses will be performed using SAS for 
Windows (version 8.2 or higher) or other widely accepted statistical or graphical software. Patient data listings and tabular and graphical presentations of results will be provided. Unless otherwise specified, a two- sided 0.05 level of significance will be used to declare treatment 
arms significantly different. Additional details on the analysis will be provided separately in the 
SPYRAL HTN OFF -MED Statistical Analysis Plan (SAP) for this study . 
 Analysis Sets  
a. Intent -to-Treat (ITT): All randomized subjects, analyzed according to their 
randomized treatment. Subjects who meet the antihypertensive medication 
escape criteria (OSBP>180 or safety reasons) will be analyzed using Last 
Observation Carried Forward (LOCF) for their blood pressure measurements.  
b. Modified Intent -to-Treat : All randomized subjects, analyzed according to their 
randomized treatment. Subjects who meet the antihypertensive m edication 
escape criteria (OSBP>180 or safety reasons) will be excluded from this population.  
c. Per-Protocol (PP):   All randomized subjects, meeting the following criteria:  
1. Subjects showing medication compliance in blood and/or urine (via drug testing data) at SV2 and 3M   
SPYRAL PIVOTAL - SPYRAL HTN -OFF MED Clinical Investigation Plan  
  
 Version  12 .0 Page 103 of 139  
 
Medtronic Confidential  
  056-F275, v3 .0 Clinical Investigation Plan Template  
  2. Exclude subjects with protocol deviation code 101 (consent not 
obtained)     
3. Exclude subjects who do not meet the following Inclusion/Exclusion criteria  
• Inclusion: Individual has an office systolic blood pressure (SBP) ≥ 150 mm Hg and <180 mm  Hg and an office DBP ≥ 90 mm Hg 
measured at Screening Visit 2, according to the guidelines in Appendix L7.   
• Inclusion: Individual has a 24- hour ABPM average SBP ≥140 and 
< 170 mm Hg measured at Screening Visit 2, according to 
guidelines in Appendix L7.     
• Exclusion: Individual has undergone prior renal denervation   
• Exclusion: Individual has renal artery anatomy that is ineligible for 
treatment     
• Exclusion: Individual has one or more of the following conditions: 
stable or unstable angina within 3 months of  enrollment, 
myocardial infarction within 3 months of enrollment; heart failure 
cerebrovascular accident or transient ischemic attack or atrial 
fibrillation at any time.     
4. Exclude subjects meeting the antihypertensive medication escape 
criteria (OSBP>180 or safety reasons).  
5. Exclude subjects who did not receive the treatment they were randomized to . 
d. As Treated Population:  All randomized subjects, analyzed according to the actual 
treatment received. Subjects randomized to RDN who do not get treated will be analyzed in the control arm. Subjects who meet the anti -hypertensive medication 
escape criteria will be analyzed using Last Observation Carried Forward (LOCF) 
for their blood pressure measurements out to 3 months. 
H.2 Primary Safety Objective 
Medtronic is using a performance goal approach to analyze the primary safety endpoint. The 
safety performance goal for the Major Adverse Event (MAE) rate was developed based on review of and comparison to event rates of other renal interventions. The reported events differed among the studies; however, for a subset of these studies, we could estimate rates 
for a composite of events similar to our protocol’s MAE composite. The major adverse event 
rate from these studies was 7.1% which will be used as the per formance goal for the primary 
safety endpoint. Additional details on the performance goal calculation can be found in the SAP.  
The primary safety null and alternative hypotheses are:  
SPYRAL PIVOTAL - SPYRAL HTN -OFF MED Clinical Investigation Plan  
  
 Version  12 .0 Page 104 of 139  
 
Medtronic Confidential  
  056-F275, v3 .0 Clinical Investigation Plan Template  
  H0: π ≥ 7.1% vs.  
Ha: π < 7.1%  
where π is the MAE rate for patients undergoing renal denervation. Under the assumption that 
the true rate is 3.5%, and using a one- sided 0.05 level of significance, an evaluable sample 
size of 253 renal denervation patients yields 80% power to reject the null hypothesis in favor of the alternative. The exact  binominal  test was used for the sample size calculation for the 
primary safety endpoint hypothesis.   
In other words, the primary safety endpoint hypothes is is designed to show whether the true 
MAE rate is lower than 7.1%. Compared to the literature reported event rates for renal intervention, it is believed  that these thresholds are appropriate for demonstrating safety of 
the device given the expected performance rates of similar renal intervention trials, particularly when balanced with the expected blood pressure reductions.  
Medtronic proposes multiple sources of study subjects  as shown in Table 10 below to ensure 
253 patients treated with the Symplicity Spyral catheter (including branch treatment) are 
available for analysis. The first cons ecutively randomized 253 subjects with evaluable safety 
data from the sources in Table 10 will be used to perform the primary safety endpoint analysis.  
With a sample size of 253 and a one- sided significance level of 0.05, a maximum of 11 
subjects with MAE  will enable us to meet the safety primary endpoint, resulting in an event 
rate of 4.3% with a one -sided 95% upper confidence bound of 7.09% using the exact binomial 
method.  
 
Table 10  Study Sources of Patients for Primary Safety Endpoint Data  
Study  
SPYRAL HTN -OFF MED (First 80 Subjects)  
Randomized 1:1 to RDN:Control  
SPYRAL PIVOTAL – SPYRAL HTN -OFF MED  
Randomized 1:1 to RDN:Control  
SPYRAL HTN -ON MED (First 106  Subjects)  
Randomized 1:1 to RDN:Control  
SPYRAL HTN ON MED Extension  
Randomized 2:1 to RDN :Control  
SPYRAL HTN -OFF MED Crossovers (from 
first 80 subjects  and Pivotal)  
SPYRAL HTN -ON MED Crossovers  
 
SPYRAL PIVOTAL - SPYRAL HTN -OFF MED Clinical Investigation Plan  
  
 Version  12 .0 Page 105 of 139  
 
Medtronic Confidential  
  056-F275, v3 .0 Clinical Investigation Plan Template  
  H.3 Secondary Safety Objectives  
The following secondary safety endpoints will be assessed:  
• Acute/Procedural Safety Secondary Endpoints – Compared Between Groups at 1 
Month Post -Procedure:  
o Significant embolic event resulting in end- organ damage  
o Renal artery perforation requiring intervention  
o Renal artery dissection requiring intervention 
o Vascular complications  
o End-Stage Renal Disease 
o ≥40% decline in eGFR  
o New Myocardial Infarction 
o New Stroke  
o Renal artery re- intervention 
o Major bleeding according to TIMI definition (i.e. intracranial hemorrhage, ≥5g/dl 
decrease in hemoglobin concentration, a ≥15% absolute decrease in 
hematocrit, or death due to bleeding within 7 days of the procedure)  
o Increase in serum creatinine > 50% from Screening Visit 2  
o New renal artery stenosis > 70%, confirmed by angiography and as determined by the angiographic core laboratory  
o Hospitalization for hypertensive crisis not related to confirmed non- adherence 
with medications or the protocol.  
 
• Chronic Safety Secondary Endpoints – Compared Between Groups at 3, 6, 12, 24, 
and 36 Months Post - Randomization:  
o All-cause mortality  
o End-Stage Renal Disease 
o ≥40% decline in eGFR  
SPYRAL PIVOTAL - SPYRAL HTN -OFF MED Clinical Investigation Plan  
  
 Version  12 .0 Page 106 of 139  
 
Medtronic Confidential  
  056-F275, v3 .0 Clinical Investigation Plan Template  
  o New Myocardial Infarction 
o New Stroke  
o Renal artery re- intervention 
o Major bleeding according to TIMI definition (i.e. intracranial hemorrhage, ≥5g/dl 
decrease in hemoglobin concentration, a ≥15% absolute decrease in hematocrit, or death due to bleeding within 7 days of the procedure)  
o Increase in serum creatinine > 50% from Screening Visit 2  
o Renal artery stenosis >70%, confirmed by angiography  
o Hospitalization for hypertensive crisis not related to confirmed non- adherence 
with medications or the protocol.  
All th e safety endpoints will be adjudicated by the Clinical Events Committee (CEC). The 
following algorithm will be used to evaluate the safety event rates: The denominator will 
include all subjects who either had a CEC adjudicated event prior to the time of interest (180 
days for 6 months events, for example), or had last contact date that is beyond the lower window of the follow up (166 days for 6 month events, for example).  The numerator will include all subjects who had CEC adjudicated events up to the time of interest (180 days for 6 months 
events, for example).  The secondary safety endpoints will be compared between treatment 
groups using Fisher’s exact test. In addition, two- sided 95% confidence intervals of the 
difference between treatment groups will be  presented. The secondary safety analyses will be 
performed using the ITT population defined in H1. 
 Renal Artery Stenosis Evaluation at 12 Months  
With the expected rate of 3.1% for stenosis at 12 months41, a sample size of 100 subjects will 
provide a 95% confidence interval of approximately (0. 6%, 8.5%) using the exact method 
(calculated using an event rate of 3/100=3%). 
Descriptive statistics of this endpoint at 12 months will be provided using counts, percentages and the 95% confidence interval.  
H.4 Primary Efficacy Objective  
The primary efficacy endpoint of the study is the baseline adjusted (analysis of 
covariance/ANCOVA) change in SBP from baseline (screening visit 2) to 3- months post -
procedure as measured by 24- hour Ambulatory Blood Pressure Monitoring (ABPM).  
In the context of an ANCOVA linear regression model, 
𝜇𝜇=𝜇𝜇𝑡𝑡−𝜇𝜇𝑐𝑐  represents the baseline-
adjusted treatment effect of BP change comparing test and control groups where 𝜇𝜇𝑡𝑡 and 𝜇𝜇𝑐𝑐are 
the baseline adjusted BP changes in the denervation and control arms respectively.  Let 𝑦𝑦=
SPYRAL PIVOTAL - SPYRAL HTN -OFF MED Clinical Investigation Plan  
  
 Version  12 .0 Page 107 of 139  
 
Medtronic Confidential  
  056-F275, v3 .0 Clinical Investigation Plan Template  
  {𝑦𝑦𝑡𝑡,𝑦𝑦𝑐𝑐} and 𝑦𝑦0={𝑦𝑦0𝑡𝑡,𝑦𝑦0𝑐𝑐}represent the current data and historical data respectively, where 𝑡𝑡= 
test group and 𝑐𝑐= control group . Let the hypotheses for the study be the following : 
𝐻𝐻0: 𝜇𝜇 = 0 
𝐻𝐻𝑎𝑎: 𝜇𝜇 < 0 
We reject 𝐻𝐻0 if the probability is greater than 97.5%, i.e. 
 𝑃𝑃(𝜇𝜇< 0|𝑦𝑦,𝑦𝑦0,𝛼𝛼0�(𝑦𝑦,𝑦𝑦0,𝜆𝜆,𝑘𝑘) )> 0. 975 
where the notation  𝛼𝛼0�(𝑦𝑦,𝑦𝑦0,𝜆𝜆,𝑘𝑘) is used to denote that the estimate of 𝛼𝛼 0� depends on the 
current data, prior data, and the Weibull shape and scale parameters. In conjunction with a 
pre-specified decision rule controlling the prior data weight, the estimate of 𝛼𝛼0�(𝑦𝑦,𝑦𝑦0,𝜆𝜆,𝑘𝑘) 
represents a measure of similarity between current current and prior data. Alternatively, in the absence of 𝛼𝛼
0�(𝑦𝑦,𝑦𝑦0,𝜆𝜆,𝑘𝑘), i.e., 𝑃𝑃(𝜇𝜇< 0|𝑦𝑦,𝑦𝑦0), full weight would be given to the prior data . 
The power
 prior discount function approach is used to estimate 𝜇𝜇, and determine 
𝛼𝛼0�(𝑦𝑦,𝑦𝑦0,𝜆𝜆,𝑘𝑘), the strength of the historical data used to estimate  𝜇𝜇.  𝛼𝛼0�(𝑦𝑦,𝑦𝑦0,𝜆𝜆,𝑘𝑘)  ranges from 
0 to 1, where 1 means that 100% of the historical data is used and 0 means that no historical 
data is used. Before beginning the study, an initial value is chosen for 𝛼𝛼0�(𝑦𝑦,𝑦𝑦0,𝜆𝜆,𝑘𝑘), call this 
value 𝛼𝛼𝑚𝑚𝑎𝑎𝑚𝑚. This 𝛼𝛼𝑚𝑚𝑎𝑎𝑚𝑚 value is the maximum  strength the historical data can receive. The 
intend to use the same enrollment criteria for the prior and pivotal studies, and therefore 
believe that a value of 𝛼𝛼𝑚𝑚𝑎𝑎𝑚𝑚= 1 is appropriate.  
At 
interim looks and at the final analysis, we analyze the data using the power prior discount 
function method, this method will discount 𝛼𝛼 𝑚𝑚𝑎𝑎𝑚𝑚 to an appropriate value 𝛼𝛼0�(𝑦𝑦,𝑦𝑦0,𝜆𝜆,𝑘𝑘) where 
𝛼𝛼0�(𝑦𝑦,𝑦𝑦0,𝜆𝜆,𝑘𝑘)≤ 𝛼𝛼𝑚𝑚𝑎𝑎𝑚𝑚. This discounting is based on the discount function which is discussed 
in more detail in the SAP . Under  the adaptive procedure, if the current data diverges from the 
historical data at an interim look, the discount function will discount the strength of the historical 
data, thus requiring continued enrollment to maintain power to achieve the endpoint. 
Alternatively, if the historical and current data agree, there will be a smaller penalty from the 
discount function, thus fewer prospective patients would be needed to maintain power, and enrollment may stop early.  A more detailed formulation of the efficacy endpoint analyses can 
be found in the S tatistical Analysis P lan.   
The ITT popul
ation defined in section H1 will be used as the primary analysis population for 
this endpoint. Secondary effectiveness analyses will also be performed using the modified ITT  
per-protocol and as -treated populations.  
 
H.5 Secondary Efficacy Objecti ve 
The secondary powered efficacy endpoint is the baseline adjusted change in office SBP from baseline (screening visit 2) to 3 -months post procedure, compared between treatment arms.  
In the context of an ANCOVA linear regression model, 𝜇𝜇=𝜇𝜇
𝑡𝑡−𝜇𝜇𝑐𝑐  represents the baseline-
adjusted treatment effect of BP change comparing test and control groups where 𝜇𝜇𝑡𝑡 and 𝜇𝜇𝑐𝑐 
are the baseline adjusted BP changes in the denervation and control arms respectively.  Let 
SPYRAL PIVOTAL - SPYRAL HTN -OFF MED Clinical Investigation Plan  
  
 Version  12 .0 Page 108 of 139  
 
Medtronic Confidential  
  056-F275, v3 .0 Clinical Investigation Plan Template  
  𝑦𝑦={𝑦𝑦𝑡𝑡,𝑦𝑦𝑐𝑐} and 𝑦𝑦0= {𝑦𝑦0𝑡𝑡,𝑦𝑦0𝑐𝑐} represent the current data and historical data respectively, 
where the subscripts  𝑡𝑡= test group and 𝑐𝑐= control group. Let the hypotheses for the study 
be the following:  
𝐻𝐻0: 𝜇𝜇 = 0 
𝐻𝐻𝑎𝑎: 𝜇𝜇 < 0 
We reject 𝐻𝐻0 if the probability is greater than 97.5%, i.e.  
 𝑃𝑃(𝜇𝜇< 0|𝑦𝑦,𝑦𝑦0,𝛼𝛼0�(𝑦𝑦,𝑦𝑦0,𝜆𝜆,𝑘𝑘) )> 0. 975  
where the notation  𝛼𝛼0�(𝑦𝑦,𝑦𝑦0,𝜆𝜆,𝑘𝑘) is used to denote that the estimate of 𝛼𝛼 0� depends on the 
current data, prior data, and the Weibull shape and scale parameters. In conjunction with a 
pre-specified decision rule controlling the prior data weight, the estimate of 𝛼𝛼0�(𝑦𝑦,𝑦𝑦0,𝜆𝜆,𝑘𝑘) 
represents a measure of similarity between current current and prior data. Alternatively, in the 
absence of 𝛼𝛼0�(𝑦𝑦,𝑦𝑦0,𝜆𝜆,𝑘𝑘), i.e., 𝑃𝑃(𝜇𝜇< 0|𝑦𝑦,𝑦𝑦0), full weight would be given to the prior data .  
A more detailed formulation of the efficacy endpoint analyses can be found in the SAP. The 
same statistical methods as outlined in section H4 will be used to analyze the powered 
secondary endpoint. The ITT population defined in section H1 will be used as the primary analysis population for this endpoint. Secondary effectiveness analyses will also be performed 
using the modified ITT population and per- protocol populations.  
 Simulation of Primary and Secondary Efficacy Endpoint Operating 
Characteristics  
As outlined in section B.6, enrollment will be stopped at an interim analysis for efficacy or 
futility only if both the primary and secondary efficacy endpoints meet the stopping criteria. 
Simulations were performed to assess operating characteristics for the primary and secondary 
efficacy endpoints. We used 8000 trial simulations to estimate the power and 15000 
simulations to estimate the type I error. Tables 11 and 12 summarize the assumptions that 
were made for the primary and secondary efficacy endpoint simulations, and table 13 
summarizes the operating characteristics for the efficacy evaluation. The overall power for the efficacy evaluation from table 13 is 94%, with a one -sided type I error rate of 0.026 for 24 -hour 
SBP and 0.028 for Office SBP.  
Table 11 : Simulation Assumptions for Primary Efficacy Endpoint  
Enrollment Rate  10 Subjects / Month  
Prior Baseline Adjusted Treatment Arm Mean/SE  -5.30 / 1.65 mmHg  
Prior Treatment Arm N  35 
Prior Baseline Adjusted Control Arm Mean/SE  -0.74 / 1.62 mmHg  
Prior Control Arm N  36 
Maximum Prior Patients  35 RDN + 36 Control = 71  
Pivotal Study Expected Treatment Difference  4.0 mmHg  
Pivotal Study Treatment Arm Mean/SD  -4.74 / 12 mmHg  
Pivotal Study Control Arm Mean/SD  -0.74 / 12 mmHg  
SPYRAL PIVOTAL - SPYRAL HTN -OFF MED Clinical Investigation Plan  
  
 Version  12 .0 Page 109 of 139  
 
Medtronic Confidential  
  056-F275, v3 .0 Clinical Investigation Plan Template  
  Weibull Discount Function Parameters  Shape: 𝑘𝑘=3, Scale: 𝜆𝜆=0.5 
 
Table 12 : Simulation Assumptions for Secondary Efficacy Endpoint  
 
Table 13 : Operating Characteristics for Primary and Secondary Efficacy Endpoints  
Trial Success Rate (Power)  94% 
Type I Error (one -sided)  24-Hr SBP: 0.02 9 
Office SBP: 0.02 6 
First Interim Look N  N=210  
Power at First Interim Look  83% 
Second Interim Look N  N=240  
Power at Second Interim Look  89% 
Maximum Study Size  N=300  
% of Simulations that Stop  for Futility   0.05%  
H.6 Other Secondary Efficacy Endpoints  
The following additional secondary efficacy endpoints will be assessed:  
• Change in systolic blood pressure (SBP) from baseline (Screening Visit 2) as 
measured by 24 -hour Ambulatory Blood Pressure Monitoring (ABPM) at 3, 6, 12, 
24 and 36 months post -procedure.  
• Change in office systolic blood pressure from baseline (Screening Visit 2) at 1 , 3, 
6, 12, 24 and 36 months post -procedure.  
• Incidence of achieving target office systolic blood pressure (SBP <140 mmHg) at 1, 3, 6, 12, 24 and 36 months post -procedure.  
• Change in office diastolic blood pressure from baseline (Screening Visit 2) at 1, 3, 6, 12, 24 and 36 months post -procedure.  Enrollment Rate  10 Subjects / Month  
Prior Baseline Adjusted Treatment Arm Mean/SE  -9.69 / 2.20 mmHg  
Prior Treatment Arm N  37 
Prior Baseline Adjusted Control Arm Mean/SE  -2.54 / 2.09 mmHg  
Prior Control Arm N  41 
Maximum Prior Patients  37 + 41 = 78  
Pivotal Study Expected Treatment Difference  6.5 mmHg  
Pivotal Study Treatment Arm Mean/SD  -9.04 / 16 mmHg  
Pivotal Study Control Arm Mean/SD  -2.54 / 16 mmHg  
Weibull Discount Function Parameters  Shape: 𝑘𝑘=3, Scale: 𝜆𝜆=0.5 
SPYRAL PIVOTAL - SPYRAL HTN -OFF MED Clinical Investigation Plan  
  
 Version  12 .0 Page 110 of 139  
 
Medtronic Confidential  
  056-F275, v3 .0 Clinical Investigation Plan Template  
  • Change in diastolic blood pressure from baseline (Screening Visit 2) as measured 
by 24- hour Ambulatory Blood Pressure Monitoring (ABPM) at 3, 6, 12, 24 and 36 
months post -procedure.  
The efficacy endpoints will be compared between treatment groups using t -tests for 
continuous endpoints and Fisher’s exact test for categorical endpoints. In addition, two -sided 
95% confidence intervals of the difference between treatment groups will be presented. 
Changes in blood pressure measurements from baseline to follow- up within each treatment 
group will be assessed using paired t -tests. Two- sided 95% confidence intervals of the mean 
change from baseline will be presented for each treatment group.  
Analysis of Covariance (ANCOVA) models, adjusting the treatment effect for the baseline BP measurements will also be presented.  
These additional efficacy analyses will be presented for all the study populations defined in 
section H1. 
H.7 Additional Objectives  
The following additional analyses will be conducted:  
• Quality of Life (QOL) measures (EQ5D and SF36)  
• Antihypertensive medication usage through 36 months.  
• Additional procedural characteristics e.g. treatment duration, frequency of distal renal 
artery treatment, ablations per vessel,  location of ablations, number of ablations per 
patient and other characteristics will be analyzed to assess their impact on blood 
pressure.  
• In accordance with FDA guidance document “FDA Guidance on Conduct of Clinical 
Trials of Medical Products during COV ID-19 Pandemic” [8], we will provide AE and 
SAE tables summarizing the site- reported adverse events attributed to COVID -19. 
Descriptive statistics will be presented by treatment arm. Statistical comparisons between 
treatment arms will be made using t -tests  for continuous outcomes and Fisher’s exact test for 
categorical outcomes.  
These additional analyses will be presented for the ITT study population defined in section 
G1. 
H.8 Safety Evaluation  
Adverse Event (AE) information will be collected by the site from subject enrollment (consent) 
through study termination. AEs will be followed until the event has resolved (in the case of 
SPYRAL PIVOTAL - SPYRAL HTN -OFF MED Clinical Investigation Plan  
  
 Version  12 .0 Page 111 of 139  
 
Medtronic Confidential  
  056-F275, v3 .0 Clinical Investigation Plan Template  
  permanent impairment, the event will be followed until it stabilizes and the overall clinical 
outcome has been ascertained)  or su bject participation in the study has ended. 
The Investigator will report any adverse events that may occur to the Sponsor, and will assess seriousness, relationship (to the device, procedure and renal denervation therapy where applicable), subsequent intervention required, resolution status and whether or not the adverse event resulted in the subject’s discontinuation from the study. The Investigator will provide further information regarding adverse events as requested by the Sponsor.  
H.9 Subgroup Analyses  
Analysis will be carried out for the following subgroups to assess consistency of results.  
• Gender  
• Age at baseline <65 vs. ≥ 65 (years)  
• BMI by tertiles (kg/m2)  
• Type 2 diabetics vs. non -diabetics  
• Current smokers vs. non -smokers 
• Baseline eGFR < 60 vs. ≥ 60 (mL/min/1.73 m2)  
• Obstructive sleep apnea yes vs. no  
• US vs. OUS Subjects  
• US African American vs. US Non African American subjects  
• European vs. Japanese vs. Australian subjects  
• Baseline ambulatory SBP by tertiles and medians (mmHg) 
• Baseline office SBP by tertiles and medians (mmHg)  
• Baseline ambulatory heart rate by tertiles and medians (bpm)  
• Baseline office heart rate by tertiles and medians (bpm) 
• 24-Hour Pulse Pressure <60 vs. >= 60 mmHg (mmHg)  
• Orthostatic Hypertension at baseline 
• Orthostatic Tachycardia at baseline  
• Plasma Renin Activity at baseline <0.65 vs. ≥0.65 (ng/mL/h)  
• Aldosterone Renin Ratio at baseline by tertiles  
• Aldosterone at baseline by tertiles (ng/dL)  
• Tertile analysis by total number of ablations performed  
• Tertile analysis by total number of ablations performed in branch vessels  
• Tertile analysis by total number of ablations performed in main renal artery vessels  
• Tertile analysis by total number of 45 second ablations performed  
• Medication adherent vs. non- adherent subjects at screening visit 2 (SV2) and 3 
months (from urine and serum tests)  
H.10  Publication Policy  
Medtronic may form a Publications Review Committee . Member(s) of the Publications Review 
Committee may include, but are not limited to, the  Executive  Steering Committee, the 
Medtronic Clin ical Study Manager or Publication Manager, and other Medtronic personnel.  
SPYRAL PIVOTAL - SPYRAL HTN -OFF MED Clinical Investigation Plan  
  
 Version  12 .0 Page 112 of 139  
 
Medtronic Confidential  
  056-F275, v3 .0 Clinical Investigation Plan Template  
  Participating investigators and members of the Executive Steering Committee may submit 
publication ideas through the Publication Committee and may author publications. The 
Publicati ons Review Committee is responsible for developing a Publication Plan overseeing 
the development of case reports, manuscripts and abstracts, identifying and appointing the manuscript/abstract first author(s)/writer(s), and identifying Medtronic personnel r esponsible 
for assisting the first author. The Publications Review Committee may refine the Publication Plan during the course of the study  if needed.  
At the conclusion of the study , a multi -center manuscript may be prepared for publication in a 
reputable scientific journal . The publication of the principal results from any single study  center 
experience within the study  is not allowed until the preparation and publication of the multi -
center results . Any follow -up publications would require prior written approval by Publications 
Review Committee. 
Authorship will be determined based on the International Committee of Medical Journal Editors 
(ICMJE) published guidelines
21 and GPP2 guidelines22 and will include, at a minimum:  
a. Substantial contributions to conception and design, or acquisition of data, or 
analysis and interpretation of data  
b. Drafting the article or revising it critically for important intellectual content  
c. Final approval of the version to be published  
d. Agreement to be accountable for all aspects of the work in ensuring that 
questions related to the accuracy or integrity of any part of the work are 
appropriately investigated and resolved.  
Final criteria for selecting first and subsequent authors will be determined and documented in 
the Publication Plan.  
I STUDY MANAGEMENT  
I.1 Study staff  
A list of sponsor staff  (including sponsor’s medical expert (s), suppliers, and core labs for this 
trial along with their contact information (i.e., name, title, address, and telephone number(s)) will b e provided separate ly and will be maintained within the study files at each site. 
I.2 Advisory committees  
 Executive Steering Committee  
The Executive Steering Committee is comprised of the Study  Coordinating Investigators and 
selected members of Medtronic. Additional individuals may be consulted as appropriate. The 
main responsibilities of the Executive Steering Committee are to provide oversight and general 
guidance for the global study  design and execution, to define the primary publication plan, and 
to prioritize publication requests and approvals. 
SPYRAL PIVOTAL - SPYRAL HTN -OFF MED Clinical Investigation Plan  
  
 Version  12 .0 Page 113 of 139  
 
Medtronic Confidential  
  056-F275, v3 .0 Clinical Investigation Plan Template  
  The Executive Steering Committee will meet periodically by teleconference and in- person to 
discuss patient enrollment and clinical site progress, as well as generally assist sites with the 
successful conduct of the study . The Executive Steering Committee will be responsible for 
reviewing the final results, determining the methods of presentation and publication, and selection of secondary projects and publications.  
 Data Safety Monitoring Board (DSMB)  
The primary responsibility of the Data Safety Monitoring Board (DSMB) is to monitor the 
health, safety and welfare of patients. The DSMB will be composed of physicians who have 
experience in clinical studies in hypertension and/or cardiovascular indications  and one 
biostatistician with experience in analysis of clinical studies. The members of the DSMB will 
not be investigators in the study  and will be independent of Medtronic. Medtronic personnel 
may attend the meetings to answer questions but will not have a vote in determining the 
committee’s recommendations.  
Prior to the first DSMB review, guidelines for the identification and evaluation of significant 
safety findings and/or increased frequency of events that may impact the rights, safety or 
welfare of patients will be established. All materials, discussions, and proceedings of the 
DSMB are completely confidential. The proceedings of each DSMB meeting will be recorded 
in minutes. The DSMB Chairperson will be responsible for providing a written recommendati on 
regarding study  conduct (e.g. continue as planned, specify a modification, or termination) to 
Medtronic and the trial Principal Investigators. Additional details on the DSMB process, 
meeting and data review schedule, as well as reporting expectations will be provided in the 
DSMB Charter.  
 Clinical Events Committee (CEC) 
The primary responsibilities of the Clinical Events Committee (CEC) are to adjudicate any events that are part of study  safety endpoints. The CEC will be composed of physicians who 
have experience in clinical studies in hypertension and/or cardiovascular indications. The members of the CEC will not be investigators in the study  or members of the DSMB and will 
be independent of Medtronic.  
During the first CEC meeting guidelines for the AE adjudication process will be established. 
Additional details on the definitions utilized for adjudication, the adjudication process as well 
as reporting of outcomes will be provided in the CEC Charter. The proceedings of each CEC 
meeting will be recorded in minutes.  
Medtronic personnel may attend the meetings to answer questions but will not have a vote in determining the committee’s recommendations. The Medtronic Safety Department will identify 
safety events meeting criteria for review by the CEC. They will provide this information based upon the established rules of the CEC. The CEC will meet regularly to review and adjudicate 
all events in which the required minimum data are available.  
 Publications Review Committee  
Member(s) of the Publications Review Committee may include, but are not limited to, the 
Executive Steering Committee, the Medtronic Clinical Study Manager or Publication Manager, and other Medtronic personnel . As this committee represents the Medtronic Global Renal 
Denervation Program and may not be study -specif ic, there is no specific timeframe for this 
SPYRAL PIVOTAL - SPYRAL HTN -OFF MED Clinical Investigation Plan  
  
 Version  12 .0 Page 114 of 139  
 
Medtronic Confidential  
  056-F275, v3 .0 Clinical Investigation Plan Template  
  committee to disband. See Section G10 Publication Policy  for details on the activities of this 
committee . 
I.3 Records and reports  
 Investigator records  
At a minimum, the following records must be kept by the investigator:  
• Medtronic and EC/IRB Clinical Investigation Plan and any amendments  
• Investigator’s Brochure (if applicable) and/or Instructions for Use and any 
amendments  
• Medtronic and EC/IRB approved Patient Information and Informed Consent Form  
• EC/IRB notification, correspondence and approval  
• EC/IRB voting list  
• Any reports to EC/IRB and regulatory authority  
• Source documentation  
• Subject Identification log 
• Subject Enrollment log  
• Normal values or ranges for lab tests  
• Lab certificate  
• Documentation for equipment maintenance and calibration 
• Regulatory Authority approval or notification and relevant correspondence  
• Fully signed Clinical Investigation Agreement and confidentiality agreement (if not included in the Clinical Investigation Agreement)  
• Financial disclosures from investigators  
• Insurance certificates  
• Completed Delegated Task List and Curriculum Vitae of all investigation site personnel  
• Training documentation of all investigation site personnel  
• Relevant communications  
SPYRAL PIVOTAL - SPYRAL HTN -OFF MED Clinical Investigation Plan  
  
 Version  12 .0 Page 115 of 139  
 
Medtronic Confidential  
  056-F275, v3 .0 Clinical Investigation Plan Template  
  • Subject screening log and/or subject identification log  
• Signed, dated and fully executed Patient Information and Informed Consent 
Form  
• Fully executed eCRFs and corrections  
• Reports of Adverse Events and Device Deficiencies  
• Device and drug accountability records  
• Randomization list and randomization forms  
• List of investigational sites  
• Statistic ian analysis and clinical investigation report (final report)  
• Any other records that may be required by hospital regulations or local law  
• Randomization list and randomization documentation 
• List of investigational  sites 
• Any other records that may be required by hospital regulations or local law  
 
 Investigator reporting responsibilities  
Report  Submitted to  Description  
Withdrawal of EC/IRB  
approval  Sponsor  Investigator will inform Medtronic  as soon as possible  
in case EC/IRB approval is withdrawn.  
In the US, the investigator must report a withdrawal of 
the reviewing IRB within 5 working days of the 
investigator’s part of the investigation.  
Final Clinical Study 
Report  EC/IRB  (all sites), 
Sponsor (US sites)  o A copy of the Final Clinical Study R eport will 
be provided to the EC/IRB . The report will be 
submitted to the local EC/IRB in accordance 
with the EC/IRB policies and procedures.  
o In the US, the final report must also be 
submitted to the Sponsor within 3 months after 
termination or completion of the investigation 
or the investigator’s part of the investigation.  
Deviations from  Clinical  Investigational Plan  
Emergency Use  Sponsor, EC/IRB , 
regulatory authority  Investigator will report deviation as soon as possible to 
the sponsor and EC/IRB . 
SPYRAL PIVOTAL - SPYRAL HTN -OFF MED Clinical Investigation Plan  
  
 Version  12 .0 Page 116 of 139  
 
Medtronic Confidential  
  056-F275, v3 .0 Clinical Investigation Plan Template  
  Report  Submitted to  Description  
Planned deviation  Sponsor, EC/IRB , 
regulatory authority  Prior approval must always be obtained from 
Medtronic. If the deviation affects scientific sound ness 
of the clinical study  or the rights, safety, or welfare of 
the subject and is not an emergency, prior approval 
must be obtained from the EC/IRB  and regulatory 
authority . 
Other Deviations  Sponsor  Deviations that are beyond the control of the 
investigator (such as subject  who fails to return to 
follow -up visit) or deviations that do not affect the 
scientific soundness of the clinical study or the rights, 
safety, or welfare of the subject and are not  an 
emergency, should be submitted as they are identified 
by the investigation al site or Medtronic staff . 
 
 Sponsor records  
At a minimum, the sponsor will keep the following records: 
• All essential study  documents and correspondence that pertains to the clinical 
study  
• All approved versions of the CIP and any amendments  
• All approved versions of the Investigator Brochure and/or Instructions for Use  
and any amendments  
• Sample of labeling attached to the investigational device  
• Curriculu m Vitae of investigators and investigational  site personnel  
• Delegated Task Lists and training records of investigators and  investigational  
site personnel 
• List of investigational  sites 
• Names/contact information of monitors  
• EC/IRB approvals/notifications and regulatory approvals/notifications  
• EC/IRB voting list 
 
• Normal values or ranges for lab test  
 
• Documentation for equipment maintenance and calibration 
•  
• Lab certificate  
SPYRAL PIVOTAL - SPYRAL HTN -OFF MED Clinical Investigation Plan  
  
 Version  12 .0 Page 117 of 139  
 
Medtronic Confidential  
  056-F275, v3 .0 Clinical Investigation Plan Template  
  • Any reports to EC/IRB and regulatory authority  
• Statisti cal analysis and clinical investigation report (final report)EC/IRB 
approvals/notifications and regulatory approvals/notifications  
• Signed Clinical Investigation Agreements and signed agreements with third 
parties  
• Insurance certificates  
• Shipping records for  investigational devices, drugs provided for purposes of the 
study,  and clinical -investigation related documents and materials  
• Sample of  approved Patient Informed Consent Form s 
• Site visit reports  
• Adverse event and Device Deficiency reports  
• Financial disclosure information  
• Fully executed CRFs and corrections  
• Randomization list and randomization forms  
 
 Sponsor reporting responsibilities  
Report  Submit to  Description  
Withdrawal of EC /IRB  
approval  EC/IRB , Investigators, 
and regulatory 
authorities, where 
applicable  In case of withdrawal of EC/IRB approval 
Medtronic will suspend the clinical study  as 
described below.  
Premature termination or 
suspension of study EC/IRB , Investigators, 
and regulatory 
authorities, where 
applicable  Medtronic will provide prompt notification of 
termination or suspension and reason(s) to 
investigator and where required to EC/IRB and 
regulatory authorities.  
SPYRAL PIVOTAL - SPYRAL HTN -OFF MED Clinical Investigation Plan  
  
 Version  12 .0 Page 118 of 139  
 
Medtronic Confidential  
  056-F275, v3 .0 Clinical Investigation Plan Template  
  Report  Submit to  Description  
Final Report  Investigators, and 
regulatory authorities, 
where applicable  Medtronic will provide all investigato rs with a 
copy of the Final Clinical Study R eport of the 
clinical study.  
EC/IRBs and regulatory authorities will be 
informed when required.  
 
• The investigator shall have the 
opportunity to review and comment on 
the final report.    
• If a clinical investigato r does not agree 
with the final report, his/her comments 
shall be communicated to the other investigator(s).    
The coordinating investigator shall sign the report. If no coordinating investigator is appointed, then the signature of the principal Investigator in each 
study site should be obtained.     
Emergency Deviations from 
Clinical Investigational Plan  Regulatory authorities, 
where applicable  If required, Medtronic will inform regulatory 
authorities as soon as possible about any 
emergency devia tions that affect scientific 
soundness of the clinical study or the rights, safety, 
or welfare of the subject.  
 
 Record retention  
The investigator must retain the Investigator Site File, patient medical files and CRFs in 
accordance with local law and regulations for a minimum period of 2 year (or longer if local 
laws require) after market -release in his/her region. The investigator should take measures to 
prevent accidental or early destruction of the clinical study  related materials.  
In Japan, investigational sites must retain all study -related documents until the later date of 
the time points below:  
• Day of marketing approval of the investigational device (day 3 years from the date 
of the decision to discontinue development when notification that development will be discontinued pursuant to the provisions of the J -GCP Ordinance has been 
received)  
• 3 years from the date of termination or closure of the clinical study  
If Medtronic wishes to retain these records for a shorter or longer period than specified above, Medtronic will notify the investigational sites of the intent and consult with the institutions on the methods of discarding or moving records. In addition, Medtronic will inform the 
investigational sites of expiration of the retention period prior to when the retention period 
SPYRAL PIVOTAL - SPYRAL HTN -OFF MED Clinical Investigation Plan  
  
 Version  12 .0 Page 119 of 139  
 
Medtronic Confidential  
  056-F275, v3 .0 Clinical Investigation Plan Template  
  expires . Upon the completion or termination of the investigation, Medtronic will maintain study  
records under its responsibility in accordance with J -GCP and Medtronic policy.  
I.4 Miscellaneous  
 Insurance  
Medtronic, Inc. (including all wholly owned subsidiaries) maintains appropriate clinical study  
liability insurance coverage as required under applicable laws and regulations and will comply 
with applicable law and custom concerning specific insurance cover age. If required, a Clinical 
Study  Insurance statement/certificate will be provided to the EC/IRB . 
 Subject compensation and indemnification  
Subjects will not receive any compensation for their participation in this study . Medtronic will 
provide subject indemnification according to local laws where this study  will be conducted and 
as outlined in the Clinical Study  Agreement . 
 Subject confidentiality  
All information and data sent to parties involved in study  conduct concerning subjects or their 
participation i n this study  will be considered confidential. Study  sites will assign a unique 
subject ID number (SID) to each subject. Records of the subject/SID relationship will be maintained by the study  site. The SID number is to be recorded on all study  documents to link 
them to the subject’s medical records at the site. A subject identification log will be maintained 
as part of the Investigator Site File. This log will serve as the link between the patient study  ID 
and an individual patient. This log must remain at the study  site at all times. 
Confidentiality of data will be observed by all parties involved at all times throughout the clinical investigation. All data shall be secured against unauthorized access. The privacy of each 
subject and confidentiality of his/her information shall be preserved in reports and w hen 
publishing any data.  
In the United States, “Protected Health Information” (PHI) will be maintained in compliance with the Health Insurance Portability and Accountability Act of 1996 (HIPAA). To maintain 
confidentiality, the subject’s name or any other  PHI should not be recorded on any study  
document other than the informed consent form, as required by EN ISO5840: 2009. This 
scenario will be covered in the Patient Information- Informed Consent Form. In the event a 
subject’s name/PHI is included for any reason, it will be blinded as applicable. In the event of inability to blind the identification (e.g., digital media), it will be handled in a confidential manner 
by the authorized personnel.  
In geographies outside the United States, investigational sites will protect the personal 
information of subjects in accordance with national, local and IRB requirements.  Data relating 
to the study  might be made available to third parties (for example in case of an audit performed 
by regulatory authorities), provided the data are treated as confidential and that the subject’s privacy is guaranteed. No identifiable subject information will be published.  
SPYRAL PIVOTAL - SPYRAL HTN -OFF MED Clinical Investigation Plan  
  
 Version  12 .0 Page 120 of 139  
 
Medtronic Confidential  
  056-F275, v3 .0 Clinical Investigation Plan Template  
  J RISKS AND BENEFITS  
The inexorable progression from asymptomatic hypertension to evidence of end organ 
disease is well k nown. Both embolic and thrombotic stroke as well as both systolic and 
diastolic heart failure, and progressive renal dysfunction are known to be companions of chronic hypertension . Beyond contributing to renal failure, hypertension plagues the treatment 
of patients with end stage renal disease treated with dialysis and transplant .  
In aggregate, reduction of blood pressure is linearly related to reduction of mortality in 
population studies
23,24, with large individual patient variability depending on the presence of 
additional cardiovascular risk factors, such as lipid abnormalities, diabetes, cigarette smoking, 
and antecedent heart disease. Despite the availability of numerous pharmaceuticals fr om 
many different pharmaceutical classes, patients often fail to attain adequate blood pressure control. Additionally, pharmaceutical interventions that rely on numerous medications are 
plagued with drug interactions and side effects, which contribute to physician decisions to discontinue medications and patient decisions to not remain persistent or compliant with the 
prescribed drug strategies. The development of an effective alternative treatment of 
hypertension, which offers an adjunct to pharmaceutical care or an alternative to undesirable 
pharmaceutical complications, may prove to be of obvious value to patients, physicians and 
the health system.  
J.1 Anticipated Clinical Benefits  
Although no assurances or guarantees can be made, there is a reasonable expectation that the renal denervation procedure may be beneficial to the subject. Treatment with the 
Medtronic Symplicity  Spyral™  multi-electrode renal denervation catheter  and the Symplicity 
G3
TM renal denervation RF generator may reduce the nerve activity to and from the kidneys, 
and cause a reduction in blood pressure. Evidence in the literature suggests that reduction of 
efferent sympathetic nerve activity to the kidney can a) cause relief of renal vasoconstriction, 
resulting in improved kidney function; b)  reduce sodium retention, which can improve the 
clinical condition of patients with medical problems related to excess salt and water; and c) reduce the release of renin - a renal produced hormone which is often elevated in patients 
with either severe hypertension or heart failure
25. Interference of afferent nerve activity from 
the kidneys can reduce central sympathetic activity, also causing reduction of blood pressure.  
A reduction in blood pressure may result in the decrease or elimination of any symptom s 
associated with high blood pressure and/or reduction of blood pressure medications and the side effects related to medications . In addition, reduction in blood pressure may decrease the 
risk of other related adverse events associated with high blood pressure (risk of stroke, heart attack, renal failure, etc .).  
Hyperactive sympathetic nervous system activity is associated with increased risk of death in 
patients with heart failure
26-30.     With a reduction in renal sympathetic nervous system activity, 
the combination of reduced intra and extra renal neurohormonal activity may either retard the progression of ventricular hypertrophy or induce regression of hypertrophy - both of which 
could ameliorate symptoms associated with heart failure.
31 
Reduction of central sympathetic activity may also reduce resistance to the action of insulin – 
potentially improving glycemic control.32,33  
There are no guaranteed benefits from participation in the study. 
SPYRAL PIVOTAL - SPYRAL HTN -OFF MED Clinical Investigation Plan  
  
 Version  12 .0 Page 121 of 139  
 
Medtronic Confidential  
  056-F275, v3 .0 Clinical Investigation Plan Template  
  J.2 Risks 
The primary risks of the renal denervation procedure are similar to the risks of all diagnostic 
procedures requiring catheterization of the arteries of the body . The following are potential 
risks of the catheterization procedure (including renal  angiogram):  
• Death – a complication or deterioration of health ultimately leading to a patient’s 
death.  
• Cardiopulmonary arrest  – cessation of blood circulation and/or respiration due to 
dysfunction of the heart and/or lungs.  
• Heart rhythm disturbances  – disruption of normal heart rate or rhythm, including 
bradycardia treated with atropine.  
• Embolism  – formation and dislodgement of a blood clot (thrombus) or dislodgement 
of cholesterol/plaque within the blood vessel, which travels downstream into small vessels, blocking blood flow and causing temporary or permanent damage to 
organs distal to blockage . Emboli are known to cause myocardial infarction, stroke 
or kidney damage, peripheral ischemia and may ultimately lead to incapacitation 
or death.  
• Complications at catheter insertion site in the groin:  
o Pain – discomfort at the catheter insertion site that can range from mild to 
severe.  
o Hematoma/Bruising – a collection of blood in the tissue surrounding the 
catheter insertion site.  
o Pseudoaneurysm  – a collection of blood in the tissue surrounding the 
catheter insertion site due to ongoing leaking of blood from a blood vessel. 
o AV fistula  – an abnormal connection between an artery and a vein ( i.e., 
caused by needle insertion through the femoral artery and vein).  
o Infection – localized redness, heat swelling and pain at the catheter 
insertion site,  
o Significant bleeding – blood loss from the catheter insertion site requiring 
surgery or transfusion of 2 or more units of packed red blood cells (PRBCs).  
• Retroperitoneal bleeding – bleeding into the retroperitoneal space.  
• Vascular complications requiring surgery  – damage to an artery ( e.g., femoral) or 
vein requiring surgical repair.  
• Perforation of a blood vessel  – unintended puncture through the wall of a blood 
vessel, such as a renal artery, requiring repair.  
SPYRAL PIVOTAL - SPYRAL HTN -OFF MED Clinical Investigation Plan  
  
 Version  12 .0 Page 122 of 139  
 
Medtronic Confidential  
  056-F275, v3 .0 Clinical Investigation Plan Template  
  • Dissection of a blood vessel – a tear within the wall of a blood vessel, which allows 
blood to separate the wall layers.  
• Hypotension – low blood pressure.  
• Hypertension – high blood pressure.  
• Nausea – a sensation of unease and discomfort in the upper stomach with an urge 
to vomit.  
• Vomiting  – forceful expulsion of stomach contents through the mouth and/or nose.  
• Complications associated with the contrast agents  – adverse effects of contrast 
agents used during the procedure ( e.g., allergic reaction or radiocontrast 
nephropathy).  
• Complications associated with medications commonly utilized during the 
procedure – known risks of medications commonly used during the procedure 
(e.g., narcotics, anxiolytics, other pain medications, ant i-vasospasm agents).  
 
There are additional risks that could possibly be associated with the denervation 
procedure/therapy. These potential risks have not yet been quantified, but may include:  
• Pain – discomfort that can range from mild to severe that may occur peri - and/or 
post-procedure.  
• Damage to one or both kidneys , loss of kidney function, and/or need to remove a 
kidney  – perforation of kidney or an occlusion of blood flow to the kidney ( e.g., from 
stenosis or embolism) and/or reduction of glomerular filtration rate  or need for 
nephrectomy . If severe enough, this could require dialysis.  
• Renal artery aneurysm  – localized weakening and ballooning of the renal artery 
from the interventional procedure or the delivery of RF energy. 
• Renal artery stenosis  - narrowing of the renal artery due to the interventional 
procedure or the delivery of RF energy.  
• Arterial spasm or constriction – Acute or chronic narrowing of the renal artery lumen 
diameter at denervation locations due to arterial muscle contraction, local tissue 
contraction or local edema.  
• Thermal injury to the vasculature or other structure from energy application - 
damage to an artery, vein or other structure due to the delivery of energy. 
• Hypertension – worsening high blood pressure  
• Hypotension – low blood pressure. BP reduction may occur too far and/or too 
quickly and may cause end organ hypoperfusion  
SPYRAL PIVOTAL - SPYRAL HTN -OFF MED Clinical Investigation Plan  
  
 Version  12 .0 Page 123 of 139  
 
Medtronic Confidential  
  056-F275, v3 .0 Clinical Investigation Plan Template  
  • Orthostatic hypotension – temporary reduction of blood pressure when going from 
lying to standing, coupled with symptoms ( e.g., dizziness, light headedness).  
• Hematuria  – blood in urine 
• Hemorrhage  – significant blood loss  
• Proteinuria – elevated levels of protein in urine  
• Electrolyte disturbances  – an imbalance of the electrolytes (sodium, potassium)  
• Skin burn – damage to the skin caused by energy conduction via the ground pad 
used with the SymplicityTM renal denervation system  
The risks associated with not having a controlled blood pressure during the first 6 months 
include:  
• Angina (chest pain, pressure or squeezing)  
• Myocardial Infarction (improper blood flow to the heart)  
• Pulmonary Edema (fluid accumulation in the air spaces of the lungs)  
• Heart Failure  
• Stroke (disturbance in the blood supply to the brain)  
• Atrial Fibrillation (abnormal heart rhythm)  
• Death 
There are additional risks that could possibly be associated with the tests and procedures 
performed for the clinical study . These potential risks are described below.  
The risks associated with subjects being off their antihypertensive medications during the washout period through 3 months post -procedure include:  
• Death 
• Stroke  
• MI 
• Angina 
• Heart Failure  
• Atrial fibrillation  
• Pulmonary Edema  
There are risks related to the blood tests required for the study , (e.g., excessive bleeding, 
fainting or light -headedness, hematoma (bruising), infection, or the requirement of multiple 
punctures to locate a vein to draw the sample).  
This study  involves exposure to a small amount of radiation. As part of everyday living, people 
are exposed to naturally occurring background radiation and receive a dose of about 3 
SPYRAL PIVOTAL - SPYRAL HTN -OFF MED Clinical Investigation Plan  
  
 Version  12 .0 Page 124 of 139  
 
Medtronic Confidential  
  056-F275, v3 .0 Clinical Investigation Plan Template  
  millisievert s (mSv) each year. The effective dose from the denervation procedure is less than 
5.5 mSv. The dose from this procedure is comparable to that received from many diagnostic 
medical x -ray and nuclear medicine procedures.  
Subjects may undergo additional renal imaging via magnetic resonance imaging (MRA) or computerized tomographic angiography (CTA). The risks of undergoing an MRA include: 
medication patches can cause a skin burn, claustrophobia from being enclosed within the 
MRA magnet, and allergic reaction to the contrast material (if used). The presence of 
implanted metal devices may be a contraindication to undergoing MRA due to heating, movement, or disruption of programming of electronic devices. Nephrogenic systemic fibrosis 
(NSF) may occur when Gadolinium is administered to subjects with reduced eGFR. The risks 
of undergoing a CT scan include ionizing radiation and contrast -induced neuropathy.  
There is a possibility of risks to an unborn child. These risks are unknown. Women who are pregnant or expect to become pregnant during the course of the study  are excluded from 
participating.  
The study  may involve unknown or unforeseen side effects or complications other than those 
mentioned above. If the above complications occur, they may lead to repeat or prolonged 
hospitalization, repeat procedures, emergency surgery, other emergency procedures, or, in 
rare cases, death.  
The risks must be continuously monitored, assessed and documented by the investigator.  
J.3 Minimization of Risk  
Residual risks of the Symplicity
TM renal denervation system have been characterized as 
acceptable per Medtronic standard operating procedures for risk management . No further risk 
mitigation is required at this time. Medtr onic will continue to evaluate the risk/benefit profile, 
safety and performance of the product as data becomes available.  
The following measures will also be taken to minimize risk to participants as part of this clinical investigation plan:  
1. Physicians and staff will receive appropriate training prior to using the study  
devices . Training will include instruction on equipment and lab setup, assessing 
renal anatomy, intra -procedural patient management and monitoring, Symplicity 
Spyral
TM catheter delivery and RF ablation, and post -procedural care.  
2. Instructions for Use are provided with each Symplicity SpyralTM catheter and a 
User’s Manual  is provided with each  Symplicity G3TM generator to ensure 
consistent use of the device within pre- tested parameters.  
3. The system’s design and software include several safety mechanisms to reduce risk to the patient (limitations on temperature, time, impedance, and power delivered to the subject).  
4. Subjects will be closely monitored by appropriately trained personnel during the procedure and at regularly scheduled intervals for the duration of the study . 
SPYRAL PIVOTAL - SPYRAL HTN -OFF MED Clinical Investigation Plan  
  
 Version  12 .0 Page 125 of 139  
 
Medtronic Confidential  
  056-F275, v3 .0 Clinical Investigation Plan Template  
  5. Physicians will employ usual and customary clinical technique (e.g., sterile 
technique during catheter use and aseptic wound care procedures).  
6. A Data Safety Monitoring Board (DSMB) will be established to monitor the health, safety and welfare of patients and provide safety surveillance. The DSMB will 
review safety and efficacy data at pre- specified time points and provide 
recommendations regarding the continuation of the study  to the Sponsor.  
J.4 Risk -to-Benefit Rationale  
The detrimental effects of uncontrolled hypertension are well established and an alternative 
treatment is worth investigation. Renal denervation using the Symplicity  Spyral ™ renal 
denervation system is one such alternative. Although there are several theoretical risks that 
could be associated with the device and procedure, the likelihood of those risks is believed t o 
be low and will be carefully monitored in the study . The potential benefits, including blood 
pressure reduction and the associated effects of lowered blood pressure, justify the investigation of renal denervation in this study . 
   
SPYRAL PIVOTAL - SPYRAL HTN -OFF MED Clinical Investigation Plan  
  
 Version  12 .0 Page 126 of 139  
 
Medtronic Confidential  
  056-F275, v3 .0 Clinical Investigation Plan Template  
  K REFERENCES  
1. Charkoudian N, Rabbitts JA. Sympathetic neural mechanisms in human 
cardiovascular health and disease. Mayo Clin Proc . 2009 ;84:822 -830 
2. Joles JA. Koomans HA. Causes and consequences of increased sympathetic 
activity in renal disease. Hypertension. 2004;43:699- 706 
3. Mancia G, Grassi G, Giannattasio, Seravalle G. Sympathetic activation in the 
pathogenesis of hypertension and progression of organ damage. Hypertension. 
1999;34:724 -728 
4. Krum H, Schlaich M, Whitbourn R,  Sobotka PA, Sadowski J, Bartus K, Kapelak B, 
Walton A, Sievert H, Thambar S, Abraham WT, Esler M.  Catheter -based renal 
sympathetic denervation for resistant hypertension: a multicentre safety and proof-
of-principle cohort study. Lancet . 2009;373:1275- 1281 
5. Coruzzi P, Musiari L, Mossini GL, Ceriati R, Mutti A.  The renin-a ldosterone system 
and renal function in kidney transplantation. Clin Nephrol . 1994;41:225 -229 
6. Symplicity HTN-1 Investigators. Catheter -based renal sympathetic denervation for 
resistant hypertension: durability of blood pressure reduction out to 24 months. 
Hypertension. 2011;57:911- 917 
7. Symplicity HTN-2 Investigators  , Esler MD, Krum H, Sobotka PA, Schlaich MP, 
Schmieder RE, Böhm  M. Renal sympathetic denervation in patients with treatment -
resistant hypertension (the Symplicity HTN- 2 study ): A randomised controlled study . 
Lancet . 2010;376:1903 -1909 
8. Krum H, Schlaich MP, Böhm M, Sobotka PA, Mahfoud F, Rocha -Singh K, Katholi 
R, Esler MD. Percutaneous renal denervation in patients with treatment -resistant 
hypertension: final 3- year report of the Symplicity HTN -1 study. Lancet.  
2014;383:622– 629. 
9. Esler MD , Böhm  M, Sievert H, Rump CL, Schmieder RE, Krum H, Mahfoud F, 
Schlaich MP . Catheter -based renal denervation for treatment of patients with 
treatment -resistant hypertension: 36 month results from the Symplicity HTN- 2 
randomized controlled study . Eur Heart J.  2014;35:1752– 1759.  
10. Bhatt DL, Kandzari DE, O'Neill WW, D'Agostino R, Flack JM, Katzen BT, Leon MB, 
Liu M, Mauri L, Negoita M, Cohen SA, Oparil S, Rocha- Singh K, Townsend RR, 
Bakris GL; SYMPLICITY HTN -3 Investigators. A controlled trial of renal denervation 
for resistant hyper tension. N Engl J Med. 2014;370:1393- 1401.  
11. Bakris GL, Townsend RR, Flack JM, et al. SYMPLICITY HTN -3 Outcomes: Results 
at Twelve Months. J Am Coll Cardiol 2015 in press.  
12. Böhm M, Mahfoud F, Ukena C et al. The First Report of the Global SYMPLICITY 
Registry on the effect of Renal Artery Denervation in Patients with Uncontrolled 
Hypertension. Hypertension 2015 in press.  
13. Townsend RR, Mahfoud F, Kandzari DE, Kario K, Pocock S, W eber MA, Ewen S, 
Tsioufis K, Tousoulis D, Sharp AS, Watkinson AF. Catheter -based renal 
denervation in patients with uncontrolled hypertension in the absence of 
antihypertensive medications (SPYRAL HTN -OFF MED): a randomised, sham -
controlled, proof -of-concept trial. The Lancet. 2017 Aug 28.  
SPYRAL PIVOTAL - SPYRAL HTN -OFF MED Clinical Investigation Plan  
  
 Version  12 .0 Page 127 of 139  
 
Medtronic Confidential  
  056-F275, v3 .0 Clinical Investigation Plan Template  
  14. Walton, T. Renal artery denervation with a new simultaneous multielectrode 
catheter for treatment of resistant hypertension: 6- month safety results from the 
SYMPLICITY Spyral First -in-Man Study. Abstract presented at: EuroPCR 
conference; 2014; Paris, France 2014  
15. Sakakura K, Ladich E, Cheng Q, Otsuka F, Yahagi K, Fowler DR, Kolodgie FD, Virmani R, Joner M. Anatomic assessment of sympathetic peri -arterial renal nerves 
in man. J Am Coll Cardiol. 2014;19;64:635 -643 
16. Tzafriri AR, Mahfoud F, Keating JH, Markham PM, Spognardi A, Wong G, Fuimaono K, Böhm M, Edelman ER. Innervation patterns may limit response to endovascular 
renal denervation. J Am Coll Cardiol. 2014;64:1079- 1087  
17. Mahfoud F, Edelman ER, Böhm M. Catheter- based renal denervation is no simple 
matter. lessons to be learned from our anatomy? J Am Coll Cardiol. 2014;64:644-
646 
18. Pekarskiy S, Baev A, Mordovin V, Ripp T, Semke G, Sitkova E, Krylov A, Popov S.  
Low efficacy of renal denervation as a result of anatomically inadequate operative 
technique Moderated poster presented at: European Society of Cardiology (ESC) 
Conference; 2014; Barcelona, Spain 2014. 
19. Plehn A. First experience with a new renal denervation device and technology: the 
Spyral device. Confluence 8, 2014  
20. White WB, Weber MA, Sica D, Bakris GL, Perez A, Cao C, Kupfer S. Effects of the angiotensin receptor blocker azilsartan medoxomil versus olmesartan and valsartan 
on ambulatory and clinic blood pressure in patients with stages 1 and 2 hypertension. 
Hypertension . 2011;57:413–420 
21. “Recommendations.” ICMJE | Recommendations, 
www.icmje.org/recommendations/  
22. 
  “GPP2.” The International Society for Medical Publication Professionals, 
www.ismpp.org/gpp2.  
23. Whelton PK, He J, Appel LJ, Cutler JA, Havas S, Kotchen TA, Roccella EJ, Stout 
R, Vallbona C, Winston MC, Karimbakas J; National High Blood Pressure Education 
Program Coordinating Committee. Primary prevention of hypertension: clinical and 
public health advisory from The National High Blood Pressure Education Program. 
JAMA  2002; 288:1882- 1888 
24. Law MR, Morris JK, Wald NJ. Use of Blood Pressure Lowering Drugs in the Prevention of Cardiovascular Disease: Meta- analysis of 147 Randomised Studies 
in the Context of Expectations from Prospective Epidemiological Studies. BMJ. 
2009;338:b1665 
25. Schlaich MP, Sobotka PA, Krum H, Whitbourn R, Walton A, Esler MD. Renal 
denervation as a therapeutic approach for hypertension: novel implications for an 
old concept. Hypertension. 2009;54:1195 -1201  
26. Cohn JN, Levine TB, Olivari MT, Garberg V, Lura D, Franci s GS, Simon AB, Rector 
T. Plasma norepinephrine as a guide to prognosis in patients with chronic congestive heart failure. N Engl J Med. 1984;311:819- 823 
27. Brunner -La Rocca HP, Esler MD, Jennings GL, Kaye DM. Effect of cardiac 
sympathetic nervous activity on  mode of death in congestive heart failure. Eur Heart 
J. 2001;22:1136 -1143  
SPYRAL PIVOTAL - SPYRAL HTN -OFF MED Clinical Investigation Plan  
  
 Version  12 .0 Page 128 of 139  
 
Medtronic Confidential  
  056-F275, v3 .0 Clinical Investigation Plan Template  
  28. Francis GS, Cohn JN, Johnson G, Rector TS, Goldman S, Simon A. Plasma 
norepinephrine, plasma renin activity, and congestive heart failure. Relations to 
survival and the effects of therapy in V -HeFT II. The V -HeFT VA Cooperative 
Studies Group. Circulation . 1993;87:VI40- 48 
29. Kaye DM, Lefkovits J, Jennings GL, Bergin P, Broughton A, Esler MD. Adverse 
consequences of high sympathetic nervous activity in the failing human heart. J Am 
Coll Cardiol . 1995;26:1257- 1263  
30. Petersson M, Friberg P, Eisenhofer G, Lambert G, Rundqvist B. Long -term outcome 
in relation to renal sympathetic activity in patients with chronic heart failure. Eur 
Heart J . 2005;26:906- 913 
31. Brandt Mathias C, Mahfoud F, Reda S, Schirmer Stephan H, Erdmann E, Bohm M, 
Hoppe Uta C. Renal sympathetic denervation reduces left ventricular hypertrophy 
and improves cardiac function in patients with resistant hypertension. Journal of the 
American College of Cardiology . 2012;59:901- 909 
32. Mahfoud F, Schlaich M, Kindermann I, Ukena C, Cremers B, Brandt MC, Hoppe UC, Vonend O, Rump LC, Sobotka PA, Krum H, Esler M, B öhm M. Effect of renal 
sympathetic denervation on glucose metabolism in patients with resistant hypertension: a pilot study. Circulation . 2011;123:1940- 1946  
33. Witkowski A, Prejbisz A, Florczak E, Kadziela J, Śliwinski P, Bieleń P, Michałowska 
I, Kabat M, Warchoł E, Januszewicz M, Narkiewicz K, Somers VK, Sobotka PA, 
Januszewicz A. Effects of renal sympathetic denervation on blood pressure,  sleep 
apnea course, and glycemic control in patients with resistant hypertension and sleep apnea. Hypertension . 2011;58:559 -565 
34. Medtronic Internal data.  
35. Calhoun, et al. “Resistant Hypertension: Diagnosis, Evaluation, and Treatment: A Scientific Statement From the American Heart Association Professional Education 
Committee of the Council for High Blood Pressure Research.” Circulation. 2008; 
117;e510- e526.  
36. http://mdic.org/computer -modeling/virtual- patients/  
37. T. Haddad, A. Himes, L. Thompson, T. Irony, R. Nair, " Incorporation of stochastic engineering models as prior information in Bayesian medical device trials", Journal 
of Biopharmaceutical Statistics, (2017) DOI: 10.1080/10543406.2017.1300907 
38. J. G. Ibrahim and M. -H. Chen, "Power prior distributions for regression models," 
Statistical Science, (2000), 15(1) 46 -60. 
39. A. Gelman, J. Carlin, H. Stern and D. Rubin, Bayesian Data Analysis, Boca Raton: 
Chapman & Hall / CRC, 2004.  
40. Whitbourn R, Harding SA, Walton A. Symplicity multi -electrode radiofrequency renal 
denervation system feasibility study. EuroIntervention 2015; 11:104 -109.  
41. Sanders, Margreet F., et al. "Renal artery and parenchymal changes after renal 
denervation: assessment by magnetic resonance angiography."  European 
radiology  27.9 (2017): 3934- 3941.  
42. 
Kandzari DE, Böhm M, Mahfoud F, Townsend RR, Weber MA, Pocokc S, Tsioufis K, 
Tousoulis D,  Choi JW, East C, Brar S, Cohen S, Fahy M, Pilcher G, Kauomi K. Effect of 
renal denervation on blood pressure in the presecent of antihypertenisve drugs: 6- month 
SPYRAL PIVOTAL - SPYRAL HTN -OFF MED Clinical Investigation Plan  
  
 Version  12 .0 Page 129 of 139  
 
Medtronic Confidential  
  056-F275, v3 .0 Clinical Investigation Plan Template  
  efficacy and safety results from the SPYRAL HTN -ON MED proof of concept reandomised 
trial. The Lancet.  2015 May 23: http://dx.doi.org/10.1016/  S0140- 6736(18)30951-6  
 
 
  
SPYRAL PIVOTAL - SPYRAL HTN -OFF MED Clinical Investigation Plan  
  
 Version  12 .0 Page 130 of 139  
 
Medtronic Confidential  
  056-F275, v3 .0 Clinical Investigation Plan Template  
  L APPENDICES 
L.1 Names and addresses  
 List of contact persons  
Coordinating investigator  
The following investigators will serve as Coordinating Investigators on the study : 
 
Professor Dr. Michael Böhm  
Universitätsklinikum des 
Saarlandes  
Kirrberger Strasse 1  
66421 Homburg  
Germany  
 David Kandzari, MD  
Piedmont Hospital  
275 Collier Rd. NW, Suite 300  
Atlanta, Georgia 30309 -1711 
United States  
Kazuomi Kario, MD  
Jichi Medical University Hospital 3311- 1 Yakushiji  
Shimotsuke, Tochigi, 329- 0498  
Japan  Raymond Townsend, MD  
University of Pennsylvania 
Medical Center  
210 White Building 3400 Spruce Str eet 
Philadelphia, Penns ylvania 
19104- 5127  
United States   
Other contacts  
A list with addresses of third parties, including the identification of the head of any core laboratory and the scope and duties to be entrusted  is provided below. The Sponsor will 
maintain a current list and it will be provided separately  if updates from the below table are 
made. 
Service Provider  Contact Information  Services  Scope and Duties Entrusted  
Medtronic, Inc.  
(Global Sponsor)  3576 Unocal Place  
Santa Rosa, CA 95403  
USA  Monitoring  Medtronic is responsible for the 
source data verification and 
compliance with the study Clinical 
Investigation Plan and applicable 
regulations (Monitoring); review 
and cleaning of the data (Data 
Management) and statistical 
programming and data analysis.   Data Management  
Statistical 
Programming and 
Data Analysis  
Beth Israel Deaconess 
Medical Center, Inc.  
 375 Longwood Avenue  
3rd Floor  
Boston, MA 02215  
USA  
 
Duane Pinto , MD  Angiographic Core 
Laboratory  The Angiographic Core Laboratory 
is responsible for review and 
analysis of angiographic renal 
imaging to assess renal artery 
stenosis.  
ACM Global 
Laboratory  160 Elmgrove Park  
Rochester, NY 14624  
USA   Blood Core 
Laboratory  Blood Core Lab is responsible for 
processing and analyzing test 
samples for renin and aldosterone.  
SPYRAL PIVOTAL - SPYRAL HTN -OFF MED Clinical Investigation Plan  
  
 Version  12 .0 Page 131 of 139  
 
Medtronic Confidential  
  056-F275, v3 .0 Clinical Investigation Plan Template  
  Service Provider  Contact Information  Services  Scope and Duties Entrusted  
ICON Clinical Research  2800 Kelly Road  
Suite 200  
Warrington, PA 18976  
USA   Central Registration 
and Randomization 
Center  The Central Registration and 
Randomization Center will be 
responsible for developing  and 
maintaining  the randomization 
system for the study.  
Cardiovascular 
Research Foundation 
(CRF)  1700 Broadway  
Floor 9  
New York, NY 10019 USA  
 Clinical Events 
Committee (CEC)  The CEC is an independent group 
whose primary responsibilities are to 
adjudicate any events that are part of 
study safety endpoints. The CEC 
will be composed of physicians who have experience in clinical studies in hypertension and/or cardi ovascular 
indications.  
Data Safety 
Monitoring Board 
(DSMB)  The DSMB is an independent group 
whose primary responsibility is to 
monitor the health, safety and 
welfare of patients. The DSMB will 
be composed of physicians who 
have experience in clinical studies in 
hypertension and/or cardiovascular 
indications and one biostatistician 
with experience in analysis of 
clinical trials.  
Klinische Toxikologie  
Universitäts klinikum 
des Saarlandes  Klinische Toxikologie  
Universitäts klinikum des 
Saarlandes, Geb. 46  
D-66421 Homburg (Saar)  
Germany  
 
Prof. Dr. Markus R. Meyer  Drug Testing Core 
Laboratory  Drug Testing Core Laboratory is 
responsible for processing and 
analyzing plasma and urine test 
samples to confirm the absence or presence of antihype rtensive 
medications.  
Medidata Solutions, 
Inc. (formerly known as 
Intelemage) 700 W. Pete Rose Way  
Suite 436  
Cincinnati, OH 45203  
USA  Media (i.e., imaging 
and file) upload  Provide platform to allow for the 
submission and management of files 
and study data/imaging studies.  
Morristown Medical 
Center  Cardiovascular Core Lab  
Morristown Medical Center  
100 Madison Avenue  
Morristown, NJ  07960  
 
Linda D. Gillam, MD, 
MPH, FACC, FAHA, 
FESC, FASE   MRA/CTA Core 
Laboratory  The MRA/CTA Core Laboratory is 
responsible for review and analysis of the MRA/CTA renal imaging to assess renal artery stenosis.  
 
VasCore – The 
Vascular Ultrasound Core Laboratory  
 The Vascular Ultrasound 
Core Laboratory  
1 Bowdoin Square  
Tenth Floor  
Boston, MA 02114  
USA  
 
Michael R. Jaff, D.O., RPVI  Renal Artery Duplex 
Ultrasound (DUS) Core Laboratory  The DUS Core Laboratory is 
responsible for review and analysis of DUS renal imaging to assess renal artery stenosis.  
Cytel   Statistical 
Programming and 
Data Analysis  Independent statistical data analysis 
and validation  
SPYRAL PIVOTAL - SPYRAL HTN -OFF MED Clinical Investigation Plan  
  
 Version  12 .0 Page 132 of 139  
 
Medtronic Confidential  
  056-F275, v3 .0 Clinical Investigation Plan Template  
  
 List of participating investigational  sites and investigators  
A list of investigational sites and investigators will be provided under a separate cover.  
L.2 Case Report Forms  
A copy  of the Case Report Form s will be provided  under a separate cover.  
L.3 Sample Investigator Agreement  
A sample Investigator Agreement will be provided under a separate cover . 
SPYRAL PIVOTAL - SPYRAL HTN -OFF MED Clinical Investigation Plan  
  
 Version  12 .0 Page 133 of 139  
 
Medtronic Confidential  
  056-F275, v3 .0 Clinical Investigation Plan Template  
  L.4 Abbreviations  
ABPM  Ambulatory Blood Pressure Monitoring  
ADE Adverse Device Effect  
AE Adverse event  
AF A trial fibrillation  
BP Blood pressure  
BPM  Beats per minute  
CEC  Clinical Events Committee  
CIP Clinical Investigation Plan 
CRF Case Report Form  
CRO  Clinical Research Organization  
DD Device Deficiency  
DSMB Data Safety Monitoring Board  
DUS  Duplex Ultrasound  
EC Ethic s Committee  
eCRF  Electronic Case Report Form  
eGFR      estimated Glomerular Filtration Rate  
EDC  Electronic Data Capture  
FDA Food and Drug Administration 
FU Follow up 
ICH-GCP  International Conference on Harmonization – Good Clinical Practice  
IDE Investigational Device Exemption  
IRB  Institutional Review Board  
MRA  Magnetic Resonance Angiography  
OBP Office Blood Pressure  
PMDA  Pharmaceuticals and Medical Devices Agency  
SADE  Serious Adverse Device Effect  
SAE Serious Adverse Event  
SOP Standard operating procedure  
TGA Therapeutic Goods Administration  
 
SPYRAL PIVOTAL - SPYRAL HTN -OFF MED Clinical Investigation Plan  
  
 Version  12 .0 Page 134 of 139  
 
Medtronic Confidential  
  056-F275, v3 .0 Clinical Investigation Plan Template  
  L.5 Definitions  
Event definitions:  
• Major Adverse Events (MAE), defined as a composite of the following events, 
compared between groups:  
o All- cause mortality  
o End- stage Renal Disease (ESRD) – defined as two or more eGFR 
measurements < 15 mL/min/1.73m2 at least 21 days apart and requiring dialysis 
for one of more of the following:  
• Volume management refractory to diuretics  
• Hyperkalemia unmanageable by  diet and diuretics  
• Acidosis bicarbonate <18 unmanageable with HCO3 supplements  
• Symptoms of uremia, nausea, vomiting  
o Significant embolic event resulting in end- organ damage (e.g. kidney/bowel 
infarct, lower extremity ulceration or gangrene, or doubling of serum creatinine 
documented by at least two measurements at least 21 days apart)  
o Renal artery perforation requiring intervention  
o Renal artery dissection requiring intervention 
o Vascular complications (e.g., clinically significant groin hematoma, 
arteriovenous fistula, pseudoaneurysm, excessive bleeding) requiring surgical 
repair, interventional procedure, thrombin injection, or blood transfusion (requiring more than 2 units of packed red blood cells within any 24 hour period 
during the first 7 days post renal denervation procedure)  
o Hospitalization for hypertensive crisis not related to confirmed non- adherence 
with medications. Hypertensive Crisis: Severely elevated blood pressure (BP), usually higher than 180/110 mmHg , together with progressive or impending 
target organ damage, requiring in- patient hospitalization and typically admission 
to the Intensive Care Unit (ICU) (e.g., with parenteral [IV] antihypertensive 
medications), not related to confirmed non -adherence with medication or the 
protocol.  
o New renal artery stenosis > 70%, confirmed by angiography by the 
angiographic core lab 
• Major bleeding according to TIMI definition (i.e. intracranial hemorrhage; ≥5g/dl decrease in hemoglobin concentration, a  ≥15% absolute decrease in hematocrit , 
or death due to bleeding within 7 days of the procedure ) 
SPYRAL PIVOTAL - SPYRAL HTN -OFF MED Clinical Investigation Plan  
  
 Version  12 .0 Page 135 of 139  
 
Medtronic Confidential  
  056-F275, v3 .0 Clinical Investigation Plan Template  
  Estimated Glomerular Filtration Rate (eGFR) calculation method for Japanese:  eGFR 
(mL/min/1.73 m2) = 194 x (sCr)－1.094× (Age)－0.287   x (0.739 if female)  
 
L.6 Center for Medicare and Medicaid Services (CMS) IDE Study Criteria  
Medicare Beneficiaries  
The results of this study are expected to be generalizable to the Medicare population based 
on the incidence of uncontrolled hypertension and estimates of the number of patients taking multiple antihypertensive medications.   
Previous data from Symplicity HTN- 3 showed that, on average, patients in both the renal 
denervation and sham procedure arms were on approximately 5 antihypertensive medications 
at baseline measurement. Approximately 28% of patients enrolled were age 65 or older.
35  
In addition, in a cross -sectional analysis of data from the Framingham Heart Study, only 48% 
of treated participants had their blood pressure controlled to <140/90 mm Hg.  Among elderly participants (> 75 years of  age), less than 40% had achieved a goal blood pressure.   
Framingham data also showed that older age was the strongest predictor of blood pressure being uncontrolled.
35 
L.7 Blood Pressure Measurement Procedures  
 
1. OFFICE BLOOD PRESSURE  
 
All Office Blood Pressure (OBP) Measurements must be taken with the automatic BP 
Monitor & printer  (if applicable) as specified by the sponsor . 
 At screening visit  1, the appropriate arm for study  measures must be selected as 
specified in section A below and then used for all subsequent follow -up visits. 
 For each study  visit, the study visit should  begin  before 10:30am . This does not apply 
to Screening Visit 1  (if the subject is consented at SV1) and  Unscheduled follow- up 
visits .  
Patient should not take their antihypertensive medication in the morning of the visit, but rather 
bring the medication with them to the visit to have observed pill taking after office blood 
pressure measurement (if applicable).  The requirement for not taking the medication in the 
morning of the visit  does not apply to Screening Visit 1, if the subject signed the Informed 
Consent Form  at SV1, medication reintroduction visit, unscheduled visits or at the discharge 
visit.  
  
SPYRAL PIVOTAL - SPYRAL HTN -OFF MED Clinical Investigation Plan  
  
 Version  12 .0 Page 136 of 139  
 
Medtronic Confidential  
  056-F275, v3 .0 Clinical Investigation Plan Template  
  A. ARM SELECTION AT SCREENING VISIT 1  ONLY  
(1) If the subject is on antihypertensive medications, the visit should begin before 10:30am 
unless the subject normally takes their anti -hypertensive medication in the afternoon 
in which the subject’s visit can occur in the afternoon.  
(2) With subject prepped  per “Preparation” section below, measure BP in each arm. 
Ensure each measurement is captured/recorded and identifies on which arm the BP 
was measured.  
(3) Use the arm with the higher  systolic  BP for screening measurements and all 
subsequent measurements  
• If there is a reason to use a particular arm, document the reason and use that 
arm for all measures going forward.  
  
B. PREPARATION AT ALL VISITS  
(1) Ensure the BP monitor and all necessary equipment are functioning appropriately (per 
sponsor  instructions).  
(2) Confirm th e subject did not drink coffee or alcohol, smoke, or exercise within 30 
minutes prior to the measurements.  
(3) Request the subject to use the bathroom prior to measurements (a full bladder can affect the reading).  
(4) The subject should be seated comfortably with the back supported and the upper arm bared with no clothing between the arm and BP cuff. The legs should not be crossed.  
(5) Ensure that the BP cuff is appropriately sized (see Table 14  below) and that the upper 
arm is supported at the level of the heart (e.g. resting on a table at the level of his/her heart) . 
The same cuff size should be used as selected at Screening Visit 1 for the remainder 
of the study.  
 
Table 10 : BP Cuff Size Chart  
Cuff Size*  Fits Arm Circumference of 
(inches)  Fits Arm Circumference of 
(centimeters)  
Small  7 – 9  17 – 22 
Medium  9 – 13 22 – 32 
Medium -Large  9 - 17 22 - 42 
Large  13 – 17  32 – 42 
Extra -Large**  17 – 20 42 – 50 
* If a subject is on the border of two cuff sizes, opt for the larger of the two sizes  
** Subjects requiring greater than an extra- large cuff size at time of screening must be 
excluded from the study  
 
SPYRAL PIVOTAL - SPYRAL HTN -OFF MED Clinical Investigation Plan  
  
 Version  12 .0 Page 137 of 139  
 
Medtronic Confidential  
  056-F275, v3 .0 Clinical Investigation Plan Template  
   
 
(6) Perform a “test” BP measure. Ensure test measurement is captured/recorded.  
(7) Have the subject sit comfortably and quietly for at least 5 minut es, but no more than  
10 minutes, with back supported and feet flat on the ground (i.e., not on an exam table, 
legs not crossed)  
C. METHOD FOR TAKING BP AT ALL VISITS  
(1) General Instructions  
a. With subject prepared per “Preparation” section above and using arm selected at Screening, take at least  three (3) seated BP measurements in order to obtain 
the BP average.  
b. Wait at least 1 minute between each measurement .  Ensure that the blood 
pressure monitor time clock is used for tracking the time intervals to 
avoid deviations due to insufficient wait time between measurements.  
c. Print (if available) and label after each measurement.  
(2) Three (3) consecutive, consistent seated BP measurements must be used to obtain 
the BP average.  
a. If the lowest and highest systolic BP (SBP) values of the first 3 consecutive measurements are >15 mmHg  apart, take one additional reading and average 
the last 3 consecutive measurements (measurements 2- 4). If the 
measurements are still >15 mmHg  apart, take one additional reading and 
average the last 3 consecutive measurements (measurements 3-5 ). If the 
measurements are still >15 mmHg  apart, take one final measurement and 
average the last 3 consecutive measurements (measurements 4-6 ). 
(3) At Screening Visit:  If the lowest and highest SBP values for the readings are more than 
20 mmHg  apart after 6 measurements, the subject must be excluded from the study . 
(4) At all Subsequent Follow Up Visits: If the lowest and highest SBP values for the 
readings are more than 20 mmHg  apart after 6 measurements, take the average of the 
last three measurements (measurements 4 – 6) and record the value on the CRF.  
(5) Record the last 3 consecutive, consistent readings  on the CRF (i.e. cannot pick the 
‘best’ 3).  
NOTE: To better ensure long- term preservation of the OBP source data, a photocopy  
labeled as certified of all automatic BP Monitor printouts  (if applicable)   should be made and 
attached to the originals . If unable to print, document BP & HR values, dates and exact 
times of readings, and label appropriately. 
  
SPYRAL PIVOTAL - SPYRAL HTN -OFF MED Clinical Investigation Plan  
  
 Version  12 .0 Page 138 of 139  
 
Medtronic Confidential  
  056-F275, v3 .0 Clinical Investigation Plan Template  
  Orthostatic Hypotension Evaluation (AT SCREENING VISIT 2 ONLY)  
In addition to the seated OBP recordings above, measure supine and standing BPs.  
(1) Have the subject lie supine for at least 5 minutes prior to taking the supine BP 
measurement.  
(2) Measure BP within 1-3 minutes upon standing for the standing measurement. Standing 
must follow the supine to measure or thostatic effect.  
o Evaluate for any symptoms (e.g., dizziness) that may occur in the subject within 
the first 3 minutes after standing.  
 
2. AMBULATORY BLOOD PRESSURE MONITORING  
All 24 Hour Ambulatory Blood Pressure Monitoring (ABPM) measurements must be taken 
with the 24- hour ABPM device provided by the sponsor  to ensure consistency.  
Cuff size identified at SV2 should be used for the duration of the study.  
(1) If the subject is on antihypertensive medications, the visit should begin  before 10:30am 
unless the subject normally takes their antihypertensive medication in the afternoon in 
which the subject’s visit can occur in the afternoon.  
(2) Study  personnel should observe the subject swallowing the antihypertensive 
medication(s) , if applicable. Once this is completed and documented, the ABPM device 
should be applied to the subject and the recording started before leaving the office.  
(3) Place cuff on the subject’s non- dominant arm .  
(4) Instruct  the subject in proper cuff positioning in case they must remove it but stress the 
importance of leaving the BP cuff on.  
(5) The ABPM has pre- set parameters and should not be adjusted. These parameters are set 
to record blood pressure every 30 minutes .  
(6) Instru ct subjects that they should engage in their usual physical level but should avoid 
strenuous exercise during the monitoring period 
(7) Instruct the subject to hold the arm still by the side while the device is taking a reading 
(8) Upon the return of the ABPM machi ne: 
o Submit the 24 Hour ABPM data to Medtronic  
o A 24 Hour ABPM will be considered adequate if the number of successful daytime 
readings captured is ≥ 21 and the number of successful nighttime readings 
captured is ≥ 12 . At SV2 , a single repeat ABPM will be allowed in case of th 
following:  
 If the 24- hr systolic ABPM measured is between 135 and <140 mmHg 
or 170 -175 mmHg  
 If a valid number of readings is not obtained 
 If there is a technical issue with the blood pressure monitor or  failure to 
follow ABPM instructions . 
In all other instances at SV2, the ABPM will not be allowed to be repeated 
and the subject will be considered a screen failure  
For all other time points with ABPM, make all efforts to obtain repeat ABPM from subject until the minimum number of readings is obtained.  
 
SPYRAL PIVOTAL - SPYRAL HTN -OFF MED Clinical Investigation Plan  
  
 Version  12 .0 Page 139 of 139  
 
Medtronic Confidential  
  056-F275, v3 .0 Clinical Investigation Plan Template  
  L.8 Sample Patient Information and Informed Consent Form  
Geography -specific informed consents will be provided separately. 
L.9 Subject Blinding Assessment  
Assessment will be provided separately.  
L.10 EQ-5D (Quality of Life) Survey 
Geography -specific EQ- 5D will be provided separately.  
L.11 SF-36 (Quality of Life) Survey 
L.12 ABPM Guidelines  
Guidelines will be provided separately. 
L.13 Serious or Unanticipated Adverse Event Report (Rush form) - Japan only  
Rush form only applies to Japan and will be provided separately.  
L.14 Angiographic Core Laboratory Guidelines  
Core Laboratory guidelines will be provided separately.  
L.15 Renal Duplex Ultrasound (DUS) Core Laboratory Guidelines  
Core Laboratory guidelines will be provided separately.  
L.16 Magnetic Resonance Angiography (MRI)/Computerized Tomography (CT) Core 
Laboratory Guidelines  
Core Laboratory guidelines will be provided separately.  
L.17 Blood Core Laboratory Guidelines  
Core Laboratory guidelines will be provided separately.  
L.18 Drug Testing Core Laboratory Guidelines  
Core Laboratory guidelines will be provided separately.  
 